<!DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Strict//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-strict.dtd">
<html xmlns="http://www.w3.org/1999/xhtml">
<head>

    <title>Pocket Medicine, 8e</title>
    <meta http-equiv="Content-Type" content="text/html; charset=utf-8"/>
  <link rel="stylesheet" type="text/css" href="../stylesheet.css"/>
<link rel="stylesheet" type="text/css" href="../page_styles.css"/>

  


<link href="../calibreHtmlOutBasicCss.css" type="text/css" rel="stylesheet" />

</head>
<body>

<div class="calibreMeta">
  <div class="calibreMetaTitle">
  
  
    
    <h1>
      <a href="../../j09u21sl.html">Pocket Medicine (Pocket Notebook Series)
</a>
    </h1>
    
    
  
  </div>
  <div class="calibreMetaAuthor">
    Marc Sabatine

  </div>
</div>

<div class="calibreMain">

  <div class="calibreEbookContent">
    
      <div class="calibreEbNavTop">
        
          <a href="part0008.html" class="calibreAPrev">previous page
</a>
        

        
          <a href="part0010.html" class="calibreANext">next page
</a>
        
      </div>
    

    
<h2 class="ct"><a id="h40" class="calibre8"></a><a id="page_3-1" class="calibre8"></a><a href="part0003.html#rh46" class="calibre8">ESOPHAGEAL AND GASTRIC DISORDERS</a></h2>
<p class="h">Dysphagia</p>
<p class="noindent1">• Oropharyngeal: inability to propel food from mouth through UES into esophagus</p>
<p class="noindent1">• Esophageal: difficulty swallowing &amp; passing food from esophagus into stomach</p>
<div class="cap">
<p class="caption"><a id="fig3-1" class="calibre4"></a><b class="calibre7">Figure 3-1</b> Etiologies of and approach to dysphagia <span class="sm">(<i class="calibre6">NCP Gastrohep</i> 2008;5:393; <i class="calibre6">Neurogastro</i> 2012;24:57)</span></p>
<p class="imagef1"><img src="../images/00051.jpeg" alt="" class="calibre5"/></p>
</div>
<p class="h">Structural dysphagia <span class="r">(solids &gt;liquids;</span> <span class="r2">JAMA</span> <span class="r1">2015;313:18;</span> <span class="r2">Gastro</span><span class="r1"> 2018;155:1022</span><span class="r">)</span></p>
<p class="noindent1">• <b class="calibre7">Oropharyngeal</b></p>
<p class="noindent2">Zenker’s divertic. (pharyngeal pouch): in elderly, a/w aspir., dx w/ video fluoro, Rx endo/surg</p>
<p class="noindent2">Malignancy; proximal strictures/rings/webs; infection; radiation injury; goiter; osteophytes</p>
<p class="noindent1">• <b class="calibre7">Esophageal</b></p>
<p class="noindent2">Rings (intermittent dysphagia, concentric obstructing tissue, Schatzki ring): near GE jxn, a/w food impaction, linked to GERD; Rx w/ PPI, dilation</p>
<p class="noindent2">Webs: thin, partially occlusive structure, proximal, a/w Fe defic. (Plummer-Vinson synd.)</p>
<p class="noindent2">Peptic or XRT strictures, foreign body, tumor, vascular rings (dysphagia lusoria), compression from dilated left atrium compression</p>
<p class="noindent2">Infxn esophagitis: odynophagia &gt;dysphagia; often immunosupp w/ <i class="calibre6">Candida</i>, HSV, CMV</p>
<p class="noindent2">Pill esophagitis: odynophagia &gt;dysphagia; NSAID, KCl, bisphosp., doxy &amp; tetracycline</p>
<p class="noindent2">Eosinophilic esophagitis <span class="r1">(</span><span class="r2">JAMA</span> <span class="r1">2021;326:1310)</span>: often young/middle-aged ♂. Dx: &gt;15 eos/hpf on bx, esoph dysfxn (ie, dysphagia, food impaction). Rx: 1<sup class="calibre19">st</sup> line is PPI (½ respond); alternative (or if fail PPI) is <b class="calibre7">3Ds</b>: 1<sup class="calibre19">st</sup> elimination <b class="calibre7">D</b>iet (Ø milk, soy, eggs, wheat, nuts, fish); if no Δ, <b class="calibre7">D</b>rugs (swallow inh steroids); if ongoing sx &amp; stricturing, <b class="calibre7">D</b>ilation <span class="r1">(</span><span class="r2">Gastro</span> <span class="r1">2020;158:1776)</span>.</p>
<p class="h">Neuromuscular dysphagia <span class="r">(solids &amp; liquids;</span> <span class="r2">Neurogastero Motil</span> <span class="r1">2021;33:e14058</span><span class="r">)</span></p>
<p class="noindent1">• Caused by aberrant motility or innervation of oropharynx/esophagus</p>
<p class="noindent1">• Oropharyngeal: consider CNS disorders (eg, stroke, ALS, myopathies, CNS tumors)</p>
<p class="noindent1">• Esophageal: motility disorder w/ dysphagia, chest pain, GERD; dx: conventional or high-res manometry w/ esophageal pressure topography. Chicago classification v4.0:</p>
<p class="noindent2">1. <span class="underline">Disorders of EGJ Outflow</span>:<i class="calibre6"> Isolated EGJ outflow obstruction or achalasia. Achalasia:</i> simult. ↓ amp contractions &amp; ↓ LES relaxation; barium swallow w/ dilated esophagus &amp; distal “bird’s beak” narrowing; mostly idiopathic, although can be a/w Chagas; Rx: pneumatic dilation as effective as Heller myotomy (local expertise dependent) <span class="r1">(</span><span class="r2">Gut</span> <span class="r1">2016;65:732)</span>; peroral endoscopic myotomy; CCB/nitrates/PDEi; botox if Ø surg cand.</p>
<p class="noindent2">2. <span class="underline">Disorders of Peristalsis</span>:<i class="calibre6"> Absent contractility</i> (failed peristalsis)<i class="calibre6">; distal esophageal spasm</i> (uncord. peristalsis w/ simult. contractions);<i class="calibre6"> hypercontractile esoph</i> (high amp contract.; Rx w/PPI, nitrates/CCB/PDEi, TCA); <i class="calibre6">ineffective esophageal motility</i> (↓ amp of distal esoph contractions; seen in scleroderma, DM, hypothyroid.; Rx w/ underlying disorder &amp; w/ PPI)</p>
<p class="h1cr">G<small class="calibre31">ASTROESOPHAGEAL</small> R<small class="calibre31">EFLUX</small> D<small class="calibre31">ISEASE</small> (GERD)</p>
<p class="h">Pathophysiology <span class="r1">(</span><span class="r2">JAMA</span> <span class="r1">2020;324:2536)</span></p>
<p class="noindent1">• ↑ acid exposure in esophagus, caused by ↑ transient LES relaxations. Worsened by ↑ intraabd pressure (eg, obesity, pregnancy), ↓ esophagogastric motility, hiatal hernia. Rarely caused by ↑ secretory states (eg, Zollinger-Ellison).</p>
<p class="noindent1">• Precipitants: supine, fatty foods, caffeine, alcohol, cigarettes, CCB, pregnancy, obesity</p>
<p class="h"><a id="page_3-2" class="calibre4"></a>Clinical manifestations</p>
<p class="noindent1">• Esophageal: <b class="calibre7">heartburn</b>, atypical chest pain, regurgitation, sour taste, dysphagia</p>
<p class="noindent1">• Extraesophageal: <b class="calibre7">dry cough</b>, asthma (often poorly controlled), laryngitis, dental erosions</p>
<p class="h">Diagnosis <span class="r1">(</span><span class="r2">Annals</span> <span class="r1">2015;163:ITC1;</span> <span class="r2">Nat Rev Gastro Hepatol</span> <span class="r1">2016;13:501)</span></p>
<p class="noindent1">• Clinical diagnosis based on sx and response to empiric trial of PPI (“PPI test”)</p>
<p class="noindent1">• EGD if: Ø response to PPI or <i class="calibre6">alarm features</i><b class="calibre7">:</b> dysphagia, vomiting, ↓ wt, anemia, age &gt;60</p>
<p class="noindent1">• If dx uncertain &amp; EGD nl → esoph manometry w/ 24-h pH monitoring ± impedance to dx:</p>
<p class="noindent2">“Nonerosive reflux disease”: no erosion, ulceration or Barrett’s; ½ abnl pH. Unpredictable response to PPI. Most will <i class="calibre6">not</i> progress to erosive esophagitis or Barrett’s.</p>
<p class="noindent2">“Reflux hypersensitivity”: nl acid exposure on pH/impedance w/ symptom–reflux assoc.</p>
<p class="noindent2">“Functional heartburn”: nl acid exposure on pH/impedance w/o symptom–reflux assoc.</p>
<p class="h">Treatment <span class="r1">(</span><span class="r2">World J Gastrointest Endosc</span> <span class="r1">2018;10:175;</span> <span class="r2">Am J Gastro</span> <span class="r1">2022;117:27)</span></p>
<p class="noindent1">• Lifestyle: avoid precipitants, lose weight, no eating 2 hrs before bed, exercise, Ø tobacco</p>
<p class="noindent1">• Medical: start low-dose PPI, uptitrate up to 40 mg bid; H2 blockers for intermittent sx</p>
<p class="noindent1">• Refractory (max dose ≥8 wks): confirm w/ pH testing on or off PPI, consider hernia repair</p>
<p class="noindent2">If acidic or sx correlate w/ reflux episodes: surgical fundoplication (emerging Rx: LES sphincter augmentation w/ radiofrequency, implantable magnetic or electrical devices)</p>
<p class="noindent2">If nl pH or no sx correlation = “fxnal dyspepsia” <span class="r1">(</span><span class="r2">Gastro</span> <span class="r1">2020;158:2286)</span>; Rx w/ TCA, SSRI</p>
<p class="h">Complications <span class="r1">(</span><span class="r2">Gastro</span> <span class="r1">2020;158:760)</span></p>
<p class="noindent1">• Reflux esophagitis (erosions/ulcers above GE jxn), strictures (caused by chronic inflamm)</p>
<p class="noindent1">• Barrett’s esoph. (BE): metaplastic columnar mucosa above GE jxn replaces squam epithel.</p>
<p class="noindent2">Screen if chronic (&gt;5 y) and/or frequent GERD (≥1/wk) in ♂ w/ ≥2 risk factor for Barrett’s/esophageal adeno: &gt;50 y, white, hiatal hernia, central adiposity, smoking, FHx of Barrett’s/esophageal adeno. In ♀, consider only if multiple RFs. 0.1–0.3%/y risk of esoph adenocarcinoma, ↑ if ↑ dysplasia <span class="r1">(</span><span class="r2">Am J Gastro</span> <span class="r1">2016;111:30)</span>.</p>
<p class="noindent2">Mgmt: PPI. W/o dysplasia: surveillance EGD q3–5y. Low-grade dysplasia: EGD q12mo; possible endoscopic eradication. High-grade dysplasia: endoscopic eradication; consider chemoprophylaxis w/ high-dose PPI &amp; ASA <span class="r1">(</span><span class="r2">Lancet</span> <span class="r1">2018;392:400)</span>.</p>
<p class="h1cr">P<small class="calibre31">EPTIC</small> U<small class="calibre31">LCER</small> D<small class="calibre31">ISEASE</small> (PUD)</p>
<p class="h">Definition &amp; etiologies <span class="r1">(</span><span class="r2">BMJ</span> <span class="r1">2019;367:5495)</span></p>
<p class="noindent1">• Ulcers (break in mucosal lining &gt;5 mm) &amp; erosions (&lt;5 mm) in stomach and duodenum</p>
<p class="noindent1">• Principal risk factors: <i class="calibre6">H. pylori</i> infection &gt;ASA/NSAID use</p>
<p class="noindent1">• <b class="calibre7"><i class="calibre6">H. pylori</i> infection:</b> causes ~80% of duodenal ulcers (DU) &amp; ~30–40% of gastric ulcers (GU). ~50% of world colonized w/ <i class="calibre6">H. pylori</i>, but only 5–10% will develop PUD.</p>
<p class="noindent1">• <b class="calibre7">ASA</b>/<b class="calibre7">NSAIDs:</b> damage to mucosa caused by ↓ prostaglandin synthesis. Cause majority of non–<i class="calibre6">H. pylori</i>-related DU &amp; GU. Regular use a/w 5–6× ↑ odds of GIB.</p>
<p class="noindent1">• Other: smoking, stress, excessive EtOH, gastric cancer/lymphoma, Crohn’s, viral infxn (eg, CMV/HSV in immunosupp), bisphosphonates, steroids (in combo w/ NSAIDs, but not risk factor alone); rarely gastrinoma (Zollinger-Ellison synd.), mastocytosis, idiopathic</p>
<p class="noindent1">• Stress ulcer: risk factors = ICU &amp; coagulopathic, mech vent, h/o GIB, steroid use; Rx w/ PPI</p>
<p class="h">Clinical manifestations</p>
<p class="noindent1">• <b class="calibre7">Epigastric gnawing abdominal pain:</b> relieved with food (DU) or worsened by food (GU)</p>
<p class="noindent1">• Complic.: UGIB, perf. &amp; penetration, gastric outlet obstruction (due to edema &amp; dysmotility)</p>
<p class="h">Diagnostic studies</p>
<p class="noindent1">• Testing for <i class="calibre6">H. pylori:</i> stool Ag, urea breath testing (UBT) or EGD + rapid urease test (RUT) False ⊖ Ag, UBT, RUT if on abx, bismuth, PPI; ∴ stop prior to testing if possible Serology: ↓ utility, useful only to exclude infection in lower prevalence areas</p>
<p class="noindent1">• EGD (definitive dx): if fail empiric Rx or alarm features (see “GERD”); bx GU to r/o malig &amp; <i class="calibre6">H. pylori;</i> repeat EGD in 6–12 wk if &gt;2 cm, malig features, risk factors for gastric cancer (ie, ⊕ FHx, ⊕ <i class="calibre6">H. pylori</i>, atrophic gastritis, metaplasia on bx, &gt;50 y), or sx persist</p>
<p class="h">Treatment <span class="r1">(</span><span class="r2">Lancet</span> <span class="r1">2016;388:2355;</span> <span class="r2">Gastro</span><span class="r1"> 2016;151:51;</span> <span class="r2">Gut</span> <span class="r1">2017;66:6;</span> <span class="r2">AJG</span> <span class="r1">2017;112:212)</span></p>
<p class="noindent1">• <b class="calibre7">If <i class="calibre6">H. pylori</i></b> ⊕ →<b class="calibre7"> eradicate</b> (“test and treat”); if ⊖ → gastric acid suppression w/ PPI</p>
<p class="noindent2">1<sup class="calibre19">st</sup> line: Quad. Rx: 14d x [MNZ + TCN + bismuth + PPI] or [MNZ + amox + clarith + PPI]</p>
<p class="noindent2">Besides PUD, test &amp; Rx if: gastric MALT lymphoma, s/p resection for early gastric ca, FHx gastric ca, unexplained iron def. anemia, ITP, uninvestigated dyspepsia in Pt &lt;60 y, or when initiating long-term NSAIDs</p>
<p class="noindent1">• “Test-of-cure”: 4 wk after Rx, off PPI x 1–2 wk. Use stool Ag, EGD + RUT, or UBT.</p>
<p class="noindent1">• Lifestyle changes: d/c smoking and probably EtOH; diet does not seem to play a role</p>
<p class="noindent1">• Surgery: if refractory to med Rx (1<sup class="calibre19">st</sup> r/o NSAID use) or for complic. (see above)</p>
<p class="h">GI prophylaxis if taking ASA/NSAID <span class="r1">(</span><span class="r2">Am J Gastro</span> <span class="r1">2009;104:728)</span></p>
<p class="noindent1">• PPI if h/o PUD/UGIB and either (a) on P2Y<sub class="calibre10">12</sub> inhib or anticoag, or (b) ≥2 of the following: &gt;60 y, steroids or dyspepsia. Low bleeding risk Pts unlikely to benefit <span class="r1">(</span><span class="r2">Gastro</span> <span class="r1">2019;157:403)</span>.</p>
<p class="noindent1">• Consider Δ non-selective NSAID to selective COX-2 inhibitor (↓ PUD &amp; UGIB but ↑ CV events), if low CV risk &amp; not on ASA</p>
<h2 class="ct"><a id="h41" class="calibre8"></a><a id="page_3-3" class="calibre8"></a><a href="part0003.html#rh47" class="calibre8">GASTROINTESTINAL BLEEDING</a></h2>
<p class="h">Definition</p>
<p class="noindent1">• Intraluminal blood loss anywhere from the oropharynx to the anus</p>
<p class="noindent1">• Classification: <b class="calibre7">upper</b> = above the ligament of Treitz; <b class="calibre7">lower</b> = below the ligament of Treitz</p>
<p class="noindent1">• “Severe” GIB: defined as having associated shock, orthostatic hypotension, ↓ Hct by 6% (or ↓ Hb by 2 g/dL), or requiring transfusion ≥2U PRBCs. Requires hospitalization.</p>
<p class="h">Clinical manifestations</p>
<p class="noindent1">• <b class="calibre7">Hematemesis</b> = blood in vomitus (UGIB)</p>
<p class="noindent1">• <b class="calibre7">Coffee-ground emesis</b> = emesis of blood exposed to gastric acid (UGIB)</p>
<p class="noindent1">• <b class="calibre7">Melena</b> = black, tarry stools from digested blood (usually UGIB, but can be SB or R colon)</p>
<p class="noindent1">• <b class="calibre7">Hematochezia</b> = bloody or maroon-colored stools (LGIB or rapid UGIB)</p>
<p class="h">Initial management <span class="r1">(</span><span class="r2">Am J Gastro</span> <span class="r1">2021;116:899)</span></p>
<p class="noindent1">• <b class="calibre7">Assess severity:</b> <i class="calibre6">VS including orthostatic</i> Δ<i class="calibre6">s, JVP.</i> Tachycardia (can be masked by βB use) suggests 10% volume loss, orthostatic hypotension 20% loss, shock &gt;30% loss. Scoring predicts rebleeding &amp; mortality: AIMS65, ABC Score &amp; Glasgow-Blatchford.</p>
<p class="noindent1">• <b class="calibre7">History:</b> prior GIB, tempo of current bleed, specific bleeding manifestations (see above), other GI s/s (eg, abd pain, Δ in bowel habits, weight loss, N/V), ASA/NSAID or EtOH use, anticoag/antiplt drugs, h/o or risk factors for cirrhosis, radiation, prior GI or aortic surgery</p>
<p class="noindent1">• <b class="calibre7">Physical exam:</b> localizable abd tenderness, peritoneal signs, masses, LAN, prior surgery, signs of liver disease (hepatosplenomegaly, ascites, jaundice, telangiectasias), rectal exam: masses, hemorrhoids, anal fissures, stool appearance, color</p>
<p class="noindent1">• <b class="calibre7">Resuscitation:</b> placement of 2 large-bore (18-gauge or larger) intravenous lines. Volume replacement: NS or LR to achieve normal VS, UOP, &amp; mental status.</p>
<p class="noindent1">• <b class="calibre7">Lab studies: Hct</b> (<i class="calibre6">may be normal</i> in first 24 h of acute GIB before equilibration) 2–3% → 500 mL blood loss; low MCV → Fe deficient and chronic blood loss; <b class="calibre7">plt</b>, <b class="calibre7">PT/INR</b>,</p>
<p class="noindent2"><b class="calibre7">PTT;</b> BUN/Cr (ratio &gt;36 in UGIB b/c GI resorption of blood ± prerenal azotemia); LFTs</p>
<p class="noindent1">• <b class="calibre7">Transfuse:</b> type &amp; cross; use O-neg if emerg; for UGIB (esp. w/ portal HTN) transfuse w/ more restrictive Hb goal (eg, &gt;7 g/dL or &gt;8 g/dL if CAD) <span class="r1">(</span><span class="r2">JAMA</span> <span class="r1">2016;316:2025)</span></p>
<p class="noindent1">• <b class="calibre7">Reverse coagulopathy:</b> consider FFP to normalize INR (however caution in ESLD where INR does not correlate with bleeding risk); plts &gt;50k, ddAVP if uremic, consider reversal agents if on anticoagulants (qv)</p>
<p class="noindent1">• <b class="calibre7">Triage:</b> alert endoscopist. Consider ICU if unstable VS or poor end organ perfusion.</p>
<p class="noindent2">Intubation for: emergent EGD, ongoing hematemesis, shock, poor resp status, Δ MS</p>
<p class="noindent2">OutPt management if SBP ≥110, HR &lt;100, Hb ≥13 (♂) or ≥12 (♀), BUN &lt;18, Ø melena, syncope, heart failure, liver disease <span class="r1">(</span><span class="r2">Clin Gastro Hepatol</span> <span class="r1">2015;13:115)</span></p>
<p class="h">Diagnostic studies <span class="r1">(</span><span class="r2">JACR</span> <span class="r1">2021;18:S139)</span></p>
<p class="noindent1">• UGIB: <b class="calibre7">EGD</b> w/in 24 h <span class="r1">(</span><span class="r2">NEJM</span> <span class="r1">2020;382:1299)</span>. If severe bleed, ↑ dx/Rx yield if <b class="calibre7">erythro 250 mg IV given 30 min prior to endoscopy</b> to clear stomach contents.</p>
<p class="noindent1">• LGIB: <b class="calibre7">colonoscopy</b> (identifies cause in &gt;70%); early colo (w/in 24 h) unlikely to improve outcome vs. late (24-96 h) <span class="r1">(</span><span class="r2">Gastro</span> <span class="r1">2020;158:168)</span>. If hematochezia a/w orthostasis, concern for brisk UGIB → <i class="calibre6">exclude UGIB w/ EGD first.</i> Push enteroscopy, anoscopy, capsule endoscopy in combo w/ urgent colo results in dx &gt;95% of cases <span class="r1">(</span><span class="r2">GI Endo</span> <span class="r1">2015;81:889)</span>.</p>
<p class="noindent1">• Imaging: if too unstable for endo or recurrent bleeding, consider IR embolization or surgery</p>
<p class="noindent2"><b class="calibre7">tagged RBC scan:</b> can identify general luminal location if bleeding rate ≥0.04 mL/min</p>
<p class="noindent2"><b class="calibre7">CT angiography:</b> faster to obtain than RBC scan, detects bleeding ≥0.3 mL/min</p>
<p class="noindent2"><b class="calibre7">arteriography:</b> can localize exact vessel if bleeding rates ≥0.5 mL/min, <i class="calibre6">allows for IR Rx</i></p>
<p class="noindent1">• Emergent exploratory laparotomy (last resort) if no localization and life-threatening bleed</p>
<table class="tabb">
<colgroup class="calibre11">
<col class="calibre12"/>
<col class="calibre12"/>
<col class="calibre13"/>
</colgroup>
<tbody class="calibre16">
<tr class="calibre15">
<td colspan="2" class="th"><p class="tbody"><b class="calibre7">Etiology UGIB</b></p></td>
<td class="th"><p class="tbody"><b class="calibre7">Comment &amp; Treatment</b> <span class="sm">(<i class="calibre6">GI Endosc Clin N Am</i> 2015;25:415)</span></p></td>
</tr>
<tr class="calibre15">
<td colspan="2" class="th1"><p class="tbody"><b class="calibre7">PUD</b> (20–60%; duodenal&gt;gastric)</p>
<p class="tbody"><span class="sm">(<i class="calibre6">Am J Gastro</i> 2021;116:899)</span></p>
<p class="tbody">See “PUD”</p></td>
<td class="th1"><p class="tbody"><i class="calibre6">Treatment:</i> <b class="calibre7">PPI:</b> 40 mg PO or IV BID</p>
<p class="tbodyh"><b class="calibre7">Endoscopic therapy:</b> epi inj + bipolar cautery or hemoclip. Bx for <i class="calibre6">H. pylori</i> and treat if ⊕.</p>
<p class="tbodyh"><i class="calibre6">High-risk (for rebleeding) ulcer</i>: arterial spurting, adherent clot, visible vessel. Endo Rx, IV PPI × 72 h post EGD, then Δ to high-dose oral PPI. If fail, arteriography w/ embolization; surgery (last resort).</p>
<p class="tbodyh"><i class="calibre6">Intermediate-risk ulcer</i>: oozing, in o/w stable Pt. Endo Rx, can Δ to oral PPI after EGD and observe 24–48 h.</p>
<p class="tbodyh"><i class="calibre6">Low-risk ulcer:</i> clean-based or flat. Oral PPI &amp; discharge.</p>
<p class="tbodyh">Hold anticoag &amp; antiplatelet Rx until hemostasis; can resume after hemostasis &amp; PPI on board <span class="sm">(<i class="calibre6">Endoscopy</i> 2015;47:a1)</span></p></td>
</tr>
<tr class="calibre15">
<td colspan="2" class="th1"><p class="tbody"><b class="calibre7">Erosive gastropathy</b></p>
<p class="tbody">(4–30%)</p></td>
<td class="th1"><p class="tbodyh">Precipitants: ASA/NSAID, EtOH, cocaine, gut ischemia, XRT</p>
<p class="tbodyh">Stress-related mucosal injury in ICU Pts. Risk factors include severe coagulopathy, mech vent &gt;48 h, high-dose glucocorticoids</p>
<p class="tbodyh">Treatment: high-dose PPI</p></td>
</tr>
<tr class="calibre15">
<td colspan="2" class="th1"><a id="page_3-4" class="calibre4"></a><p class="tbody"><b class="calibre7">Esophagitis</b> (15%)</p></td>
<td class="th1"><p class="tbody">Rx offending cause + high-dose PPI; repeat EGD to r/o Barrett’s.</p></td>
</tr>
<tr class="calibre15">
<td colspan="2" class="th1"><p class="tbody"><b class="calibre7">Esophageal or gastric varices</b> (4–20%)</p>
<p class="tbody"><span class="sm">(<i class="calibre6">Clin Gastro Hepatol</i> 2015;13:2109; <i class="calibre6">J Gastro Hepatol</i> 2016;31:1519; <i class="calibre6">Hep</i> 2017;65:310)</span></p>
<p class="tbody">See “Cirrhosis”</p></td>
<td class="th1"><p class="tbody">2° to portal HTN. If isolated gastric → r/o splenic vein thrombosis.</p>
<p class="tbodyh"><i class="calibre6"><span class="underline">Pharmacologic</span></i></p>
<p class="tbodyh">Start <b class="calibre7">octreotide</b> pending EGD if suspect varices: Rx for 2–5 d</p>
<p class="tbodyh">Abx: 20% cirrhotics p/w GIB have infxn, &amp; ~50% develop infxn during hospitalization; Ppx w/ IV CTX, cipro, or levoflox × 7 d</p>
<p class="tbodyh"><i class="calibre6"><span class="underline">Nonpharmacologic</span></i></p>
<p class="tbodyh">Esophageal varices: <b class="calibre7">endoscopic band ligation</b> (&gt;90% success). Covered esophageal stent placement or balloon tamponade if refractory as bridge to TIPS (consider early espec. if Child-Pugh C).</p>
<p class="tbodyh">Gastric varices: arteriography w/ coiling, or if available, endoscopic injection of cyanoacrylate (glue). If refractory: TIPS or balloon-retrograde transvenous obliteration (BRTO).</p></td>
</tr>
<tr class="calibre15">
<td colspan="2" class="th1"><p class="tbody">Portal HTN gastropathy</p></td>
<td class="th1"><p class="tbody">↑ portal venous pressure → ectatic vessels, hyperemia in gastric antrum. Rx: reduce portal HTN (octreotide), βB, TIPS.</p></td>
</tr>
<tr class="calibre15">
<td class="tb" rowspan="4"><p class="tbodyc"><b class="calibre7">Vascular</b> (5–10%)</p></td>
<td class="th1"><p class="tbody">Angioectasia AVMs, HHT (see below)</p></td>
<td class="th1"><p class="tbody">AVMs congenital. Angioectasia (ectatic submucosal vessels) a/w ↑ age, CKD, cirrhosis, CTD, severe CV dis. <i class="calibre6">Heyde syndrome:</i> GIB due to angioectasias + aortic stenosis. Rx: endoscopic Rx.</p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbody">Dieulafoy’s lesion</p></td>
<td class="th1"><p class="tbody">Large (1–3 mm) submucosal artery protruding through fundal mucosa → sudden, massive UGIB. <i class="calibre6">Difficult to identify.</i> Endo Rx.</p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbody">Gastric antral vasc. ectasia (GAVE)</p></td>
<td class="th1"><p class="tbody">“<i class="calibre6">Watermelon stomach</i>”; ectatic gastric vessels, often a/w cirrhosis, CTD, typically older ♂. Rx w/ EGD w/ thermal hemostasis, repeat q4–8wk to eradicate lesions. TIPS does <i class="calibre6">not</i> improve outcomes.</p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbody">Aortoenteric fistula</p></td>
<td class="th1"><p class="tbody">AAA or aortic graft erodes into 3<sup class="calibre27">rd</sup> portion of duodenum. P/w “herald bleed.” If low suspicion → endoscopy; if high → CT angiography.</p></td>
</tr>
<tr class="calibre15">
<td colspan="2" class="th1"><p class="tbody">Malignancy (5%)</p></td>
<td class="th1"><p class="tbody">Endoscopic hemostasis of mass temporizing measure till cancer Rx</p></td>
</tr>
<tr class="calibre15">
<td colspan="2" class="th1"><p class="tbody">Mallory-Weiss tear (5–10%)</p></td>
<td class="th1"><p class="tbody">GE jxn lacerations due to vomiting → ↑ intraabd pressure &amp; shearing Often self-resolve; Rx→ antiemetics, PPI, endoscopic therapy</p></td>
</tr>
<tr class="calibre15">
<td colspan="2" class="th1"><p class="tbody">Cameron’s lesions</p></td>
<td class="th1"><p class="tbody">Linear erosions in hiatal hernia due to mech trauma of diaphragm</p></td>
</tr>
<tr class="calibre15">
<td colspan="2" class="th1"><p class="tbody">Post-sphincter- otomy bleeding</p></td>
<td class="th1"><p class="tbody">Occurs in ~2% of ERCP w/ sphincterotomy; ↑ risk w/ more complic. procedure. Bleeding into duodenum. Rx w/ endo hemostasis.</p></td>
</tr>
</tbody>
</table>
<table class="tabb">
<colgroup class="calibre11">
<col class="calibre23"/>
<col class="calibre35"/>
</colgroup>
<tbody class="calibre16">
<tr class="calibre15">
<td class="th"><p class="tbody"><b class="calibre7">Etiology LGIB</b></p></td>
<td class="th"><p class="tbody"><b class="calibre7">Comment &amp; Treatment</b> <span class="sm">(<i class="calibre6">NEJM</i> 2017;376:1054)</span></p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbody"><b class="calibre7">Diverticular bleed</b> (30%)</p></td>
<td class="th1"><p class="tbodyh"><i class="calibre6">Pathophysiology:</i> Intimal thickening and medial thinning of vasa recta as they course over dome of diverticulum → weakening of vascular wall → arterial rupture. Diverticula more common in left colon; but <i class="calibre6">bleeding diverticula more often in right colon.</i></p>
<p class="tbodyh"><i class="calibre6">Clinical:</i> older, ASA/NSAIDs, usually painless hematochezia ± abd cramping</p>
<p class="tbodyh"><i class="calibre6">Treatment:</i> Usually stops spontaneously (~75%); ~20% recur. Can perform endoscopic hemostasis. Surgery (partial colectomy) last resort.</p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbody">Polyp/Tumor (20%)</p></td>
<td class="th1"><p class="tbody">Typically slow ooze, p/w fatigue, weight loss, iron deficiency, anemia</p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbody">Colitis (20%)</p></td>
<td class="th1"><p class="tbody">Infectious (see “Acute Diarrhea”), IBD, ischemic colitis, XRT</p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbody">Anorectal disorders (20%)</p></td>
<td class="th1"><p class="tbody">Internal, external hemorrhoids; anal fissures, rectal ulcers, rectal varices (Rx by ↓ portal venous pressure in cirrhosis), XRT</p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbody">Vascular (&lt;10%)</p></td>
<td class="th1"><p class="tbody">Angioectasia &amp; AVMs. <i class="calibre6">Hereditary hemorrhagic telangiectasia</i> (Weber-Osler-Rendu): diffuse AVMs throughout GI mucosa (also involve lips, oral mucosa, fingertips).</p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbody">Meckel’s diverticulum</p></td>
<td class="th1"><p class="tbody">Congenital intestinal pouch due to incomplete obliteration of vitelline duct. <span class="underline">2</span>% of pop, w/in <span class="underline">2</span>′ of IC valve, <span class="underline">2</span>″ long, ♂:♀ <span class="underline">2</span>:1, can present as obscure GIB in adults. Dx w/ <sup class="calibre27">99m</sup>Tc-pertechnetate scintigraphy. Rx w/ angioembo, surgical resection.</p></td>
</tr>
</tbody>
</table>
<p class="h">Obscure GIB <span class="r1">(</span><span class="r2">Am J Gastro</span> <span class="r1">2015;110:1265;</span> <span class="r2">Gastro</span> <span class="r1">2017;152:497)</span></p>
<p class="noindent1">• <b class="calibre7">Definition:</b> continued bleeding (melena, hematochezia) despite ⊖ EGD &amp; colo; 5% of GIB</p>
<p class="noindent1">• <b class="calibre7">Etiologies:</b> Dieulafoy’s lesion, GAVE, small bowel angiodysplasia, ulcer or cancer, Crohn’s disease, aortoenteric fistula, Meckel’s diverticulum, hemobilia</p>
<p class="noindent1">• <b class="calibre7">Diagnosis:</b> repeat EGD w/ push enteroscopy/colonoscopy when bleeding is active</p>
<p class="noindent2">If ⊖, video capsule to evaluate small intestine (contraindic. if stricture) <span class="r1">(</span><span class="r2">GIE</span> <span class="r1">2015;81:889)</span></p>
<p class="noindent2">If still ⊖, consider <sup class="calibre19">99m</sup>Tc-pertechnetate scan (“Meckel’s scan”), enteroscopy (single-balloon, double-balloon, or spiral), tagged RBC scan and arteriography</p>
<h2 class="ct"><a id="h42" class="calibre8"></a><a id="page_3-5" class="calibre8"></a><a href="part0003.html#rh48" class="calibre8">DIARRHEA</a></h2>
<p class="h1cr">A<small class="calibre31">CUTE</small> D<small class="calibre31">IARRHEA</small> <span class="r5">(&lt;4 weeks’ duration)</span></p>
<table class="tabb">
<colgroup class="calibre11">
<col class="calibre25"/>
<col class="calibre23"/>
<col class="calibre13"/>
</colgroup>
<thead class="calibre14">
<tr class="calibre15">
<td class="th" colspan="3"><p class="tbodyc"><b class="calibre7">Acute Infectious Etiologies</b> <span class="sm">(<i class="calibre6">Am J Gastro</i> 2016;111:602; <i class="calibre6">JAMA</i> 2019; 321:891)</span></p></td>
</tr>
</thead>
<tbody class="calibre16">
<tr class="calibre15">
<td class="th1" colspan="2"><p class="tbody"><b class="calibre7"><span class="underline">NONINFLAMMATORY</span></b></p></td>
<td class="th1"><p class="tbody"><b class="calibre7">Predom. disruption small intestine absorp. &amp; secretion. Voluminous diarrhea, N/V.</b> ⊖ <b class="calibre7">Fecal WBC &amp; FOB.</b></p></td>
</tr>
<tr class="calibre15">
<td class="th1" colspan="2"><p class="tbody"><b class="calibre7">Preformed toxin</b></p></td>
<td class="th1"><p class="tbody">“Food poisoning,” &lt;24 h dur. <i class="calibre6">S. aureus</i> (meats &amp; dairy),</p>
<p class="tbody"><i class="calibre6">B. cereus</i> (fried rice), <i class="calibre6">C. perfringens</i> (rewarmed meats).</p></td>
</tr>
<tr class="calibre15">
<td class="tb" rowspan="2"><p class="tbody"><b class="calibre7">Viral</b> <span class="sm">(<i class="calibre6">Lancet</i> 2018; 392:175)</span></p></td>
<td class="th1"><p class="tbody">Rotavirus</p></td>
<td class="th1"><p class="tbody">Outbreak person to person (PTP), daycare; lasts 4–8 d.</p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbody">Norovirus</p></td>
<td class="th1"><p class="tbody">~50% of all diarrhea. Winter outbreaks; PTP &amp; food/water; no immunity. Lasts 1–3 d. Vomiting prominent.</p></td>
</tr>
<tr class="calibre15">
<td class="tb" rowspan="2"><p class="tbody"><b class="calibre7">Bacterial</b></p></td>
<td class="th1"><p class="tbody"><i class="calibre6">E. coli</i> (toxigenic)</p></td>
<td class="th1"><p class="tbody">&gt;50% of traveler’s diarrhea; cholera-like toxin; &lt;7 d.</p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbody"><i class="calibre6">Vibrio cholerae</i></p></td>
<td class="th1"><p class="tbody">Contam H<sub class="calibre17">2</sub>O, shellfish; “rice water” stools w/ dehydration</p></td>
</tr>
<tr class="calibre15">
<td class="tb" rowspan="3"><p class="tbody"><b class="calibre7">Parasitic</b></p>
<p class="tbody">(± malab for mos after Rx)</p></td>
<td class="th1"><p class="tbody"><i class="calibre6">Giardia</i></p></td>
<td class="th1"><p class="tbody">Streams/outdoor sports, travel, outbreaks. Bloating.</p>
<p class="tbody">Acute (profuse, watery) → chronic (greasy, malodorous).</p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbody"><i class="calibre6">Cryptosporidia</i></p></td>
<td class="th1"><p class="tbody">In soil; water-borne outbreak; usually self-limited, can → chronic infxn if immunosupp. Abd pain (80%), fever (40%).</p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbody"><i class="calibre6">Cyclospora</i></p></td>
<td class="th1"><p class="tbody">Contaminated produce, intl travel (Latin America)</p></td>
</tr>
<tr class="calibre15">
<td class="th1" colspan="2"><p class="tbody"><b class="calibre7"><span class="underline">INFLAMMATORY</span></b></p></td>
<td class="th1"><p class="tbody"><b class="calibre7">Predom. colonic invasion. Small-vol diarrhea. LLQ cramps, tenesmus, fever, typically</b> ⊕ <b class="calibre7">fecal WBC or FOB.</b></p></td>
</tr>
<tr class="calibre15">
<td class="th1" rowspan="8"><p class="tbody"><b class="calibre7">Bacterial</b></p></td>
<td class="th1"><p class="tbody"><i class="calibre6">Campylobacter</i></p></td>
<td class="th1"><p class="tbody">Undercooked poultry, unpasteurized milk; carried by -puppies &amp; kittens. Prodrome w/ abd pain, “pseudoappendicitis”; c/b GBS, reactive arthritis.</p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbody"><i class="calibre6">Salmonella</i></p>
<p class="tbody">(nontyphoidal)</p></td>
<td class="th1"><p class="tbody">Eggs, poultry, milk, hamsters. Bacteremia in 5–10%. 10–33% of bacteremic Pts &gt;50 y may develop aortitis.</p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbody"><i class="calibre6">Shigella</i></p></td>
<td class="th1"><p class="tbody">Abrupt onset; no N/V; gross blood &amp; pus in stool; ↑↑ WBC</p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbody"><i class="calibre6">E. coli</i> (O157:H7 &amp; inv/hemorrhagic</p>
<p class="tbody">non-O157:H7)</p></td>
<td class="th1"><p class="tbody">Undercooked beef, unpasteurized milk, raw produce; PTP.</p>
<p class="tbody">O157 &amp; non-O157 sp. (40%) produce <i class="calibre6">Shiga</i> toxin → HUS</p>
<p class="tbody">(typically in children). Gross blood in stool.</p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbody"><i class="calibre6">C. difficile</i></p></td>
<td class="th1"><p class="tbody">Vide infra</p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbody"><i class="calibre6">Vibrio parahaem.</i></p></td>
<td class="th1"><p class="tbody">Undercooked seafood</p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbody"><i class="calibre6">Salmonella typhi</i></p></td>
<td class="th1"><p class="tbody">Travel to Asia, Africa, South America. Systemic toxicity, relative bradycardia, rose spot rash, ileus → ”pea-soup” diarrhea, bacteremia.</p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbody">Other</p></td>
<td class="th1"><p class="tbodyh"><i class="calibre6">Yersinia:</i> undercooked pork; unpasteurized milk, abd pain → ”pseudoappendicitis” (aka mesenteric adenitis)</p>
<p class="tbody"><i class="calibre6">Aeromonas, Plesiomonas, Listeria</i> (meats &amp; cheeses)</p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbody"><b class="calibre7">Parasitic</b></p></td>
<td class="th1"><p class="tbody"><i class="calibre6">E. histolytica</i></p></td>
<td class="th1"><p class="tbody">Contaminated food/water, travel (rare in U.S.); liver abscess</p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbody"><b class="calibre7">Viral</b></p></td>
<td class="th1"><p class="tbody">CMV</p></td>
<td class="th1"><p class="tbody">Immunosuppressed; dx by shell vial cx of colon bx</p></td>
</tr>
</tbody>
</table>
<p class="h">Evaluation <span class="r1">(</span><span class="r2">NEJM</span> <span class="r1">2014;370:1532;</span> <span class="r2">Digestion</span> <span class="r1">2017;95:293;</span> <span class="r2">PLOS One</span> <span class="r1">2017;12:11)</span></p>
<p class="noindent1">• <b class="calibre7">Ddx:</b> hyperthyroid, adrenal insufficiency, meds (abx, antacids, immune checkpt inhibitors), appendicitis, diverticulitis, radiation, 1<sup class="calibre19">st</sup> presentation of bowel disorder (eg, IBD, celiac)</p>
<p class="noindent1">• <b class="calibre7">History:</b> stool freq, blood, abd pain, duration of sxs [~1 wk for viral &amp; bacterial (except <i class="calibre6">C. diff</i>), &gt;1 wk for parasitic], travel, food, recent abx, immunocompromise</p>
<p class="noindent1">• <b class="calibre7">PEx:</b> vol depletion (VS, UOP, axillae, skin turgor, MS), fever, abd tenderness, ileus, rash</p>
<p class="noindent1">• <b class="calibre7">Laboratory:</b> calprotectin, stool cx, BCx, lytes, <i class="calibre6">C. diff</i> (if recent hosp/abx), stool O&amp;P (if &gt;10 d, travel to endemic area, exposure to unpurified H<sub class="calibre10">2</sub>O, community outbreak, daycare, HIV ⊕ or MSM); ± stool ELISAs (viruses, <i class="calibre6">Crypto</i>, <i class="calibre6">Giardia</i>), serologies (<i class="calibre6">E. histolytica</i>); PCR available (but high ⊕ rate &amp; unclear if true vs. colonized; consider if immunocompromised)</p>
<p class="noindent1">• <b class="calibre7">Imaging/endoscopy:</b> consider if <b class="calibre7"><i class="calibre6">warning signs (WS)</i></b> of fever, severe abd pain, blood or pus in stool, &gt;6 stools/d, severe dehydration, immunosupp, elderly, duration &gt;7 d, hosp-acquired. CT/KUB if ? toxic megacolon; sig/colo if immunosupp or cx ⊖.</p>
<p class="h">Treatment <span class="r1">(</span><span class="r2">Am J Gastro</span> <span class="r1">2016;111:602;</span> <span class="r2">Clin Infect Dis</span> <span class="r1">2017;65:e45)</span></p>
<p class="noindent1">• If no WS, nl PO intake → supportive: hydrate, loperamide, bismuth subsalicylate (Ø antichol)</p>
<p class="noindent1">• If mod. dehydration: 50–200 mL/kg/d of oral solution or Gatorade, etc. If severe: IV fluids.</p>
<p class="noindent1">• If suspect traveler’s diarrhea → azithro 1 g x 1 d (due to FQ resistance in Asia), rifaximin, or rifamycin; if suspect protozoal → flagyl or nitazoxanide</p>
<p class="noindent1">• <i class="calibre6">Empiric</i> abx for non–<i class="calibre6">C. diff inflammatory</i> diarrhea reasonable for severe disease (fever, &gt;6 BMs/d, hospitalization, bloody or mucoid stools or high-risk Pt [&gt; 70 yrs, immunosupp]: azithro 1 g x 1 d (preferred if fever or dysentery) or FQ × 3–5 d (↑ resistance)</p>
<p class="noindent1">• <i class="calibre6">Avoid</i> abx if suspect <i class="calibre6">E. coli</i> O157:H7 (exposure hx, gross blood) as may ↑ risk of HUS</p>
<p class="h1cr"><a id="page_3-6" class="calibre8"></a><i class="calibre38">C<small class="calibre31">LOSTRIDIOIDES</small> D<small class="calibre31">IFFICILE</small></i> I<small class="calibre31">NFECTION</small> (CDI)</p>
<p class="h">Pathogenesis &amp; epidemiology <span class="r1">(</span><span class="r2">NEJM</span> <span class="r1">2015;372:825)</span></p>
<p class="noindent1">• Ingestion of <i class="calibre6">C. diff</i> spores → colonization when colonic flora Δ’d by abx or chemo → release of toxin A/B → colonic mucosal necrosis &amp; inflammation → pseudomembranes</p>
<p class="noindent1">• Most frequently reported nosocomial infxn; community-acquired w/o abx ~⅓of new cases. A/w <i class="calibre6">any</i> abx during or up to 10 wks post Rx (esp. β-lactams, clinda, FQ).</p>
<p class="noindent1">• Elderly, immunocompromised, and IBD Pts can develop CDI w/o recent abx exposure</p>
<p class="h">Clinical manifestations <span class="r">(a spectrum of disease)</span></p>
<p class="noindent1">• Asx colonization: &lt;3% healthy adults; ~20% in hospitalized patients on antibiotics</p>
<p class="noindent1">• Acute watery diarrhea (&gt;3 stool/d), occ bloody ± mucus, lower abd pain, fever, ↑↑↑ WBC</p>
<p class="noindent1">• Pseudomembranous colitis: above sx + pseudomembranes + bowel wall thickening</p>
<p class="noindent1">• Fulminant colitis (2–3%): <b class="calibre7">toxic megacolon</b> (colonic atony/absence of BMs, colon dilatation ≥6 cm on KUB, systemic toxicity) and/or bowel perforation</p>
<p class="h">Diagnosis <span class="r1">(</span><span class="r2">Ann Intern Med</span> <span class="r1">2018;169:49)</span></p>
<p class="noindent1">• Only test if <i class="calibre6">symptomatic</i> (diarrhea, s/s of colitis); test <i class="calibre6">liquid</i> stool (unless concern for ileus)</p>
<p class="noindent1">• <b class="calibre7">Stool toxin immunoassay</b> (high Sp) + <b class="calibre7">glutamate dehydrogenase</b> (GDH) (high Se)</p>
<p class="noindent1">• <b class="calibre7">Stool PCR:</b> has ↑ Se, but ⊕ if colonized in absence of active infxn; should not necessarily Rx if ⊕ PCR w/ neg toxin assay <span class="r1">(</span><span class="r2">JAMA IM</span> <span class="r1">2015;175;1792)</span></p>
<p class="noindent1">• Obtain CT abdomen/pelvis if suspect complication (toxic megacolon). Consider flex sig if dx uncertain and/or evidence of no improvement on standard Rx.</p>
<p class="h">Initial treatment <span class="r1">(</span><span class="r2">CID</span> <span class="r1">2021;73:5;</span> <span class="r2">Am J Gastro</span> <span class="r1">2021;116:1124)</span></p>
<p class="noindent1">• If possible, d/c abx ASAP; stop antimotility agents &amp; cholestyramine if using (binds vanco)</p>
<p class="noindent1">• Fidaxomicin is now preferred over vancomycin regardless of severity; may be limited by $</p>
<p class="noindent1">• <b class="calibre7">Mild-mod:</b> fidaxomicin 200 mg BID (↓ recurrence rate) or vanco 125 mg PO q6h × 10 d</p>
<p class="noindent1">• <b class="calibre7">Severe</b> (any of the following: &gt;12 BM/d, Temp &gt;103°F, WBC &gt;15, HoTN, ICU care required, ileus): as above; could consider PO+PR vanco</p>
<p class="noindent1">• <b class="calibre7">Fulminant disease</b>: vanco 500 mg PO qid + MNZ 500 mg IV q8h; consider FMT</p>
<p class="noindent1">• If <b class="calibre7">worsening</b> (ileus, ↑ WBC, ↑ lactate, shock, toxic megacolon, peritonitis): abd CT &amp; urgent surgical consult - subtotal colectomy, diverting loop ileostomy or colonic lavage</p>
<p class="noindent1">• If need to cont abx, cont <i class="calibre6">C. diff.</i> Rx for ≥7 d post-abx cessation <span class="r1">(</span><span class="r2">Am J Gastro</span> <span class="r1">2016;111:1834)</span></p>
<p class="noindent1">• Stool carriage 3–6 wk postcessation; retesting for <i class="calibre6">C. diff</i> of limited utility during this time</p>
<p class="h">Recurrent infection <span class="r">(15–30% risk after d/c of abx, most w/in 2 wk of stopping abx)</span></p>
<p class="noindent1">• 1<sup class="calibre19">st</sup> recurrence: fidaxomicin 200 mg PO bid × 10 d or vanco 125 mg PO q6h × 10–14 d. Consider adding bezlotoxumab 10 mg/kg IV × 1 during abx Rx (mAb that binds toxin B) as ↓ recurrence; caution in CHF <span class="r1">(</span><span class="r2">NEJM</span> <span class="r1">2017;376:305)</span>.</p>
<p class="noindent1">• Subsequent recurrences: fidaxomicin or vanco PO pulse → taper. Consult ID. Fecal microbial transplant <span class="r1">(</span><span class="r2">JAMA</span> <span class="r1">2017;318:1985)</span> recommended after 3 CDI.</p>
<p class="noindent1">• Prevention: vanco 125 mg PO QD ↓ risk of recurrence <span class="r1">(</span><span class="r2">CID</span> <span class="r1">2016;65:651)</span>; consider for Pts needing abx w/ h/o severe or recurrent CDI. Avoid acid suppression/abx as able.</p>
<p class="h1cr">C<small class="calibre31">HRONIC</small> D<small class="calibre31">IARRHEA</small> <span class="r5">(&gt;4 wk)</span></p>
<p class="h">General evaluation <span class="r1">(</span><span class="r2">JAMA</span> <span class="r1">2016;315:2712;</span> <span class="r2">Gastro</span> <span class="r1">2019;157:3)</span></p>
<p class="noindent1">• Clinically can be classified as <i class="calibre6">watery</i>, <i class="calibre6">fatty</i>, <i class="calibre6">inflammatory</i></p>
<p class="noindent1">• Additional hx: timing (freq, relation to meals; <i class="calibre6">nocturnal diarrhea</i> a/w organic causes like IBD rather than IBS), abd pain, wt loss, prior surg, chemo/XRT, diet (incl caffeine or poorly absorbed carbs/sugars), infectious sxs, immunocompromise, travel, laxative use, stress</p>
<p class="noindent1">• Hx offending meds: PPI, colchicine, abx, H2RA, SSRIs, ARBs, NSAIDs, chemo, caffeine</p>
<p class="noindent1">• PEx: gen appearance (BMI), signs of systemic disease, surgical scars, rectal tone/DRE</p>
<p class="noindent1">• Lab testing: CBC, metabolic profile, alb, TSH, Fe, fecal calpro; <i class="calibre6">see under each category</i></p>
<p class="noindent1">• Imaging/endoscopy: colonoscopy for chronic diarrhea of unknown cause. Abd CT/MRI usually warranted if systemic problem suspected.</p>
<p class="h">Osmotic <span class="r">(watery; ⊖ fecal fat,</span> ↑<span class="r"> osmotic gap,</span> ↓<span class="r"> diarrhea w/ fasting)</span></p>
<p class="noindent1">• Caused by ingestion of poorly absorbed cations/anions (Mg, sulfate, phos; found in laxatives) or poorly absorbed carbs (eg, mannitol, sorbitol [found in chewing gum]) or lactose if lactose intolerant. <i class="calibre6">Diarrhea resolves w/ cessation of offending substance.</i></p>
<p class="noindent1">• Dx: ↑<b class="calibre7"> stool osmotic gap</b> (see Figure); stool pH &lt;6 if unabsorbed carbohydrates</p>
<p class="noindent1">• <b class="calibre7">Lactose intolerance</b>: can be acquired after gastroenteritis, med illness, GI surg. Clin: bloating, flatulence, discomfort, diarrhea. Dx: H<sup class="calibre19">+</sup> breath test or empiric lactose-free diet. Rx: lactose-free diet &amp; lactase tablets.</p>
<p class="h">Secretory <span class="r">(watery; nl osmotic gap, no</span> Δ<span class="r"> diarrhea w/ fasting, nocturnal, cramps)</span></p>
<p class="noindent1">• Caused by secretion of anions or K+ into lumen or inhib of Na absorption → ↑ H<sub class="calibre10">2</sub>O in stool. Most commonly caused by bacterial toxins from <b class="calibre7">infxn</b> (see above). Other causes:</p>
<p class="noindent1"><a id="page_3-7" class="calibre4"></a>• <b class="calibre7">Endocrine:</b> Addison’s, VIPoma, carcinoid, Zollinger-Ellison, mastocytosis, hyperthyroid (↑ motility). ✓ serum peptide levels (eg, gastrin, calcitonin, VIP) &amp; urinary histamine.</p>
<p class="noindent1">• <b class="calibre7">GI neoplasm:</b> carcinoma, lymphoma, villous adenoma</p>
<p class="noindent1">• <b class="calibre7">Microscopic colitis:</b> common cause of chronic diarrhea w/ obscure origin. Often seen in middle-aged women w/ autoimmune disorders. NSAIDs, SSRIs, PPIs notable triggers. Grossly normal on colo but bx shows lymphocytic &amp; plasmacytic infiltration of mucosa ± thickened submucosal collagen. Rx: budesonide (1<sup class="calibre19">st</sup> line), antidiarrheals, cholestyramine, bismuth; consider anti-TNFs if refractory <span class="r1">(</span><span class="r2">Gastro</span> <span class="r1">2016;150:242)</span>.</p>
<p class="noindent1">• <b class="calibre7">Bile acid-induced diarrhea:</b> ileal resection or disease (eg, Crohn’s) → bile acids in colon → electrolyte &amp; H<sub class="calibre10">2</sub>O secretion. Rx w/ empiric bile-acid binders (eg, cholestyramine).</p>
<p class="h">Functional/IBS <span class="r">(normal osmotic gap,</span> ↓<span class="r"> diarrhea with fasting): see “Dysmotility”</span></p>
<p class="h">Malabsorption <span class="r">(fatty;</span> ↑<span class="r"> fecal fat,</span> ↑<span class="r"> osmotic gap,</span> ↓<span class="r"> diarrhea w/ fasting)</span></p>
<p class="noindent1">• Defective mucosal absorption of nutrients b/c Δs in: mucosal surface (surgical resection) or gen. mucosal dis. (celiac, IBD). Bloating, foul-smelling, floating stools (steatorrhea).</p>
<p class="noindent1">• <b class="calibre7">Celiac disease</b> <span class="r1">(</span><span class="r2">JAMA</span> <span class="r1">2017;318:647;</span> <span class="r2">Lancet</span><span class="r1"> 2018;391:70;</span> <span class="r2">Gastro</span><span class="r1"> 2019;156:4)</span></p>
<p class="noindent2">Immune rxn in genetically predisposed Pts (~1% pop) to gliadin, a component of gluten (wheat protein) → small bowel inflammatory infiltrate → impaired absorption</p>
<p class="noindent2">Other s/s: Fe/folate/B<sub class="calibre10">12</sub> defic anemia; osteoporosis; dermatitis herpetiformis; ↑ ALT/AST</p>
<p class="noindent2">Dx: best if eating gluten when tested; IgA anti-tissue transglutaminase Ab (most Se), IgA anti-deaminated gliadin peptide Ab; IgA α-endomysial Ab. Duodenal bx confirms dx (blunted villi, crypt hyperplasia, inflamm infiltrate); absence of HLA-DQ2/8 excludes dx.</p>
<p class="noindent2">Rx: gluten-free diet; 7–30% do not respond to diet → ? wrong dx or noncompliant</p>
<p class="noindent2">Complic: ~5% refractory sx, risk of T-cell lymphoma and small bowel adenocarcinoma</p>
<p class="noindent1">• <b class="calibre7">Whipple’s disease:</b> infxn w/ <i class="calibre6">T. whipplei</i> <span class="r1">(</span><span class="r2">Lancet</span> <span class="r1">2016;16:13)</span></p>
<p class="noindent2">Other s/s: fever, LAN, edema, arthritis, CNS Δs, gray-brown skin pigmentation, AI &amp; MS, oculomasticatory myorhythmia (eye oscillations + mastication muscle contract).</p>
<p class="noindent2">Dx: bx/path, IHC, PCR. Rx: PCN + streptomycin or 3<sup class="calibre19">rd</sup>-gen ceph × 10–14 d → Bactrim ≥1 y.</p>
<p class="noindent1">• <b class="calibre7">Small intestinal bacterial overgrowth</b> (SIBO): colonic bacteria in SI → steatorrhea, B12/Fe defic, protein-losing enteropathy. A/w dysmotility (DM neuropathy, scleroderma), Δ’d anatomy (Crohn’s, surgery, fistulae), immune deficiency, celiac, CF. Dx w/ H<sup class="calibre19">+</sup> or <sup class="calibre19">14</sup>C -xylose breath testing or empiric abx. Rx w/ 7–10 d abx (rifaximin, MNZ, or FQ).</p>
<p class="noindent1">• Other: s/p short bowel resection (short bowel syndrome), chronic mesenteric ischemia, eosinophilic gastroenteritis, intestinal lymphoma, tropical sprue, <i class="calibre6">Giardia</i> infection</p>
<p class="h">Maldigestion <span class="r">(fatty;</span> ↑<span class="r"> fecal fat,</span> ↑<span class="r"> osmotic gap,</span> ↓<span class="r"> diarrhea w/ fasting)</span></p>
<p class="noindent1">• Defective intraluminal hydrolysis of nutrients, typ. 2/2 pancreatic/hepatobiliary pathology</p>
<p class="noindent1">• <b class="calibre7">Pancreatic insufficiency:</b> most commonly from chronic pancreatitis or pancreatic cancer. Test w/ stool elastase, chymotrypsin levels, fecal fat, or empiric pancreatic enzyme Rx.</p>
<p class="noindent1">• ↓ <b class="calibre7">bile acids</b> due to ↓ synthesis (cirrhosis), cholestasis (PBC), or s/p ileal resection. Test w/ empiric bile acid replacement therapy.</p>
<p class="h">Inflammatory <span class="r">(⊕ fecal WBC, calprotectin, lactoferrin; ⊕ FOB; fever, abd pain)</span></p>
<p class="noindent1">• <b class="calibre7">Infections:</b> chronic <i class="calibre6">C. diff</i>, <i class="calibre6">Entamoeba histolytica</i>, <i class="calibre6">Yersinia</i>, CMV, TB especially in immunocompromised hosts. CMV, <i class="calibre6">C. diff</i> notorious for causing exacerbations of IBD.</p>
<p class="noindent1">• <b class="calibre7">Inflammatory bowel disease</b> (Crohn’s, UC); fecal calprotectin helpful for ruling out IBD</p>
<p class="noindent1">• Radiation enteritis, ischemic colitis, neoplasia (colon cancer, lymphoma)</p>
<div class="cap">
<p class="caption"><a id="fig3-2" class="calibre4"></a><b class="calibre7">Figure 3-2</b> Workup of chronic diarrhea</p>
<p class="imagef1"><img src="../images/00052.jpeg" alt="" class="calibre5"/></p>
</div>
<h2 class="ct"><a id="h43" class="calibre8"></a><a id="page_3-8" class="calibre8"></a><a href="part0003.html#rh49" class="calibre8">DYSMOTILITY &amp; NUTRITION</a></h2>
<p class="h">Functional GI disease <span class="r">(~30 types per Rome IV criteria;</span> <span class="r2">Gastro</span><span class="r1"> 2016;150:1257</span><span class="r">)</span></p>
<p class="noindent1">• Recurrent GI sx caused by disorders of gut-brain interaction rather than structural cause</p>
<p class="noindent1">• <b class="calibre7">Irritable bowel syndrome (IBS)</b> <span class="r1">(</span><span class="r2">JAMA</span> <span class="r1">2015;313:949;</span> <span class="r2">Gastro</span><span class="r1"> 2015;149:1399 &amp; 2018;154:1140)</span></p>
<p class="noindent2">Abd discomfort for 6+ mos a/w ≥2: improves w/ defecation, Δ stool frequency, Δ stool form</p>
<p class="noindent2"><b class="calibre7">IBS-C</b> (constipation predominant) vs. <b class="calibre7">IBS-D</b> (diarrhea predominant) vs. IBS-M (mixed) vs. IBS-U (unclassified). Sx may be affected by stress, diet, lifestyle, probably microbiome.</p>
<p class="noindent2"><b class="calibre7">Treatment:</b> cog. behavior Rx, probiotics, anti-spasmodics, exercise, neuromodulators (eg, TCA, SSRI), Δ diet (↓ fermentable carbs w/ low FODMAP diet, lactose-free diet)</p>
<p class="noindent2">IBS-C: ↑ fiber, laxatives (lubiprostone, linaclotide, tegaserod, tenapanor), biofeedback</p>
<p class="noindent2">IBS-D: loperamide, rifaximin, eluxadoline, bile acid sequestrants, alosetron</p>
<p class="noindent1">• <b class="calibre7">Cyclic vomiting syndrome (CVS):</b> acute recurrent vomiting; a/w marijuana use, personal or FHx of migraine. Acute Rx: antiemetics, IVF, sumatriptan (1<sup class="calibre19">st</sup> line, followed by aprepitant x 3 d), BDZs; prevention: TCAs/AEDs; avoid marijuana.</p>
<p class="h">Gastroparesis <span class="r1">(</span><span class="r2">Nat Rev Dis Primers</span> <span class="r1">2018;4:41)</span></p>
<p class="noindent1">• Delayed gastric emptying w/o mechanical obstruction, typically p/w nausea (&gt;90%), vomiting (&gt;80%), early satiety (60%), postprandial fullness/pain</p>
<p class="noindent1">• Etiol: DM, post-surg, post-viral, crit. illness, Parkinson’s, opiates, CCB, anti-cholin, idiopath</p>
<p class="noindent1">• Dx: r/o mechanical cause then gastric emptying scintigraphy; (⊕ if retained solids &gt;4 h)</p>
<p class="noindent1">• Treatment: prokinetics (metoclopramide or erythromycin), antiemetics for sx; feeding tube if refractory; consider pyloromyotomy, botox injection, pyloroplasty, or gastric stimulator</p>
<p class="h">Paralytic ileus of the colon &amp; small bowel <span class="r1">(</span><span class="r2">Dis Colon Rectum</span> <span class="r1">2021;64:1046)</span></p>
<p class="noindent1">• Definition: loss of intestinal peristalsis in absence of mechanical obstruction</p>
<p class="noindent1">• Abd discomfort &amp; distention, ↓ or absent bowel sounds, ± N/V, hiccups</p>
<p class="noindent1">• Typically in elderly, hospitalized, ill Pts; precipitated by: intra-abd process (surgery, pancreatitis, peritonitis, intestinal ischemia), severe illness (eg, sepsis), meds (opiates, CCB, anticholin.), metab/endo abnl (thyroid, DM, kidney failure, liver failure, hypoK), spinal cord compression/trauma, neurologic d/o (Parkinson’s, Alzheimer’s, MS)</p>
<p class="noindent1">• KUB/CT w/ colonic dilatation (in ileus, dilated loops of SB) w/o mech obstruction; cecal diam &gt;12 cm a/w high-risk perf in Ogilvie’s syndrome (colonic pseudo-obstruction)</p>
<p class="noindent1">• <b class="calibre7">Treatment:</b> NPO, avoid offending meds, IV <b class="calibre7">neostigmine</b> (monitor for bradycardia), methylnaltrexone; bowel decompression w/ NGT, rectal tube, nutrition support. Ogilvie’s only: colonoscopic decompression; if refractory, colostomy or colectomy.</p>
<p class="h">Constipation <span class="r1">(</span><span class="r2">Annals</span> <span class="r1">2015;162:ITC1,</span> <span class="r2">Nat Rev Dis Primers</span> <span class="r1">2017;3:17095;</span> <span class="r2">JAMA</span> <span class="r1">2019;322:2239)</span></p>
<p class="noindent1">• Defined as dissatisfaction w/ defecation or (per Rome IV): ≥2 of following during last 3–6 mos ≥25% of the time: straining, lumpy/hard stools, incomplete evacuation, sensation of anorectal obstruction, manual maneuvers to facilitate defecation, stool frequency &lt;3/wk</p>
<p class="noindent1">• <b class="calibre7">Primary etiologies:</b> slow transit vs. pelvic floor dyssynergia</p>
<p class="noindent1">• <b class="calibre7">Secondary etiologies</b> (4 Ms; <span class="r2">JAMA</span><span class="r1"> 2016:315:185</span>)</p>
<p class="noindent2">Mech obstruction: malignancy, compression, rectocele, strictures</p>
<p class="noindent2">Meds: opioids, TCAs, anticholinergics, CCB, NSAIDs, diuretics, Ca<sup class="calibre19">2+</sup>, Fe, low fiber diet</p>
<p class="noindent2">Metabolic/endo: DM, hypothyroid, uremia, preg, panhypopit, porphyria, ↑ Ca, ↓ K, ↓ Mg</p>
<p class="noindent2">Myopathy/Neuro: Parkinson’s, Hirschsprung’s, amyloid, MS, spinal injury, dysautonomia</p>
<p class="noindent1">• <b class="calibre7">Dx:</b> H&amp;P w/ DRE. Labs: consider CBC, electrolytes w/ Ca, TSH. Colonoscopy if alarm sx. Anorectal manometry/balloon expulsion test; colonic transit study; defecography.</p>
<p class="noindent1">• <b class="calibre7">Treatment:</b> <i class="calibre6">1<sup class="calibre19">st</sup> line:</i> ↑ fluid, fiber, &amp; exercise; emollient laxative (docusate) to soften stool.</p>
<p class="noindent2"><i class="calibre6">2<sup class="calibre19">nd</sup> line:</i> Bulk laxatives (psyllium, methylcellulose) to ↑ colonic residue, ↑ peristalsis. Stimulant laxatives (senna, castor oil, bisacodyl) to ↑ motility &amp; secretion. Osmotic laxatives (Mg, NaPO<sub class="calibre10">4</sub> [avoid in CKD], PEG) to ↑ H<sub class="calibre10">2</sub>O in colon.</p>
<p class="noindent2"><i class="calibre6">3<sup class="calibre19">rd</sup> line:</i> Enema/suppository (phosphate, mineral oil, tap water, soapsuds, bisacodyl)</p>
<p class="noindent2">After above failed: linaclotide ↑ stool freq, ↓ straining/bloating <span class="r1">(</span><span class="r2">Am J Gastro</span> <span class="r1">2018;113:105)</span>.</p>
<p class="noindent2">Lubiprostone (↑ secretion); methylnaltrexone and alvimopan for opioid-induced.</p>
<p class="noindent2">Plecanitide (cGMP agonist) for chronic idiopathic constipation <span class="r1">(</span><span class="r2">Gastroenterol</span> <span class="r1">2016;150:S317)</span></p>
<p class="h">Nutrition in critical illness <span class="r">(also see “Mech Ventilation”)</span> <span class="r1">(</span><span class="r2">Crit Care</span> <span class="r1">2015;19:35)</span></p>
<p class="noindent1">• Enteral &amp; parenteral with similar clinical outcomes <span class="r1">(</span><span class="r2">Lancet</span> <span class="r1">2018;391:133)</span></p>
<p class="noindent1">• <b class="calibre7">Enteral</b> (EN): starting w/in 48 h of ICU admit may ↓ infection &amp; mortality. Contraindic. if bowel obstruction, major GIB, uncontrolled shock. Possible complic: ischemic bowel b/c ↑ demand for splanchnic blood, aspiration PNA, metabolic abnormality.</p>
<p class="noindent1">• <b class="calibre7">Parenteral</b> (PN): start after 7 d if unable to tolerate EN; no clear benefit to early initiation. Contraindic: hyperosmolality, severe electrolyte disturbances, severe hyperglycemia; sepsis is <i class="calibre6">relative</i> contraindication. Complications: hyperglycemia, sepsis (↑ risk of fungal infections), catheter-associated thrombus, refeeding syndrome, abnl LFTs (steatosis, cholestasis, gallbladder sludge due to lack of enteric stimulation).</p>
<h2 class="ct"><a id="h44" class="calibre8"></a><a id="page_3-9" class="calibre8"></a><a href="part0003.html#rh50" class="calibre8">DISORDERS OF THE COLON</a></h2>
<p class="h1cr">D<small class="calibre31">IVERTICULOSIS</small></p>
<p class="h">Definition &amp; pathophysiology <span class="r1">(</span><span class="r2">Aliment Pharm Ther</span> <span class="r1">2015;42:664)</span></p>
<p class="noindent1">• Acquired herniations of colonic mucosa &amp; submucosa in areas where vasa recta penetrate</p>
<p class="noindent1">• Abnormal motility and ↑ intraluminal pressure cause protrusion of colonic wall</p>
<p class="h">Epidemiology</p>
<p class="noindent1">• Risk factors: ↓ fiber, chronic constipation, obesity, smoking, physical inactivity, EtOH, NSAIDs, ↑ age (10% if &lt;40 y; 50–66% if &gt;80 y); ↑ red meat consumption</p>
<p class="noindent1">• <b class="calibre7">Left side</b> (90%, mostly sigmoid) &gt;R side of colon (except in Asia where 75–85% R-sided)</p>
<p class="h">Clinical manifestations</p>
<p class="noindent1">• Usually asx; 5–15% develop diverticular hemorrhage (see “GIB”) and 10–25% diverticulitis</p>
<p class="noindent1">• Limited data for ↑ fiber diet or avoiding nuts/seeds <span class="r1">(</span><span class="r2">Thera Adv Gastro</span> <span class="r1">2016;9:213)</span></p>
<p class="h1cr">D<small class="calibre31">IVERTICULITIS</small></p>
<p class="h">Pathophysiology <span class="r1">(</span><span class="r2">NEJM</span> <span class="r1">2007;357:2057;</span> <span class="r2">Gastro</span> <span class="r1">2015;149:1944)</span></p>
<p class="noindent1">• Retention of undigested food and bacteria in diverticulum → fecalith formation → obstruction → compromise of diverticulum’s blood supply, infection, microperforation</p>
<p class="noindent1">• <b class="calibre7">Uncomplicated</b> (75%): microperforation → localized infection, LLQ pain, fever, ↑ WBC</p>
<p class="noindent1">• <b class="calibre7">Complicated</b> (25%): macroperf → abscess, peritonitis, fistula (65% w/ bladder), obstrxn</p>
<p class="h">Clinical manifestations</p>
<p class="noindent1">• <b class="calibre7">LLQ abdominal pain</b>, <b class="calibre7">fever</b>, nausea, vomiting, constipation or diarrhea</p>
<p class="noindent1">• PEx ranges from LLQ tenderness ± palpable mass to peritoneal signs &amp; septic shock</p>
<p class="noindent1">• Ddx includes IBD, infectious colitis, PID, tubal pregnancy, cystitis, colorectal cancer</p>
<p class="h">Diagnostic studies</p>
<p class="noindent1">• <b class="calibre7">Abdominal CT</b> (I<sup class="calibre19">+</sup>O<sup class="calibre19">+</sup>): diverticula, bowel wall thickening, pericolic fat ± abscess, fistula</p>
<p class="noindent1">• Colonoscopy <i class="calibre6">contraindic.</i> acutely as ↑ risk of perforation; for Pts w/o colonoscopy in the past year, perform 6–8 wks after to r/o neoplasm</p>
<p class="h">Treatment <span class="r1">(</span><span class="r2">JAMA</span> <span class="r1">2017;318:291;</span> <span class="r2">NEJM</span> <span class="r1">2018;379:1635;</span> <span class="r2">Gastro</span> <span class="r1">2021;160:906)</span></p>
<p class="noindent1">• Mild: outPt Rx indicated if Pt has few comorbidities and can tolerate POs</p>
<p class="noindent2">PO abx: (MNZ + FQ) or amox/clav for 7 d; liquid diet until clinical improvement</p>
<p class="noindent2">No abx is noninferior to abx in uncomplicated diverti <span class="r1">(</span><span class="r2">Clin Gastroenterol Hepatol</span> <span class="r1">2021;19:503)</span></p>
<p class="noindent1">• Severe: inPt Rx if cannot take POs, narcotics needed for pain, or complications</p>
<p class="noindent2">NPO, IVF, NGT (if ileus); IV abx (GNR &amp; anaerobic coverage; eg, CTX/MNZ or pip-tazo)</p>
<p class="noindent1">• Abscesses &gt;4 cm should be drained percutaneously or surgically</p>
<p class="noindent1">• Surgery: if progression despite med Rx, undrainable abscess, free perforation</p>
<p class="noindent2">After source control, 4 d abx may be sufficient <span class="r1">(</span><span class="r2">NEJM</span> <span class="r1">2015;372:1996)</span></p>
<p class="noindent2">Resection for recurrent bouts of diverticulitis on a case-by-case basis</p>
<p class="noindent2">Consider lower threshold for urgent &amp; elective surgery for immunocompromised Pts</p>
<p class="h">Prevention <span class="r1">(</span><span class="r2">Gastro</span> <span class="r1">2021;160:906)</span></p>
<p class="noindent1">• Avoid smoking and NSAIDs; insufficient evidence to recommend mesalamine or rifaximin</p>
<p class="noindent1">• Risk of recurrence 10–30% w/in 10 y of 1<sup class="calibre19">st</sup> episode; nuts, seeds ∅ increase risk</p>
<p class="h1cr">P<small class="calibre31">OLYPS</small></p>
<p class="h">Pathophysiology &amp; epidemiology <span class="r1">(</span><span class="r2">NEJM</span><span class="r1"> 2016;374:1065)</span></p>
<p class="noindent1">• Accumulation of mutations in colonic epithelial cell DNA affecting oncogenes &amp; tumor suppressor genes → <i class="calibre6">tumor initiation</i> (formation of adenoma; <i class="calibre6">APC</i> loss of fxn) → <i class="calibre6">tumor progression</i> (adenoma → carcinoma; <i class="calibre6">K-ras</i> gain of fxn, <i class="calibre6">DCC, p53</i> loss of fxn)</p>
<p class="noindent1">• Risk factors: ↑ age, FHx (sporadic in 1° relatives, Lynch, FAP), IBD, ↑ dietary fat, central adiposity, ↑ EtOH, ↓ fiber, ↑ red meat, smoking, DM</p>
<p class="noindent1">• Protective factors: ↑ physical activity, ASA/NSAIDs, Ca<sup class="calibre19">2+</sup> intake, HRT, ↓ BMI; possibly ↑ fiber, vitamin D, fish oil, statins, selenium</p>
<p class="noindent1">• <b class="calibre7">Neoplastic polyps</b>: adenomas (tubular, villous, tubulovillous dysplasia), sessile serrated adenomas/polyps (concern for interval CRC), carcinomas</p>
<p class="noindent1">• <b class="calibre7">Non-neoplastic polyps</b>: hyperplastic, juvenile, Peutz-Jeghers (can undergo malignant transformation), inflammatory</p>
<p class="h">CRC screening <span class="r1">(</span><span class="r2">JAMA</span> <span class="r1">2021;325:1978)</span></p>
<p class="noindent1">• <i class="calibre6">Colonoscopy</i> gold standard. Other options: FOBT/FIT yearly, flex sig q5y or flex sig q10y + FIT every year, fecal DNA testing (eg, Cologuard) q3y or CT colonography q5y</p>
<p class="noindent1">• Start screening in average risk Pts at age 45 (typically q10y unless abnl found)</p>
<p class="noindent1">• If ⊕ FHx, start age 40, or 10 y before age of dx in youngest family member, repeat q5y</p>
<h2 class="ct"><a id="h45" class="calibre8"></a><a id="page_3-10" class="calibre8"></a><a href="part0003.html#rh51" class="calibre8">INFLAMMATORY BOWEL DISEASE</a></h2>
<p class="h">Definition <span class="r1">(</span><span class="r2">NEJM</span> <span class="r1">2020;383:2652)</span></p>
<p class="noindent1">• <b class="calibre7">Ulcerative colitis (UC):</b> inflammation of the colonic <i class="calibre6">mucosa; contiguous</i>, starting at rectum</p>
<p class="noindent1">• <b class="calibre7">Crohn’s disease (CD):</b> <i class="calibre6">transmural</i> inflammation anywhere along GI tract, <i class="calibre6">skip lesions</i></p>
<p class="h">Epidemiology &amp; pathophysiology <span class="r1">(</span><span class="r2">Lancet</span> <span class="r1">2016;387:156 &amp; 2017;390:2769)</span></p>
<p class="noindent1">• Age of onset 15–30 y; bimodal w/ 2<sup class="calibre19">nd</sup> peak at 50–70 y; 1:1 M:F in N America</p>
<p class="noindent1">• Genetic predisposition (↑ Caucasian/Jewish) + environmental risk factors (smoking ↑ risk for CD, defective mucosal barrier) → T cell dysregulation → inflammation</p>
<p class="h1cr">U<small class="calibre31">LCERATIVE</small> C<small class="calibre31">OLITIS</small> <span class="r3">(</span><span class="r4">Lancet</span> <span class="r3">2018;389:1756;</span> <span class="r4">Am J Gastro</span> <span class="r3">2019:114:384)</span></p>
<p class="h">Clinical manifestations</p>
<p class="noindent1">• <b class="calibre7">Grossly bloody diarrhea</b>, lower abdominal cramps, tenesmus, small, frequent BM</p>
<p class="noindent1">• Extracolonic (&gt;25%): erythema nodosum, pyoderma gangrenosum, aphthous ulcers, uveitis, episcleritis, thromboembolic events (esp. during a flare; <span class="r2">Lancet</span><span class="r1"> 2010;375:657</span>), AIHA, seroneg arthritis (most common), PSC (↑ risk cholangio CA, CRC)</p>
<p class="noindent1">• Several scores for severity assessment: Truelove &amp; Witts; Mayo Score/DAI; Montreal</p>
<p class="h">Diagnosis</p>
<p class="noindent1">• <b class="calibre7">Colonoscopy:</b> involves rectum (95%) &amp; extends prox., circumfer., &amp; <i class="calibre6">contig. w/in colon</i></p>
<p class="noindent1">• Location: proctitis (30–60%), L-sided (15–45%) and extensive (pancolitis; 15–35%)</p>
<p class="noindent1">• Appearance: vascularity loss, friable mucosa, diffuse ulceration, <i class="calibre6">pseudopolyps</i> (chronicity)</p>
<p class="noindent1">• Histology: superficial chronic inflammation; crypt abscesses &amp; architectural distortion</p>
<p class="noindent1">• Barium enema with featureless and tubular appearance of colon (<i class="calibre6">leadpipe appearance</i>)</p>
<p class="noindent1">• Flares: ↑ ESR &amp; CRP (not Se or Sp); ⊕ fecal calprotectin helpful in distinguishing IBD vs. IBS and monitoring for IBD flare <span class="r1">(</span><span class="r2">Gastro Hep</span> <span class="r1">2017;13:53)</span>; must rule out infection</p>
<p class="h">Complications</p>
<p class="noindent1">• <b class="calibre7">Toxic megacolon</b> (5%): colon dilatation (≥6 cm on KUB), colonic atony, systemic toxicity, &amp; ↑ risk of perf. Rx w/ IV steroids &amp; broad-spectrum abx; surgery if needed.</p>
<p class="noindent1">• Stricture (rectosigmoid), dysmotility, anorectal dysfxn after recurrent inflammation</p>
<p class="noindent1">• ↑ Risk of CRC and dysplasia (<i class="calibre6">see below</i>) after 8 years of active disease</p>
<p class="noindent1">• For Pts s/p surgery w/ ileal pouch, may develop <i class="calibre6">pouchitis</i> (inflammation of ileal pouch, up to ½ of Pts). Rx w/ abx (MNZ, cipro), probiotics.</p>
<p class="h">Prognosis</p>
<p class="noindent1">• 50% in remission at any given time. Intermittent exacerbations in 90%; continual active disease in ~18%. Prox progression in 25% at 10 y. Rate of colectomy at 10 y is 24%.</p>
<p class="noindent1">• Mortality rate of severe UC flare is &lt;2%, &amp; overall life expectancy in UC = non-UC Pts</p>
<p class="h1cr">C<small class="calibre31">ROHN’S</small> D<small class="calibre31">ISEASE</small> <span class="r3">(</span><span class="r4">Lancet</span> <span class="r3">2017;389:1741)</span></p>
<p class="h">Clinical manifestations <span class="r1">(</span><span class="r2">Nat Rev Gastro Hep</span> <span class="r1">2016;13:567)</span></p>
<p class="noindent1">• <b class="calibre7">Abdominal pain</b>, loose/frequent stools (up to 50% ⊕ FOBT), malaise, wt loss</p>
<p class="noindent1">• Mucus-containing, <b class="calibre7">often nonbloody diarrhea</b></p>
<p class="noindent1">• N/V, bloating, obstipation if presence of obstruction; extracolonic manifestations as in UC</p>
<p class="noindent1">• Several scoring systems: CD Activity Index (CDAI), Harvey-Bradshaw Index</p>
<p class="h">Diagnosis</p>
<p class="noindent1">• <b class="calibre7">Ileocolonoscopy</b> +<b class="calibre7"> bx along w/ small bowel assessment</b> (eg, MR-enterography)</p>
<p class="noindent1">• Small bowel/ileitis (~25%), ileocolonic (~50%), colonic (~25%); isolated upper tract rare</p>
<p class="noindent1">• Appearance: nonfriable mucosa, cobblestoning, aphthous ulcers, deep &amp; long <b class="calibre7">fissures</b></p>
<p class="noindent1">• Histology: <b class="calibre7">transmural inflammation</b> with mononuclear cell infiltrate, <b class="calibre7">noncaseating granulomas</b> (seen in &lt;25% of mucosal biopsies), fibrosis, ulcers, fissures, skip areas</p>
<p class="noindent1">• Montreal classification: age at dx, disease location &amp; behavior (stricturing vs. nonstricturing, penetrating vs. nonpenetrating), plus modifiers for upper tract &amp; perianal disease</p>
<p class="h">Complications</p>
<p class="noindent1">• <b class="calibre7">Perianal disease:</b> fissures, fistulas, skin tags, perirectal abscesses (in 24% of Pts; perianal disease <i class="calibre6">precedes</i> intestinal symptoms)</p>
<p class="noindent1">• <b class="calibre7">Stricture:</b> small bowel, postprandial abd pain; can lead to complete SBO &amp; require surgery</p>
<p class="noindent1">• <b class="calibre7">Fistulas:</b> perianal, enteroenteric, rectovaginal, enterovesicular, enterocutaneous</p>
<p class="noindent1">• <b class="calibre7">Abscess:</b> fever, tender abd mass, ↑ WBC; <i class="calibre6">steroids mask sx</i>, ∴ need high level of suspicion</p>
<p class="noindent1">• <b class="calibre7">Malabsorption:</b> ileal disease/resection: ↓ bile acids abs → gallstones; ↓ fatty acid abs → Ca oxalate kidney stones; ↓ fat-soluble vitamin abs → vit D deficiency → <i class="calibre6">osteopenia</i></p>
<p class="h">Prognosis</p>
<p class="noindent1">• Variable at 1 y: ~50% in remission, ~20% flare, ~20% low activity, ~10% chronic active</p>
<p class="noindent1">• At 20 y, majority will have required some surgery; overall life expectancy is slightly ↓</p>
<p class="h1cr"><a id="page_3-11" class="calibre8"></a>M<small class="calibre31">ANAGEMENT</small> <span class="r3">(</span><span class="r4">Lancet</span> <span class="r3">2017;398:1756;</span> <span class="r4">Mayo</span><span class="r3"> 2017;92:1088)</span></p>
<p class="h">Initial evaluation</p>
<p class="noindent1">• <b class="calibre7">H&amp;P</b> (✓ for intestinal &amp; extraintestinal manifestations) and <b class="calibre7">dx studies</b> as above</p>
<p class="noindent1">• <b class="calibre7">Lab:</b> consider CBC/diff, LFTs, iron studies, B12, folate, vit D, ESR, CRP, fecal calprotectin</p>
<p class="noindent1">• <b class="calibre7">Exclude other etiologies:</b> infectious (espec. TB), ischemic colitis, intestinal lymphoma, CRC, IBS, vasculitis, Behçet’s, celiac disease, small intestinal bacterial overgrowth</p>
<p class="noindent1">• <b class="calibre7">R/o infection</b> (esp. TB, HBV, CMV, O&amp;P) before treating with immunosuppressants and biologics (although not all acutely hospitalized Pts w/ IBD need infxn r/o prior to Rx)</p>
<p class="h">Goals of treatment <span class="r1">(</span><span class="r2">Ther Adv Gastro</span> <span class="r1">2015;8:143)</span></p>
<p class="noindent1">• Induce remission of acute flare → maintain remission; mucosal healing 1° goal</p>
<p class="noindent1">• Step-up Rx (least → most toxic) vs. top-down; (strongest → de-escalate) approach; consider early biologic if severe disease</p>
<table class="tabb">
<colgroup class="calibre11">
<col class="calibre23"/>
<col class="calibre35"/>
</colgroup>
<thead class="calibre14">
<tr class="calibre15">
<td class="th" colspan="2"><p class="tbodyc"><b class="calibre7">Medical Therapy for IBD</b> <span class="sm">(<i class="calibre6">NEJM</i> 2021;385:1302)</span></p></td>
</tr>
</thead>
<tbody class="calibre16">
<tr class="calibre15">
<td class="th1" colspan="2"><p class="tbodyc"><b class="calibre7"><i class="calibre6">Ulcerative Colitis</i></b> <span class="sm">(<i class="calibre6">Am J Gastrol</i> 2019:114:384)</span></p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbody"><b class="calibre7">Mild</b></p></td>
<td class="th1"><p class="tbody"><b class="calibre7">Rectal mesalamine</b> or <b class="calibre7">glucocorticoids</b> as suppository or enema</p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbody"><b class="calibre7">Mild- moderate</b></p></td>
<td class="th1"><p class="tbodyh"><b class="calibre7">Oral 5-ASA:</b> many formulations (sulfasalazine, mesalamine, olsalazine, balsalazide) depending on disease location. Used for induction &amp; maintenance of remission. Complications: pancreatitis, abd pain, diarrhea.</p>
<p class="tbodyh"><b class="calibre7">MMX-budesonide:</b> PO budesonide released throughout colon for flare. 1<sup class="calibre27">st</sup>-pass metab ↓ systemic steroid adverse effects of steroid.</p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbody"><b class="calibre7">Moderate- severe</b></p></td>
<td class="th1"><p class="tbodyh"><b class="calibre7">PO prednisone:</b> 40–60 mg w/ taper over several wks to induce remission</p>
<p class="tbodyh"><b class="calibre7">AZA/6-MP:</b> 0.5–1 mg/kg and uptitrate over several wks for maintenance</p>
<p class="tbodyh">Complications: BM suppression, lymphoma, pancreatitis, hepatitis</p>
<p class="tbodyh">✓ TPMT levels prior to dosing to ↓ risk of generation of toxic metabs.</p>
<p class="tbodyh">In selected cases, add allopurinol to boost activity in non-responders.</p>
<p class="tbodyh"><b class="calibre7">Anti-TNF:</b> ↑ remission rate when AZA combined w/ IFX <span class="sm">(<i class="calibre6">Gastro</i> 2014;146:392)</span></p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbody"><b class="calibre7">Severe or refractory disease</b></p>
<p class="tbody"><span class="sm">(<i class="calibre6">Lancet</i> 2017; 389:1218; <i class="calibre6">NEJM</i> 2016; 374:1754 &amp; 2017; 76:1723; <i class="calibre6">JAMA</i> 2019; 321:156)</span></p></td>
<td class="th1"><p class="tbodyh"><b class="calibre7">IV steroids:</b> 100 mg hydrocort q8h or 16–20 mg methylpred q8h to induce remission w/ plan to taper &amp; switch to non-steroid maintenance.</p>
<p class="tbodyh"><b class="calibre7">Cyclosporine:</b> for severe flares refractory to steroids, 2–4 mg/kg infusion × 7 d w/ goal to Δ to maintenance medication (eg, AZA/6-MP)</p>
<p class="tbodyh"><b class="calibre7">Anti-TNF</b> (infliximab, adalimumab &amp; golimumab): for steroid-refractory flares or to maintain remission. Complic: reactivation of TB (✓ PPD prior to Rx) or viral hepatitis; small ↑ risk NHL; lupus-like rxn, psoriasis, MS, CHF.</p>
<p class="tbodyh"><b class="calibre7">Alternative agents:</b> vedolizumab (α4β7 integrin inhibitor); tofacitinib (JAK inhibitor); ustekinumab (IL-12/23 inhibitor); ozanimod (sphinosine-1- phosphate receptor agonist)</p>
<p class="tbodyh"><i class="calibre6">Investigational:</i> fecal microbiota transplant; etrolizumab (α4β7 inhibitor)</p></td>
</tr>
<tr class="calibre15">
<td class="th1" colspan="2"><p class="tbodyc"><b class="calibre7"><i class="calibre6">Crohn’s Disease</i></b> <span class="sm">(<i class="calibre6">JAMA</i> 2021;325:69)</span></p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbody"><b class="calibre7">Mild</b></p></td>
<td class="th1"><p class="tbodyh"><b class="calibre7">Oral 5-ASA:</b> for colonic Crohn’s disease</p>
<p class="tbodyh"><b class="calibre7">Symptom control:</b> loperamide/cholestyramine for diarrhea management.</p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbody"><b class="calibre7">Mild-mod</b></p></td>
<td class="th1"><p class="tbodyh"><b class="calibre7">PO budesonide:</b> enteric-coated for ileal release (taper over 3 mos)</p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbody"><b class="calibre7">Moderate- severe</b></p></td>
<td class="th1"><p class="tbodyh"><b class="calibre7">PO prednisone:</b> same as UC, for inducing remission, not maintenance</p>
<p class="tbodyh"><b class="calibre7">AZA/6-MP:</b> same as UC; ↑ remission w/ AZA+IFX <span class="sm">(<i class="calibre6">NEJM</i> 2010;362:1383)</span></p>
<p class="tbodyh"><b class="calibre7">MTX:</b> 15–25 mg IM/SC or PO qwk for maintenance; 1–2 mo to take effect</p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbody"><b class="calibre7">Severe or refractory disease</b> <span class="sm">(<i class="calibre6">NEJM</i> 2016; 375:1946)</span></p></td>
<td class="th1"><p class="tbodyh"><b class="calibre7">IV steroids:</b> same as UC, for inducing remission, not maintenance</p>
<p class="tbodyh"><b class="calibre7">Anti-TNF:</b> infliximab, adalimumab or certolizumab (pegylated); consider combination therapy with AZA/6-MP</p>
<p class="tbodyh"><b class="calibre7">Alternative agents:</b> vedolizumab (α4β7 integrin inhibitor); ustekinumab (IL-12/23 inhibitor); natalizumab (α4 integrin inhibitor)</p>
<p class="tbodyh"><i class="calibre6">Investigational</i>: tofacitinib (JAK inhibitor); ozanimod (S-1-P receptor agonist)</p></td>
</tr>
</tbody>
</table>
<p class="h">Surgery</p>
<p class="noindent1">• <b class="calibre7">UC:</b> colectomy if sx refractory to or intolerable side effects from meds, CRC, perforation, toxic megacolon, uncontrolled hemorrhage. Often <i class="calibre6">ileal pouch-anal anastomosis</i> (IPAA).</p>
<p class="noindent1">• <b class="calibre7">CD:</b> resection if refractory; surgery for strictures; diverting ileostomy for perineal disease</p>
<p class="h">Cancer screening <span class="r1">(</span><span class="r2">NEJM</span> <span class="r1">2015;372:1441)</span></p>
<p class="noindent1">• <b class="calibre7">Colon cancer:</b> risk in UC ~2% at 10 y, ~8% at 20 y, ~18% at 30 y. Similar for pancolonic CD, plus risk of small bowel cancer as well. Dysplasia best marker for risk. Other risk factors include: PSC, ⊕ FHx, greater extent of disease, stricture, &amp; pseudopolyps.</p>
<p class="noindent1">• <b class="calibre7">Surveillance:</b> <i class="calibre6">colonoscopy</i> w/ random bx 8 y after dx to eval for dysplasia, q1–3y thereafter based on risk factors. <i class="calibre6">Chromoendoscopy</i> using dye to stain high-risk lesions for targeted bx may be preferable. If high-grade dysplasia or dysplasia-assoc. lesion/mass → colectomy.</p>
<h2 class="ct"><a id="h46" class="calibre8"></a><a id="page_3-12" class="calibre8"></a><a href="part0003.html#rh52" class="calibre8">INTESTINAL ISCHEMIA</a></h2>
<p class="h1cr">A<small class="calibre31">CUTE</small> M<small class="calibre31">ESENTERIC</small> I<small class="calibre31">SCHEMIA</small></p>
<p class="h">Definition and causes <span class="r1">(</span><span class="r2">NEJM</span> <span class="r1">2016;374:959)</span></p>
<p class="noindent1">• Reduced or absent blood flow to small intestine, typically caused by <i class="calibre6">arterial</i> (ie, SMA or its branches) occlusion or transient hypoperfusion or less often by <i class="calibre6">venous</i> occlusion</p>
<p class="noindent1">• <b class="calibre7">Arterial embolism</b> (~40–50%): embolic occlusion to SMA (has narrow take-off angle), often in setting of AF, valvular disease incl. endocarditis, atherosclerotic plaque in aorta</p>
<p class="noindent1">• <b class="calibre7">SMA thrombosis</b> (~20–30%): typically due to atherosclerosis at origin of SMA; other risk factors incl. vascular injury from abd trauma, infxn, or mesenteric dissections/aneurysms</p>
<p class="noindent1">• <b class="calibre7">Nonocclusive mesenteric ischemia</b> (~10%): transient intestinal hypoperfusion due to ↓ CO, athero, sepsis, drugs that ↓ gut perfusion (pressors, cocaine, amphetamines)</p>
<p class="noindent1">• <b class="calibre7">Mesenteric venous thrombosis</b> (MVT, ~5%): a/w hypercoag. states, portal hypertension, IBD, malignancy, inflammation (pancreatitis, peritonitis), pregnancy, trauma, surgery</p>
<p class="noindent1">• <b class="calibre7">Focal segmental ischemia of small bowel</b> (&lt;5%): vascular occlusion to small segments of small bowel (vasculitis, atheromatous emboli, strangulated hernias, XRT)</p>
<p class="h">Clinical manifestations</p>
<p class="noindent1">• Arterial occlusion: <b class="calibre7">sudden intense abd pain out of proportion to tenderness on exam</b></p>
<p class="noindent1">• Venous occlusion: <i class="calibre6">often more insidious in onset</i>, intermittent pain with peaks and valleys</p>
<p class="noindent1">• Nonocclusive: abd distention &amp; pain, n/v, <b class="calibre7">lower GI bleeding</b> due to mucosal sloughing; often occurring after episode of hypoperfusion (eg, cardiac event or shock)</p>
<p class="noindent1">• Exam ranges: unremarkable ± abd distention to peritoneal (infarction); ⊕ <b class="calibre7">FOBT ~75%</b></p>
<p class="h">Diagnostic studies</p>
<p class="noindent1">• Dx relies on high level of suspicion; rapid dx essential to avoid infarction (occurs w/in hrs)</p>
<p class="noindent1">• Mortality 20 to &gt;70% if bowel infarcted; dx prior to infarction strongest predictor of survival</p>
<p class="noindent1">• Laboratory: often nl; ~75% ↑ WBC; ↑ amylase, LDH, PO<sub class="calibre10">4</sub>, D-dimer; ~50% ↑ lactate (late)</p>
<p class="noindent1">• KUB: nl early before infarct; “thumbprinting,” ileus, pneumatosis in later stages</p>
<p class="noindent1">• <b class="calibre7">CT angiography</b> (arterial phase): noninvasive test of choice; <i class="calibre6">venous</i> phase for dx MVT</p>
<p class="noindent1">• <b class="calibre7">Angiography:</b> gold standard; potentially therapeutic; indicated if vasc occlusion suspected</p>
<p class="h">Treatment <span class="r1">(</span><span class="r2">NEJM</span> <span class="r1">2016;374:959;</span> <span class="r2">World J Emerg Surg</span> <span class="r1">2017;12:38)</span></p>
<p class="noindent1">• IVF, NPO,<b class="calibre7"> optimize hemodynamics</b> (minimize pressors), <b class="calibre7">broad-spectrum abx</b>, <b class="calibre7">anticoagulation</b> w/ heparin ± <b class="calibre7">tPA</b> (for occlusive disease), <b class="calibre7">IV papaverine</b> (vasodilator; for non-occlusive mesenteric ischemia)</p>
<p class="noindent1">• If evidence of peritonitis: to OR for surgical endovascular therapies &amp; bowel resection</p>
<p class="noindent1">• <b class="calibre7">SMA thrombosis:</b> percutaneous (stenting) or surgical revascularization</p>
<p class="noindent1">• <b class="calibre7">SMA embolism:</b> embolectomy (catheter-based aspiration vs. surgical)</p>
<p class="noindent1">• <b class="calibre7">Nonocclusive:</b> correct underlying cause (esp. cardiac)</p>
<p class="noindent1">• <b class="calibre7">Mesenteric venous thrombosis:</b> 3–6 mo anticoag after initial heparinization. Fibrinolysis or thrombectomy typically reserved for Pts w/ hemodynamic instability or refractory sx.</p>
<p class="noindent1">• <b class="calibre7">Focal segmental ischemia:</b> typically surgical resection</p>
<p class="h1cr">C<small class="calibre31">HRONIC</small> M<small class="calibre31">ESENTERIC</small> I<small class="calibre31">SCHEMIA</small></p>
<p class="noindent1">• Pathophysiology: ↓ blood flow to gut typically because of mesenteric atherosclerosis</p>
<p class="noindent1">• Sx: “intestinal angina” = <b class="calibre7">postprandial abd pain</b>, early satiety, &amp; ↓ wt due to fear of eating. If pain becomes constant → could represent acute thrombosis (see above).</p>
<p class="noindent1">• Dx: duplex U/S or CTA; angiography gold stnd; gastric tonometry exercise testing</p>
<p class="noindent1">• Treatment: surgical revascularization (1<sup class="calibre19">st</sup> line); angioplasty ± stenting; TPN for nutrition</p>
<p class="h1cr">I<small class="calibre31">SCHEMIC</small> C<small class="calibre31">OLITIS</small></p>
<p class="h">Definition &amp; pathophysiology</p>
<p class="noindent1">• Nonocclusive disease 2° to Δs in systemic circulation or anatomic/fxnal Δs in local mesenteric vasculature; often underlying etiology unknown, frequently seen in elderly</p>
<p class="noindent1">• “Watershed” areas (splenic flexure &amp; rectosigmoid) most susceptible; 25% involve R side; confers worse prognosis <span class="r1">(</span><span class="r2">Clin Gastroenterol Hepatol</span> <span class="r1">2015;13:1969)</span></p>
<p class="h">Clinical manifestations, diagnosis, &amp; treatment</p>
<p class="noindent1">• Usually p/w <b class="calibre7">cramping LLQ pain w/ overtly bloody stool;</b> fever and peritoneal signs should raise clinical suspicion for infarction</p>
<p class="noindent1">• Disease spectrum: reversible colopathy (35%), transient colitis (15%), chronic ulcerating colitis (20%), resulting stricture (10%), gangrene (15%), fulminant colitis (&lt;5%)</p>
<p class="noindent1">• Dx: <b class="calibre7">flex sig/colonoscopy</b> or <b class="calibre7">CT abd/pelvis</b> to make diagnosis; r/o IBD, infectious colitis</p>
<p class="noindent1">• Treatment: bowel rest, IV fluids, broad-spectrum abx, serial abd exams; <b class="calibre7">surgery</b> for infarction, fulminant colitis, hemorrhage, failure of med Rx, recurrent sepsis, stricture</p>
<p class="noindent1">• Resolution w/in 48 h w/ conservative measures occurs in &gt;50% of cases</p>
<h2 class="ct"><a id="h47" class="calibre8"></a><a id="page_3-13" class="calibre8"></a><a href="part0003.html#rh53" class="calibre8">PANCREATITIS</a></h2>
<p class="h1cr">A<small class="calibre31">CUTE</small> P<small class="calibre31">ANCREATITIS</small> <span class="r3">(</span><span class="r4">Lancet</span> <span class="r3">2020; 396:726;</span> <span class="r4">JAMA</span><span class="r3"> 2021;325:382)</span></p>
<p class="h">Pathogenesis</p>
<p class="noindent1">• Pancreatic duct and acinar injury via direct or indirect toxicity → impaired secretion and premature activation of digestive enzymes → autodigestion and acute inflammation</p>
<p class="h">Etiologies <span class="r1">(</span><span class="r2">JAMA</span> <span class="r1">2021;325:382)</span></p>
<p class="noindent1">• <b class="calibre7">Gallstones</b> (40%): ♀ &gt;♂; usually due to small stones (&lt;5 mm) or microlithiasis/sludge</p>
<p class="noindent1">• <b class="calibre7">Alcohol</b> (30%): ♂ &gt;♀; 4–5 drinks/day over ≥5 yrs; usually chronic w/ acute flares</p>
<p class="noindent1">• Metabolic: hypertrig. (2–5%; TG &gt;1000; type I &amp; V familial hyperlipemia); hyperCa</p>
<p class="noindent1">• Drugs (&lt;5%): 5-ASA, 6-MP/AZA, ACEI, cytosine, didanosine, dapsone, estrogen, furosemide, isoniazid, MNZ, pentamidine, statins, sulfa, thiazides, tetracycline, valproate</p>
<p class="noindent1">• Anatomic: divisum, annular pancreas, duodenal duplication cysts, Sphincter of Oddi dysfxn</p>
<p class="noindent1">• Autoimmune (vide infra)</p>
<p class="noindent1">• Familial: suspect if age &lt;20 y; (often a/w mutation in PRSS1, SPINK1 or CFTR gene)</p>
<p class="noindent1">• Infections: ascaris, clonorchis, coxsackie, CMV, EBV, HIV, mumps, mycoplasma, TB, toxo</p>
<p class="noindent1">• Ischemia: shock, vasculitis, cholesterol emboli</p>
<p class="noindent1">• Neoplastic: panc/ampullary tumors, mets (RCC most common, breast, lung, melanoma)</p>
<p class="noindent1">• Post ERCP (5%): Ppx w/ PR indomethacin can ↓ sx; temporary panc duct stent if high risk</p>
<p class="noindent1">• Trauma: blunt abdominal trauma, post-pancreatic/biliary surgery</p>
<p class="h">Clinical manifestations</p>
<p class="noindent1">• <b class="calibre7">Epigastric abdominal or LUQ pain (90%)</b>, only ½ w/ bandlike pain radiating to back</p>
<p class="noindent1">• 10% pain-free (due to analgesic/steroid use, immunosuppressed, ΔMS, ICU); ∴ ✓ lipase in unexplained shock, periumbilical or flank (Cullen or Grey Turner signs) bruising</p>
<p class="noindent1">• <b class="calibre7">N/V (90%),</b> abd tenderness/guarding, ↓ bowel sounds, jaundice if biliary obstruction</p>
<p class="noindent1">• Ddx: acute cholecystitis, perforated viscus, SBO, mesenteric ischemia, IMI, AAA leak, distal aortic dissection, ruptured ectopic pregnancy</p>
<p class="noindent1">• <b class="calibre7">Early phase</b> (&lt;1 wk): possible SIRS ± organ failure; <b class="calibre7">late</b> (&gt;1 wk): local complications (qv)</p>
<p class="h">Diagnostic studies <span class="r1">(</span><span class="r2">Am J Gastro</span> <span class="r1">2013;108:1400)</span></p>
<p class="noindent1">• <b class="calibre7">Dx requires 2 of 3:</b> characteristic abd pain; lipase or amylase &gt;3× ULN; ⊕ imaging</p>
<p class="noindent1">• Laboratory: levels of amylase &amp; lipase do <i class="calibre6">not</i> correlate w/ severity of disease</p>
<p class="noindent2">↑ <b class="calibre7">amylase</b>: rises w/in hrs, normalizes w/in 3–5 d (faster than lipase)</p>
<p class="noindent2">false ⊖: 20% EtOH pancreatitis; 50% hypertriglyceridemia (assay interference)</p>
<p class="noindent2">false ⊕: other abd or salivary gland process, acidemia, ↓ GFR, macroamylasemia</p>
<p class="noindent2">↑ <b class="calibre7">lipase</b>: longer t<sub class="calibre10">½</sub> than amylase</p>
<p class="noindent2">&gt;3× ULN 99% sensitive, 99% specific for acute pancreatitis</p>
<p class="noindent2">&gt;10k has 80% PPV for biliary dx, 99% NPV for EtOH <span class="r1">(</span><span class="r2">Dig Dis Sci</span> <span class="r1">2011;56:3376)</span></p>
<p class="noindent2">false ⊕: renal failure, other abd process, DKA, HIV, macrolipasemia</p>
<p class="noindent2">ALT &gt;3× ULN has 95% PPV for gallstone pancreatitis <span class="r1">(</span><span class="r2">Am J Gastro</span> <span class="r1">1994;89:1863)</span></p>
<p class="noindent1">• Imaging studies <span class="r1">(</span><span class="r2">Am J Gastro</span> <span class="r1">2013;108:1400)</span></p>
<p class="noindent2"><b class="calibre7">Abd U/S:</b> bowel gas often obscures pancreas visualization; however <i class="calibre6">should be ordered to r/o biliary etiology</i> (ie, gallstones, BD dilatation)</p>
<p class="noindent2"><b class="calibre7">Abd CT:</b> not rec for first 3 days (local complic. not yet visible &amp; concern for AKI w/ IV contrast). However, if persistent pain and/or clinical deterioration after 48–72 h, CT(I<sup class="calibre19">+</sup>) useful to r/o local complications (necrosis, fluid collections).</p>
<p class="noindent2"><b class="calibre7">MRI/MRCP</b>: Can detect necrosis, assess for stones &amp; ductal disruption earlier than CT</p>
<p class="noindent2"><b class="calibre7">Endoscopic U/S (EUS):</b> useful for occult biliary disease (microlithiasis)</p>
<p class="h">Severity <span class="r1">(</span><span class="r2">Gut</span> <span class="r1">2013;62:102;</span> <span class="r2">Gastro</span> <span class="r1">2018;154:1096)</span></p>
<p class="noindent1">• Severity defined by presence of organ failure (AKI, resp failure, GIB, shock) &amp; local or systemic complic. (panc necrosis, fluid collections, gastric outlet obstrxn, splenic &amp; PVT).</p>
<p class="noindent2"><b class="calibre7">Mild:</b> 80% of cases; no organ failure or local/systemic complications; low mortality</p>
<p class="noindent2"><b class="calibre7">Moderate:</b> transient (&lt;48 h) organ failure ± local/systemic complications, high morbidity</p>
<p class="noindent2"><b class="calibre7">Severe:</b> persistent (&gt;48 h) organ failure, very high mortality</p>
<p class="h">Prognosis <span class="r1">(</span><span class="r2">NEJM</span> <span class="r1">2016;375:1972)</span></p>
<p class="noindent1">• <b class="calibre7">Ranson’s, APACHE II:</b> predict severity at 48 h using multiple physiolog. criteria; poor PPV</p>
<p class="noindent1">• <b class="calibre7">BISAP:</b> simple 5-point scoring system (BUN &gt;25, impaired MS, SIRS, age &gt;60 y, pleural effusion) used w/in first 24 h; score ≥3 predicts ↑ risk of organ failure, mortality</p>
<p class="noindent1">• <b class="calibre7">CTSI:</b> CT data at 48–72 h (fluid collect., necrosis) to predict mortality; lags behind clinical sx</p>
<p class="h">Treatment <span class="r1">(</span><span class="r2">Am J Gastro</span> <span class="r1">2017;112:797;</span> <span class="r2">JAMA</span> <span class="r1">2020;323:2331)</span></p>
<p class="noindent1">• <b class="calibre7">Fluid resusc.:</b> <i class="calibre6">aggressive in 1<sup class="calibre19">st</sup> 24 hrs, even if mild.</i> 20 mL/kg IVB → 3 mL/kg/hr. Goal ↓ BUN &amp; Hct over 12–24 h. ✓ UOP (goal 0.5–1 cc/kg/hr); LR superior to NS (↓ SIRS; avoid if ↑ Ca).</p>
<p class="noindent1"><a id="page_3-14" class="calibre4"></a>• <b class="calibre7">Nutrition</b> <span class="r1">(</span><span class="r2">NEJM</span> <span class="r1">2014;317:1983)</span></p>
<p class="noindent2">Early enteral feeding encouraged, though not superior to oral feeding at 72 h</p>
<p class="noindent2">Mild: Start feeding once without N/V or ileus; may not need to be completely pain free. Low-fat low-residue diet as safe as liquid diet and a/w shorter LOS.</p>
<p class="noindent2">Severe: early (w/in 48–72 h) enteral nutrition indicated and preferred over TPN b/c ↓ infectious complications. Nasogastric non-inferior to nasojejunal feeding.</p>
<p class="noindent1">• <b class="calibre7">Analgesia:</b> IV opioids (monitor respiratory status, adjust dosing if ↑ renal impairment)</p>
<p class="noindent1">• <b class="calibre7">Gallstone pancreatitis:</b> urgent (w/in 24 h) ERCP w/ sphincterotomy if cholangitis, sepsis, or Tbili ≥5. If mild, CCY during initial hosp. to ↓ risk of recurrence <span class="r1">(</span><span class="r2">Lancet</span> <span class="r1">2015;386:1261)</span>; defer surgery if necrotizing panc. until improvement in inflam. &amp; fluid collections.</p>
<p class="noindent1">• <b class="calibre7">Hypertriglyceridemia:</b> insulin gtt (activates lipoprotein lipase), fibrates, ± apheresis</p>
<p class="noindent1">• No role for Ppx abx in absence of infectious complications <span class="r1">(</span><span class="r2">World J Gastro</span> <span class="r1">2012;18:279)</span></p>
<p class="h">Complications</p>
<p class="noindent1">• Systemic: ARDS, abdominal compartment syndrome, AKI, GIB (pseudoaneurysm), DIC</p>
<p class="noindent1">• Metabolic: hypocalcemia, hyperglycemia, hypertriglyceridemia</p>
<p class="noindent1">• Fluid collections:</p>
<p class="noindent2"><b class="calibre7">Acute fluid collection:</b> seen early; not encapsulated; asymptomatic; resolve in 1–2 wk</p>
<p class="noindent2"><b class="calibre7">Pseudocyst:</b> ~4 wk after initial attack, encapsulated. No need for Rx if asx (regardless of size/location). If sx → endoscopic <span class="r1">(</span><span class="r2">Gastro</span> <span class="r1">2013;145:583)</span> vs. perc/surg drainage.</p>
<p class="noindent1">• Pancreatic necrosis: Nonviable pancreatic tissue. CT-guided FNA if infection suspected.</p>
<p class="noindent2"><b class="calibre7">Sterile necrosis:</b> if asx, can be managed expectantly, no role for Ppx abx</p>
<p class="noindent2"><b class="calibre7">Infected necrosis</b>: most often GN gut organism; high mortality. Rx w/ carbapenem, pip/tazo, or [(3<sup class="calibre19">rd</sup> gen ceph or FQ) + MNZ]. If stable, defer drainage to &gt;4 wk to allow liquefication &amp; WOPN (qv). If sx or unstable, perc. drainage &amp; minimally invasive surgical debridement or endoscopic necrosectomy superior to open necrosectomy.</p>
<p class="noindent2"><b class="calibre7">WOPN</b> (walled off panc. nec.): fibrous wall surrounds necrosis over ≥4 wk; endoscopic or perc. drainage (preferred over open necrosectomy) if infected or symptomatic</p>
<p class="noindent1">• Peripancreatic vascular complications: pseudoaneurysm, abdominal compartment syndrome, <b class="calibre7">splanchnic venous thrombosis</b> (splenic vein most common site)</p>
<p class="h1cr">C<small class="calibre31">HRONIC</small> P<small class="calibre31">ANCREATITIS</small> <span class="r3">(</span><span class="r4">Lancet</span> <span class="r3">2020;396:499)</span></p>
<p class="h">Pathogenesis &amp; etiology <span class="r1">(</span><span class="r2">Gastro</span> <span class="r1">2013;144:1292;</span> <span class="r2">JAMA</span> <span class="r1">2019;322:2422)</span></p>
<p class="noindent1">• Often recurrent acute attacks → inflam infiltrate → fibrosis → loss of exocrine &amp; endocrine tissue. Pancreatic insufficiency (DM, fat/protein malabsorption) when 90% panc fxn lost.</p>
<p class="noindent1">• TIGAR-O: <b class="calibre7">T</b>oxins (60–80% due to EtOH; smoking), <b class="calibre7">I</b>diopathic, <b class="calibre7">G</b>enetic (PRSS1, SPINK1, CFTR, CTRC, CASR), <b class="calibre7">A</b>utoimmune, <b class="calibre7">R</b>ecurrent panc., <b class="calibre7">O</b>bstruction</p>
<p class="h">Clinical manifestations</p>
<p class="noindent1">• Epigastric pain, N/V; over time can be painless; signs of exocrine insuff (steatorrhea, wt loss) or endocrine insuff (DM: polydipsia, polyuria); 13× ↑ risk of pancreatic cancer</p>
<p class="h">Diagnostic studies <span class="r1">(</span><span class="r2">Pancreas</span> <span class="r1">2014;43:1143;</span> <span class="r2">Am J Gastro</span> <span class="r1">2020;115:322)</span></p>
<p class="noindent1">• Labs: amylase/lipase ↑ early, may be nl later. ⊕ fecal fat, ↓ stool elastase &amp; A1AT. Mixed TG breath test alternative to stool elastase. ✓A1c, consider IgG4/ANA &amp; genetic testing if young or ⊕ FHx. If dx w/ CP, measure baseline fat-soluble vitamins (ADEK).</p>
<p class="noindent1">• Imaging: Ca<sup class="calibre19">2+</sup> on KUB/CT. ERCP/MRCP/EUS: high sens for dx; may show stricture, dilated ducts. IV secretin stim w/ MRI may ↑ dx yield. Panc fxn testing not widely available.</p>
<p class="h">Treatment <span class="r1">(</span><span class="r2">JAMA</span> <span class="r1">2019;322:2422;</span> <span class="r2">Lancet</span> <span class="r1">2020;396:499)</span></p>
<p class="noindent1">• Pancreatic enzyme replacement (may ↓ pain by reducing CCK). Rx routine vitamin D &amp; Ca.</p>
<p class="noindent1">• Pain control: smoking &amp; EtOH cessation, analgesics (start with non-opioids; eg, pregabalin), endoscopy (stone removal or stenting strictures), celiac nerve plexus block, surgery</p>
<p class="h1cr">A<small class="calibre31">UTOIMMUNE</small> P<small class="calibre31">ANCREATITIS</small></p>
<p class="h">Pathogenesis <span class="r1">(</span><span class="r2">Am J Gastro</span> <span class="r1">2018;113:1301)</span></p>
<p class="noindent1">• Type 1: lymphoplasmacytic sclerosing panc. w/ dense fibrosis; ↑ IgG4; high relapse</p>
<p class="noindent1">• Type 2: idiopathic duct-centric pancreatitis; minimal ↑ IgG4; a/w IBD; fewer relapses</p>
<p class="h">Clinical manifestations</p>
<p class="noindent1">• <b class="calibre7">Abdominal pain</b>, can p/w obstructive jaundice and panc mass mimicking panc Ca</p>
<p class="noindent1">• Can be primary, or in a/w IgG4 cholangiopathy, salivary gland disease (eg, Sjögren’s), mediastinal or RP fibrosis, interstitial nephritis, autoimmune thyroiditis, UC/PSC, RA</p>
<p class="h">Diagnosis</p>
<p class="noindent1">• Labs: cholestatic LFTs (↑ Aϕ &gt;AST/ALT), ↑ γ-globulins and IgG4, ⊕ ANA, RF</p>
<p class="noindent1">• HISORt criteria: Histology, Imaging (“sausage pancreas,” bile duct stricture), Serology, other Organ involvement, Response to therapy</p>
<p class="h">Treatment</p>
<p class="noindent1">• Glucocorticoids 1<sup class="calibre19">st</sup>-line; immunomod. (AZA, MMF, cyclophosphamide, rituximab) if relapse</p>
<h2 class="ct"><a id="h48" class="calibre8"></a><a id="page_3-15" class="calibre8"></a><a href="part0003.html#rh54" class="calibre8">ABNORMAL LIVER TESTS</a></h2>
<p class="h">Tests of hepatocellular injury or cholestasis <span class="r1">(</span><span class="r2">J Clin Transl Hepatol</span> <span class="r1">2017;5:394)</span></p>
<p class="noindent1">• <b class="calibre7">Aminotransferases</b> (AST, ALT): intracellular enzymes released 2° necrosis/inflammation</p>
<p class="noindent2">ALT more specific for liver than is AST (heart, skeletal muscle, kidney, brain, RBC/WBC)</p>
<p class="noindent2">↑ levels seen w/ most types of hepatocellular injury; AST &gt;ALT → MSK injury, MI</p>
<p class="noindent1">• <b class="calibre7">Alkaline phosphatase</b> (Aϕ): enzyme bound in hepatic canalicular membrane ↑ levels seen w/ biliary obstrxn, intrahepatic cholestasis or infiltration of the liver also found in bone, intestines, kidney, placenta; confirm from liver w/: ↑ GGT (or ↑ 5′-NT)</p>
<p class="noindent1">• <b class="calibre7">Bilirubin:</b> product of heme metab (unconjugated, “indirect”) carried by alb to liver where taken up for conjugation (“direct”) to make soluble, then excreted into bile.</p>
<p class="noindent2">↑ indirect hyperbili seen with hemolysis, enzymatic disorders (eg, Crigler-Najjar, Gilbert’s)</p>
<p class="noindent2">↑ direct hyperbili seen with cholestasis, enzymatic disorders (eg, Dubin-Johnson, Rotor’s)</p>
<p class="noindent2">jaundice seen when bili &gt;2.5 mg/dL (esp. in sclera or under tongue); direct ↑ urine bili</p>
<p class="h">Tests of hepatic function</p>
<p class="noindent1">• <b class="calibre7">Albumin:</b> marker for liver protein synthesis, can help differentiate acute vs. chronic liver failure, may be normal in acute hepatocellular injury (t<sub class="calibre10">1/2</sub> ~15–18 d)</p>
<p class="noindent1">• <b class="calibre7">Prothrombin time</b> (PT): depends on synthesis of coag factors by liver (except FVIII); b/c t<sub class="calibre10">1/2</sub> of some factors (eg, V, VII) is short, ↑ PT can occur w/in hrs of liver dysfxn</p>
<p class="imaget"><img src="../images/00053.jpeg" alt="" class="calibre5"/></p>
<p class="noindent1">• <b class="calibre7">R-value</b> = ratio of ALT:Aϕ normalized to ULN for each = (ALT/ULN) ÷ (Aϕ/ULN)</p>
<p class="noindent2">R &gt;5 suggests hepatocellular injury, &lt;2 suggests cholestatic injury, 2–5 suggests mixed</p>
<p class="h">Acute mild-to-moderate elevation in ALT/AST <span class="r">(&lt;15× ULN)</span></p>
<p class="noindent1">• Assess risk of <b class="calibre7">EtOH/drug/toxin</b>: H&amp;P; in EtOH AST:ALT ratio &gt;2:1</p>
<p class="noindent1">• Obtain abdominal imaging to r/o cirrhosis, congestion, or biliary obstruction (mixed LFTs)</p>
<p class="noindent1">• Other infectious etiologies: tick borne illnesses, CMV/EBV, COVID-19, others</p>
<p class="noindent1">• Can be initial manifestation of chronic etiologies noted below</p>
<p class="h">Chronic mild-to-moderate elevation in ALT/AST <span class="r">(&lt;</span>1<span class="r">5× ULN)</span></p>
<p class="noindent1">• <b class="calibre7">Viral hepatitis</b>: ✓ HBsAg, anti-HBs, anti-HBc, anti-HCV, IgM anti-HAV</p>
<p class="noindent1">• <b class="calibre7">NAFLD</b>: consider BMI, ✓ lipid panel, Hb<sub class="calibre10">A1c</sub>, liver U/S or elastography</p>
<p class="noindent1">• Other etiologies of cirrhosis (qv)</p>
<p class="noindent2">Hemochromatosis: ✓ TIBC, serum iron, serum ferritin</p>
<p class="noindent2">Wilson disease: serum ceruloplasmin, urine Cu</p>
<p class="noindent2">α-1 antitrypsin (can cause liver disease w/o lung involvement)</p>
<p class="noindent1">• Chronic autoimmune hepatitis ✓ ANA, ASMA, anti-LKMA, IgG, SPEP</p>
<p class="noindent1">• TSH (both hypo &amp; hyperthyroidism associated with abnormal LFTs), celiac disease</p>
<p class="noindent1">• If workup negative, consider biopsy</p>
<p class="h">Acute severe elevation in ALT/AST <span class="r">(&gt;</span>1<span class="r">000)</span></p>
<p class="noindent1">• Massive elevations (&gt;5000) usually due to ischemic injury or drug-induced hepatitis</p>
<p class="noindent1">• <b class="calibre7">Ischemia</b>: hypotension, shock or severe HF (often &gt;50× ULN), Budd-Chiari: usually diagnosed based on clinical hx, U/S w/ Doppler; ratio ALT:LDH &lt;1.5 if ischemic because of concomitant ↑ LDH (vs. ratio &gt;1.5 w/ toxins, viruses)</p>
<p class="noindent1">• <b class="calibre7">Meds/toxins</b>: acetaminophen, meds (eg, INH, amio, nitrofuratonin), OTC/herbal, cocaine (nb, EtOH should not produce this degree of elevation). Obtain acet. level, tox screen.</p>
<p class="noindent1">• <b class="calibre7">Acute viral infection</b>: hepatitis A–E or reactivation of HBV, EBV/CMV</p>
<p class="noindent1">• Acute autoimmune hepatitis (qv): ✓ IgG, ANA, ASMA</p>
<p class="noindent1">• Acute biliary obstruction (often with sig drop in ALT/AST the next day, Aϕ takes longer to rise &amp; fall): start w/ liver U/S, if unrevealing obtain CT or MRCP</p>
<p class="noindent1">• Rhabdomyolysis and heat stroke</p>
<div class="cap">
<p class="caption"><a id="page_3-16" class="calibre4"></a><a id="fig3-3" class="calibre4"></a><b class="calibre7">Figure 3-3</b> Approach to abnormal liver tests with cholestatic pattern</p>
<p class="imagef1"><img src="../images/00054.jpeg" alt="" class="calibre5"/></p>
</div>
<div class="cap">
<p class="caption"><a id="fig3-4" class="calibre4"></a><b class="calibre7">Figure 3-4</b> Approach to abnormal liver tests with infiltrative pattern</p>
<p class="imagef1"><img src="../images/00055.jpeg" alt="" class="calibre5"/></p>
</div>
<p class="imaget"><img src="../images/00056.jpeg" alt="" class="calibre5"/></p>
<h2 class="ct"><a id="h49" class="calibre8"></a><a id="page_3-17" class="calibre8"></a><a href="part0003.html#rh55" class="calibre8">HEPATITIS</a></h2>
<p class="h1cr">V<small class="calibre31">IRAL</small></p>
<p class="h">Hepatitis A <span class="r">(ssRNA; 30–45% of acute viral hepatitis in U.S;</span> <span class="r2">MMWR</span><span class="r1"> 2018;67:1208</span><span class="r">)</span></p>
<p class="noindent1">• Transmission &amp; RFs: fecal–oral route; contam. food, water, shellfish; daycare ctr; intl travel</p>
<p class="noindent1">• Incubation: 2–6 wk; no chronic carrier state; once antibody forms → lifelong immunity</p>
<p class="noindent1">• Sx: ↓ appetite, malaise, fever, N/V, RUQ pain, jaundice; rarely ALF (↑ w/ chronic HCV)</p>
<p class="noindent1">• Diagnosis: acute hepatitis = ⊕ IgM anti-HAV; past exposure = ⊕ IgG anti-HAV (⊖IgM)</p>
<p class="noindent1">• Rx for acute HAV: supportive care; refer to liver txplnt center if acute liver failure</p>
<p class="noindent1">• Vaccinate if: MSM, IVDU, chronic liver disease, international travel; Havrix (2 doses)</p>
<p class="h">Hepatitis B <span class="r">(dsDNA; ~45% of acute viral hepatitis in U.S.;</span> <span class="r2">JAMA</span><span class="r1"> 2020;324:2452</span><span class="r">)</span></p>
<p class="noindent1">• Transmission: blood (IVDU, transfusion), sexual, perinatal (vertical)</p>
<p class="noindent1">• Incubation: 6 wk–6 mo (mean 12–14 wk)</p>
<p class="noindent1">• Acute infxn: 70% subclinical, 30% jaundice, &lt;1% acute liver failure (up to 60% mortality)</p>
<p class="noindent1">• Chronic infxn: HBsAg ⊕ &gt;6 mo in &lt;5% of adult-acquired (↑ if immunosupp), &gt;90% of perinatal; ~40% chronic HBV → cirrhosis (↑ risk w/ HCV, HDV, or HIV coinfxn, EtOH)</p>
<p class="noindent1">• HCC: ↑ risk if cirrhosis, ⊕ FHx HCC, African &gt;20 y old, Asian ♂ &gt;40 y old or ♀ &gt;50 y old, or &gt;40 y old w/ ↑ ALT ± HBV DNA &gt;2000. Screen w/ AFP &amp; U/S q6mo.</p>
<p class="noindent1">• Extrahepatic syndromes: PAN (&lt;1%), membranous nephropathy, MPGN, arthritis</p>
<p class="noindent1">• Serologic and virologic tests (screening guidelines: <span class="r2">Hepatology</span><span class="r1"> 2018:67:1560</span>)</p>
<p class="noindent2">HBsAg: appears before sx; used to screen blood donors; persists &gt;6 mo = chronic HBV</p>
<p class="noindent2">HBeAg: evidence of viral replication and ↑ infectivity</p>
<p class="noindent2">IgM anti-HBc: 1<sup class="calibre19">st</sup> Ab to appear; indicates acute infection window period = HBsAg becomes ⊖, anti-HBs not yet ⊕, anti-HBc only clue to infxn</p>
<p class="noindent2">IgG anti-HBc: indicates previous (HBsAg ⊖) or ongoing (HBsAg ⊕) HBV infection</p>
<p class="noindent2">anti-HBe: indicates waning viral replication, ↓ infectivity</p>
<p class="noindent2">anti-HBs: indicates resolution of acute disease &amp; immunity (sole marker after vaccination)</p>
<p class="noindent2">HBV DNA: presence in serum correlates w/ active viral replication in liver</p>
<p class="imaget"><img src="../images/00057.jpeg" alt="" class="calibre5"/></p>
<p class="tfn"><sup class="calibre22"><a id="rfn62-s1" class="calibre8"></a>*</sup>Precore mutant: HBeAg not made, but anti-HBe can develop due to x-reactivity w/ HBcAg; a/w ↑ HBV DNA</p>
<p class="noindent1">• <b class="calibre7">Treatment for acute HBV:</b> supportive; hospitalize for Δ MS or ↑ INR (liver transplant center); consider antiviral therapy if severe or protracted course</p>
<p class="imaget"><img src="../images/00058.jpeg" alt="" class="calibre5"/></p>
<p class="tfn"><sup class="calibre22"><a id="rfn62-s3" class="calibre8"></a>*</sup>ALT ULN &lt;35 U/L for ♂, &lt;25 U/L for ♀. Adapted from <i class="calibre6">Hepatology</i> 2018;67:1560</p>
<p class="noindent1">• <b class="calibre7">When to treat chronic HBV with anti-virals?</b> (1) immune active phase; (2) HBeAg ⊖ chronic hepatitis B; (3) cirrhosis w/ HBV DNA ≥2K; (4) decomp. cirrhosis due to hep B; (5) acute liver failure due to acute hepatitis B; (6) special pop: preg (3<sup class="calibre19">rd</sup> trimester w/ HBV DNA ≥200k), inactive carriers treated w/ immunosuppression, HCC, HCV co-infection</p>
<p class="noindent1">• <b class="calibre7">Entecavir</b> or <b class="calibre7">tenofovir:</b> nucleo(s/t)ide analogs, well tolerated, low resistance; at 5 y, HBeAg seroconversion is 30–40% &amp; loss of HBsAg is 5–10% <span class="r1">(</span><span class="r2">Lancet Gastro Hep</span> <span class="r1">2016;1:185)</span>. Tenofovir preferred if h/o lamivudine resistance; no known tenofovir resistance to date.</p>
<p class="noindent1"><a id="page_3-18" class="calibre4"></a>• Rx duration: (1) HBeAg ⊕ immune active w/o cirrhosis: if seroconversion (HBeAg ⊖, anti- HBe ⊕), can stop after 1 y if ALT nl &amp; HBV DNA suppressed or until HBsAg clears; (2) HBeAg ⊖ immune reactivation: indefinite; (3) cirrhosis: indefinite</p>
<p class="noindent1">• If undergo liver transplant: HBIG + nucleo(s/t)ide analogue effective in preventing reinfection</p>
<p class="noindent1">• HIV/HBV <i class="calibre6">coinfection:</i> Rx w/ 2 drugs active against both HBV &amp; HIV (<a href="https://aidsinfo.nih.gov" class="calibre4">https://aidsinfo.nih.gov</a>)</p>
<p class="noindent1">• Immunosuppression: prior to initiating chemoRx, anti-TNF, rituximab, steroids (&gt;20 mg/d &gt;1 mo), screen for HBV; Rx if mod-to-high risk of reactive (incl anti-HBs ⊕ getting rituximab)</p>
<p class="noindent1">• Postexposure (risk infxn ~30%) Ppx: HBIG → vaccine (if unvac or known nonresponder)</p>
<p class="h">Hepatitis C <span class="r">(ssRNA; ~</span>1<span class="r">0% of acute viral hepatitis in U.S.;</span> <span class="r2">Lancet</span><span class="r1"> 2015;385:1124</span><span class="r">)</span></p>
<p class="noindent1">• Transmission: blood (IVDU, transfusion before 1992) &gt;sexual; 20–30% w/o clear precipitant</p>
<p class="noindent1">• Incubation: 1–5 mo; mean 6–7 wk</p>
<p class="noindent1">• Acute infxn: 80% subclinical; 10–20% sx hepatitis w/ jaundice; acute liver failure rare; prob of spont clearance a/w <i class="calibre6">IL28B</i> &amp; HLA class II genotypes <span class="r1">(</span><span class="r2">Annals</span> <span class="r1">2013;158:235)</span></p>
<p class="noindent1">• Chronic: up to 85% → chronic hepatitis, 20–30% of whom develop cirrhosis (after ~20 y)</p>
<p class="noindent2">↑ risk of cirrhosis in men, EtOH, HIV; HCC in 1–4% of Pts w/ cirrhosis per year</p>
<p class="noindent1">• Extrahepatic syndromes: mixed cryoglobulinemia, porphyria cutanea tarda, lichen planus, leukocytoclastic vasculitis, thyroiditis, MPGN, IPF, NHL and monoclonal gammopathies</p>
<p class="noindent1">• Serologic, virologic, &amp; genetic tests (screen all adults [✓ anti-HCV] <span class="r2">JAMA</span><span class="r1"> 2020;323:970</span>)</p>
<p class="noindent2">anti-HCV (ELISA): ⊕ in 6 wk, does <i class="calibre6">not</i> = recovery or immunity; can be ⊖ after recovery</p>
<p class="noindent2">HCV RNA: ⊕ w/in 2 wk, marker of active infection</p>
<p class="noindent2">HCV genotype (1–6): guides duration &amp; predicts response to Rx; geno. 3 a/w ↑ risk HCC</p>
<p class="noindent1">• Dx: <i class="calibre6">acute</i> hepatitis = ⊕ HCV RNA, ± anti-HCV; <i class="calibre6">resolved</i> = ⊖ HCV RNA, ± anti-HCV; <i class="calibre6">chronic</i> = ⊕ HCV RNA, ⊕ anti-HCV</p>
<p class="noindent1">• Treatment indications (<span class="underline"><a href="http://www.hcvguidelines.org" class="calibre4">www.hcvguidelines.org</a></span>) <span class="r1">(</span><span class="r2">Lancet</span> <span class="r1">2019;393:1453;</span> <span class="r2">Hepatology</span><span class="r1"> 2020;71:686)</span></p>
<p class="noindent2">Acute: if no spont. clearance at 12–16 wk, can Rx w/ same regimens for chronic HCV</p>
<p class="noindent2">Chronic: ↓ HCC &amp; mortality. Recommended for all except if ↓ life expectancy.</p>
<table class="tabb">
<colgroup class="calibre11">
<col class="calibre23"/>
<col class="calibre35"/>
</colgroup>
<thead class="calibre14">
<tr class="calibre15">
<td class="th" colspan="2"><p class="tbodyc"><b class="calibre7">Recommended First-Line Oral Direct-Acting Antiviral (DAA) Regimens</b></p></td>
</tr>
</thead>
<tbody class="calibre16">
<tr class="calibre15">
<td class="th1"><p class="tbody"><b class="calibre7">Regimen (simplified)</b></p></td>
<td class="th1"><p class="tbody"><b class="calibre7">Indication</b></p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbody">Sofosbuvir &amp; velpatasvir</p></td>
<td class="th1"><p class="tbody">Genotypes 1–6, 12 weeks Rx</p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbody">Glecaprevir &amp; pibrentasvir</p></td>
<td class="th1"><p class="tbody">Gentotypes 1–6; 8 weeks Rx</p></td>
</tr>
<tr class="calibre15">
<td class="th1" colspan="2"><p class="tbody">Simplified treatment: adults w/ HCV w/o cirrhosis or w/ compensated cirrhosis &amp; no prior HCV treatment; cannot have HIV, HBsAg ⊕, pregnancy, HCC, ESRD, or liver transplant; if decompensated or previously treated, refer to GI for assistance.</p></td>
</tr>
</tbody>
</table>
<p class="tfn">Based on <i class="calibre6">Hepatology</i> 2020;71:686. Antiviral classes: RNA <i class="calibre6">polymerase inhibitor</i> (“…buvir”); <i class="calibre6">NS5a inhibitor</i> (“…asvir”); <i class="calibre6">NS3/4A protease inhibitor</i> (“…previr”).</p>
<p class="noindent1">• Monitoring on Rx: CBC, INR, LFTs, GFR, HCV VL prior to starting Rx. PIs contraindicated if decomp. liver dx (ascites, encephalopathy) or CPS ≥7. D/c Rx if jaundice, N/V, weakness, 10x ↑ in ALT, or significant ↑ in bili, Aϕ, INR after 4 wks.</p>
<p class="noindent1">• Goal is <i class="calibre6">sustained virologic response</i> (SVR) = Ø viremia 12 wks after completion of Rx. Success depends on genotype but SVR rates &gt;90% with current regimens.</p>
<p class="noindent1">• Special populations (HCV/HIV coinfection, decompensated cirrhosis, s/p liver transplant, renal impairment): <a href="http://www.hcvguidelines.com" class="calibre4">www.hcvguidelines.com</a> for updated recs on mgmt</p>
<p class="noindent1">• Vaccinate all chronic HCV patients against HBV and HAV if not immune</p>
<p class="noindent1">• Postexposure (needlestick risk ~3%) Ppx: none, although sofosbuvir-velpatasivir under investigation in clinical trial; if HCV RNA → ⊕, consider Rx w/in 3 mos</p>
<p class="h">Hepatitis D <span class="r">(RNA;</span> <span class="r2">Gastro</span><span class="r1"> 2019:156;461</span><span class="r">)</span></p>
<p class="noindent1">• Transmission: blood or sexual; endemic in Africa &amp; E. Europe. Generally requires host to already have HBV infxn in order to cause co-infection or superinfection; in rare cases (immunosupp s/p liver transplant) can replicate autonomously.</p>
<p class="noindent1">• Natural hx: acute HBV–HDV coinfection resolves in &gt;80% of cases; however, acute HDV superinfection leads to chronic HBV–HDV in most cases (↑ progression to cirrhosis, HCC)</p>
<p class="noindent1">• Dx: ✓ total anti-HDV once in all HBV-infected patients, if antibody ⊕, confirm w/ HDV RNA</p>
<p class="h">Hepatitis E <span class="r">(ssRNA;</span> <span class="r2">World J Gastro</span> <span class="r1">2016;22:7030;</span> <span class="r2">Gastro Clin N Am</span> <span class="r1">2017;46:393</span><span class="r">)</span></p>
<p class="noindent1">• Most common cause of acute viral hepatitis in endemic areas</p>
<p class="noindent1">• Transmission: fecal–oral; travelers to central &amp; SE Asia, Africa and Mexico, exposure to swine. ↑ rates of cases in Europe.</p>
<p class="noindent1">• Natural hx: often asx, sometimes causes acute hepatitis w/ ↑ mort. (10–20%) if pregnant; rarely can become chronic in transplant Pts</p>
<p class="noindent1">• Dx: IgM anti-HEV (through CDC), HEV RNA; treatment is generally supportive only</p>
<p class="noindent1">• Extrahepatic sx: arthritis, pancreatitis, anemia, neuro (GBS, meningoencephalitis)</p>
<p class="h">Other viruses <span class="r">(human pegivirus, CMV, EBV, HSV, VZV)</span></p>
<p class="h1cr"><a id="page_3-19" class="calibre8"></a>A<small class="calibre31">UTOIMMUNE</small> H<small class="calibre31">EPATITIS</small> (AIH)</p>
<p class="h">Classification <span class="r1">(</span><span class="r2">J Hep</span> <span class="r1">2015;62:S100,</span> <span class="r2">World J Gastro</span> <span class="r1">2015;21:60)</span></p>
<p class="noindent1">• Type 1: anti-smooth muscle Ab (ASMA), ANA; anti-soluble liver antigen (anti-SLA), a/w more severe disease and relapsing disease (found in 10–30% Pts), IgG often ↑</p>
<p class="noindent1">• Type 2: anti-liver/kidney microsome 1 (anti-LKM1); anti-liver cytosol type 1 (anti-LC-1)</p>
<p class="noindent1">• Overlap syndrome: AIH + PBC (suspect if ⊕ AMA or ⊕ histology → “autoimmune cholangitis”)</p>
<p class="noindent1">• Drug-induced: minocycline, nitrofurantoin, infliximab, hydralazine, α-methyldopa, statins</p>
<p class="h">Diagnosis and treatment <span class="r1">(</span><span class="r2">J Hepatol</span> <span class="r1">2015;63:1543,</span> <span class="r2">Clin Liver Dis</span> <span class="r1">2015;19:57)</span></p>
<p class="noindent1">• 70% female; bimodal presentation in the second and fifth decades of life</p>
<p class="noindent1">• 40% present w/ severe AIH (3% ALF) w/ ALT &gt;10 × ULN; 34–45% asx</p>
<p class="noindent1">• Extrahepatic syndromes: thyroiditis, arthritis, UC, Sjögren’s, Coombs’ ⊕ anemia, celiac</p>
<p class="noindent1">• Dx: scoring system combining serologies, ↑ IgG, Ø viral hepatitis, &amp; liver bx (interface hepatitis &amp; lymphoplasmacytic infiltrate) has high Sp &amp; mod Se <span class="r1">(</span><span class="r2">Dig Dis</span> <span class="r1">2015;33[S2]:53)</span></p>
<p class="noindent1">• Rx: (1) ALT or AST &gt;10× ULN (2) IgG &gt;2× ULN + ALT &gt;5× ULN (3) bridging/multiacinar necrosis (4) cirrhosis w/ inflammation on biopsy (5) AST/ALT &gt;2x ULN + symptoms</p>
<p class="noindent1">• Induction Rx: (1) prednisone monoRx; (2) prednisone + AZA, or (3) budesonide (if non-cirrhotic) + AZA → 65–80% remission (asx, nl LFTs, bili, &amp; IgG, none-to-minimal interface hepatitis); taper steroids as able; relapse rate of 50–80% <span class="r1">(</span><span class="r2">J Hep</span> <span class="r1">2015;62:S100)</span></p>
<p class="noindent1">• Nonresponders or AZA intolerant: cyclosporine, tacrolimus, MMF, rituximab, infliximab</p>
<p class="h1cr">O<small class="calibre31">THER</small> C<small class="calibre31">AUSES</small> <small class="calibre31">OF</small> H<small class="calibre31">EPATITIS</small> <small class="calibre31">OR</small> H<small class="calibre31">EPATOTOXICITY</small></p>
<p class="h">Alcohol-associated hepatitis <span class="r1">(</span><span class="r2">J Hepatol</span> <span class="r1">2016;69:154;</span> <span class="r2">Am J Gastro</span> <span class="r1">2018;113:175)</span></p>
<p class="noindent1">• Sx: progressive jaundice, tender hepatomegaly, fever, ascites, GIB, encephalopathy</p>
<p class="noindent1">• Labs: ALT usually &lt;300–500 w/ AST:ALT &gt; 2:1, ↓ plt, ↑ Tbili &amp; INR indicate severe hepatitis</p>
<p class="noindent1">• Prognosis: scoring systems include Maddrey’s discriminant fxn (MDF), Lille model, MELD</p>
<p class="noindent2">MDF (4.6 × [PT – control] + Tb) ≥32 w/ 30–50% 1-mo mortality if unRx’d <span class="r1">(</span><span class="r2">Gastro</span> <span class="r1">1996;110:1847)</span></p>
<p class="noindent2">Lille model: predicts nonresponse to steroids after 1<sup class="calibre19">st</sup> week of Rx; score &gt;0.45 predicts poor response to further steroid Rx and a/w ↓ in 6-mo survival <span class="r1">(</span><span class="r2">Hep</span> <span class="r1">2007;45:1348)</span></p>
<p class="noindent2">Combination of Lille + MELD scores best predictor of mortality <span class="r1">(</span><span class="r2">Gastro</span> <span class="r1">2015;149:398)</span></p>
<p class="noindent1">• Rx: consider if MDF ≥32, MELD &gt;18, or presence of encephalopathy</p>
<p class="noindent2">Glucocorticoids (eg, methylprednisolone 32 mg/d or prednisolone 40 mg/d × 4 wk → 4–6 wk taper) may ↓ 1-mo but not 6-mo mortality, a/w ↑ infection <span class="r1">(</span><span class="r2">NEJM</span> <span class="r1">2015;372:1619, CD001511)</span></p>
<p class="noindent2">Contraindic: active GIB, pancreatitis, untreated HBV, uncontrolled bact/fungal/TB infxn</p>
<p class="noindent2">Addition of NAC to steroids ↓ 1-mo but not 6-mo mortality <span class="r1">(</span><span class="r2">NEJM</span> <span class="r1">2011;365:1781)</span></p>
<p class="noindent1">• Consider early transplantation in carefully selected Pts <span class="r1">(</span><span class="r2">Gastro</span> <span class="r1">2018;155:422)</span></p>
<p class="h">Acetaminophen hepatotoxicity <span class="r1">(</span><span class="r2">Clin J Transl Hepatol</span> <span class="r1">2016;4:131;</span> <span class="r2">BMJ</span> <span class="r1">2016;353:i2579)</span></p>
<p class="noindent1">• Pathophysiology: &gt;90% of acetaminophen (N-acetyl-p-aminophenol, APAP) metab into nontoxic metab, but ~5% metab by CYP2E1 into NAPQI, a hepatotoxic metab detoxified by glutathione conjugation; APAP overdose (&gt;10 g) depletes glutathione stores → injury</p>
<p class="noindent1">• CYP2E1 <i class="calibre6">induced</i> by fasting, alcohol, certain anticonvulsants and anti-TB drugs, resulting in injury with even low doses (2–6 g) of acetaminophen</p>
<p class="noindent1">• Liver dysfunction may not be apparent for 2–6 d; nausea, vomiting &amp; abdominal pain 1<sup class="calibre19">st</sup> sx</p>
<p class="noindent1">• Rx: NG lavage, activated charcoal if w/in 4 h. Consider early transfer to transplant ctr</p>
<p class="noindent2"><b class="calibre7"><i class="calibre6">N</i>-acetylcysteine:</b> administer up to 72 h after ingestion, if time of ingestion unknown or chronic ingestion &gt;4g/d; low threshold to start NAC w/ low or undetectable APAP levels</p>
<p class="noindent2">PO NAC (preferred): 140 mg/kg loading dose → 70 mg/kg q4h × 17 additional doses</p>
<p class="noindent2">IV NAC: 150 mg/kg × 1 h → 50 mg/kg × 4 h → 100 mg/kg × 16 h; risk of anaphylaxis (↓ w/ 12-h regimen; <span class="r2">Lancet</span><span class="r1"> 2014;383:697</span>); use if unable to tolerate POs, GIB, pregnancy, liver injury</p>
<p class="h">Ischemic hepatitis</p>
<p class="noindent1">• “Shock liver” w/ AST &amp; ALT &gt;1000 + ↑↑ LDH (ALT:LDH ratio often &lt;1:5); delayed ↑↑ Tbili</p>
<p class="noindent1">• Seen in HoTN &amp; CHF; often requires ↑ venous + ↓ portal/arterial pressure + hypoxia</p>
<p class="h">Nonalcoholic fatty liver disease (NAFLD) <span class="r1">(</span><span class="r2">JAMA</span> <span class="r1">2020;323:1175;</span> <span class="r2">Lancet</span> <span class="r1">2021;397:2212)</span></p>
<p class="noindent1">• Definition: fatty infiltration of liver + absence of EtOH or other cause of steatosis (HCV, etc.)</p>
<p class="noindent2"><b class="calibre7">NAFL</b> = steatosis, Ø inflam; <b class="calibre7">NASH</b> = steatosis + inflam ± fibrosis on bx</p>
<p class="noindent1">• NAFLD: 25% of U.S. pop. &amp; over 60% in T2DM &amp; obesity</p>
<p class="noindent1">• NASH: 2–5% of NAFLD &amp; risk of cirrhosis in NASH w/ fibrosis on bx is 30% at 10 y</p>
<p class="noindent1">• Clinical: 80% asx, ↑ ALT &gt; AST, but nl ALT/AST does not exclude poss. of NASH on bx</p>
<p class="noindent1">• Dx: liver bx remains gold standard. VCT elastography emerging alternative <span class="r1">(</span><span class="r2">J Hepatol</span> <span class="r1">2017;66:1022)</span>. FIB-4/NAFLD fibrosis score predicts NASH w/ advanced fibrosis w/ PPV &gt;80%.</p>
<p class="noindent1">• Rx <span class="r1">(</span><span class="r2">Gastro</span><span class="r1"> 2021;161:1657)</span>: wt loss (≥10%), exercise, DM control, liraglutide <span class="r1">(</span><span class="r2">Lancet</span> <span class="r1">2016;387:679)</span>, statins <span class="r1">(</span><span class="r2">Metabolism</span> <span class="r1">2017;71:17)</span>, vit E in Pts w/o DM <span class="r1">(</span><span class="r2">Hepatol</span> <span class="r1">2018;67:328)</span>, bariatric surgery <span class="r1">(</span><span class="r2">World J Hepatol</span> <span class="r1">2019;11:138)</span>. New therapies (eg, PPAR agonist lanifibranor, <span class="r2">NEJM</span><span class="r1"> 2021;385:1547</span>) emerging. HCC a complication of NAFLD, usually in setting of NASH cirrhosis.</p>
<h2 class="ct"><a id="h50" class="calibre8"></a><a id="page_3-20" class="calibre8"></a><a href="part0003.html#rh56" class="calibre8">ACUTE LIVER FAILURE (ALF)</a></h2>
<p class="h">Definition</p>
<p class="noindent1">• Acute liver injury + coagulopathy + encephalopathy w/o preexisting liver dis. (&lt;26 wks)</p>
<p class="noindent1">• Fulminant if encephalopathy &lt;8 wks from jaundice onset, subfulminant if 8–26 wks</p>
<p class="noindent1">• Acute on chronic liver failure: acute insult to liver in Pt w/ underlying chronic liver disease</p>
<p class="h">Etiology <span class="r1">(</span><span class="r2">J Hepatol</span> <span class="r1">2015;62:S112)</span></p>
<p class="noindent1">• <b class="calibre7">Drugs</b>/<b class="calibre7">toxins</b> (nearly 80% of cases in U.S.; <span class="r2">Gastro</span><span class="r1"> 2015;148:1353,</span> <span class="r2">Clin Liver Dis</span> <span class="r1">2017;21:151</span>)</p>
<p class="noindent2"><i class="calibre6">Dose-dependent:</i> acetaminophen (most common cause; &gt;40% of cases in U.S.)</p>
<p class="noindent2"><i class="calibre6">Idiosyncratic, not dose related:</i> anti-TB drugs (INH, RIF, PZA); AEDs (phenytoin, valproate, carbamazepine); NSAIDs; abx (eg, fluoroquinolones, macrolides, nitro-furantoin); drugs of abuse (MDMA &amp; cocaine); others (amiodarone, TCAs)</p>
<p class="noindent2">Toxins: <i class="calibre6">Amanita phalloides</i> (mushroom sp. in West Coast), certain herbal preparations</p>
<p class="noindent1">• <b class="calibre7">Viral</b>: HAV, HBV, HCV (rare), HDV + HBV, HEV (esp. if pregnant). In immunosupp: HSV (50% have skin lesions), EBV, VZV, CMV, HHV6</p>
<p class="noindent1">• <b class="calibre7">Vascular:</b> Budd-Chiari, ischemic hepatitis, hepatic sinusoidal obstruction syndrome</p>
<p class="noindent1">• <b class="calibre7">Other:</b> Wilson disease, pregnancy-related ALF (acute fatty liver, preeclampsia, HELLP), initial presentation of autoimmune hepatitis; idiopathic</p>
<p class="h">Clinical manifestations</p>
<p class="noindent1">• Initial presentation: N/V, malaise, RUQ pain, jaundice, encephalopathy, multiorgan failure</p>
<p class="noindent1">• Neurologic: <b class="calibre7">encephalopathy:</b> grade 1 = attn deficit, disordered sleep; grade 2 = <i class="calibre6">asterixis</i>, confusion; grade 3 = somnolence, rigidity; grade 4 = coma; ↑ ICP w/ bradycardia &amp; HTN</p>
<p class="noindent2"><b class="calibre7">cerebral edema:</b> astrocyte swelling related in part to ↑ ammonia levels</p>
<p class="noindent1">• Cardiovascular: <b class="calibre7">hypotension</b> with low SVR, shock</p>
<p class="noindent1">• Pulmonary: <b class="calibre7">respiratory alkalosis</b>, impaired peripheral O<sub class="calibre10">2</sub> uptake, pulm edema, ARDS</p>
<p class="noindent1">• GI: GI tract bleed common (need PPI Ppx), pancreatitis (due to ischemia, drugs, infxn)</p>
<p class="noindent1">• Renal: ATN, <b class="calibre7">hepatorenal syndrome</b>, hyponatremia, hypokalemia, hypophosphatemia</p>
<p class="noindent1">• Hematology: <b class="calibre7">bleeding diathesis</b> w/ thrombocytopenia, ↑ PT/PTT, ↓ fibrinogen, ↓ synthesis of coag factors balanced by ↓ protein C/S; bleeding mostly due to low platelet count, DIC</p>
<p class="noindent1">• <b class="calibre7">Infection</b>: espec. with <i class="calibre6">Staph</i>, <i class="calibre6">Strep</i>, GNRs, and fungi (↓ immune fxn, invasive procedures); <i class="calibre6">fever and</i> ↑ <i class="calibre6">WBC may be absent, most common sites are respiratory, urinary &amp; blood</i></p>
<p class="noindent1">• Endocrine: <b class="calibre7">hypoglycemia</b> (↓ glc synthesis), metabolic acidosis (↑ lactate), adrenal insuf.</p>
<p class="h">Workup <span class="r1">(</span><span class="r2">Clin Liver Dis</span> <span class="r1">2017;21:769)</span></p>
<p class="noindent1">• CBC, PT/PTT, LFTs, lytes, BUN/Cr, NH<sub class="calibre10">3</sub>, pH, <i class="calibre6">arterial</i> lactate, acetaminophen level, HIV, amylase/lipase, viral serologies (qv) in all Pts, with additional labs as below if suspected</p>
<p class="noindent1">• Autoimmune hep serologies &amp; IgG levels, ceruloplasmin &amp; serum/urine copper, preg test</p>
<p class="noindent1">• Imaging studies (RUQ U/S or abd CT, Doppler studies of portal and hepatic veins)</p>
<p class="noindent1">• Liver biopsy if underlying etiology remains elusive after initial testing</p>
<p class="h">Management <span class="r1">(</span><span class="r2">J Clin Exp Hepatol</span> <span class="r1">2015;5:S104;</span> <span class="r2">Gastro</span> <span class="r1">2017;152:644)</span></p>
<p class="noindent1">• <b class="calibre7">ICU care at liver transplant center</b> for hemodynamic &amp; ventilatory support; CVVH for AKI</p>
<p class="noindent1">• Early listing for liver transplantation in selected Pts (see below)</p>
<p class="noindent1">• Cerebral edema: consider ICP monitoring if grade 3/4 enceph; if ↑ ICP → mannitol 0.5–1.0 mg/kg; if arterial NH<sub class="calibre10">3</sub> &gt;150, grade 3/4 enceph, AKI or on vasopressors → prophylactic 3% saline with goal Na 145–155 mEq/L; barbiturates &amp; hypothermia if refractory ↑ ICP</p>
<p class="noindent1">• Encephalopathy: intubate for grade 3 or 4; lactulose is of little benefit &amp; may be detrimental</p>
<p class="noindent1">• Coagulopathy: vit K, FFP/plts/cryo only if active bleeding (↑ risk of volume overload)</p>
<p class="noindent1">• Infection: low threshold for abx (broad spectrum, eg, vancomycin &amp; 3<sup class="calibre19">rd</sup>-gen ceph.) if suspect infection; anti-fungal coverage in high-risk Pts (TPN, CVVH)</p>
<p class="noindent1">• Rx of specific causes: NAC if acetaminophen; antiviral for HBV; plasma exchange can be temporizing measure for Wilson disease; IV acyclovir for HSV; PCN-G for <i class="calibre6">A. phalloides;</i> delivery of child for pregnancy-related; TIPS, anticoag for Budd-Chiari. Lack of data for use of steroids in autoimmune, but often given <span class="r1">(</span><span class="r2">Hepatology</span> <span class="r1">2014;59:612)</span>.</p>
<p class="noindent1">• NAC may benefit Pts w/ non-APAP ALF but data inconclusive <span class="r1">(</span><span class="r2">Clin Drug Investig</span> <span class="r1">2017;37:473)</span></p>
<p class="noindent1">• <b class="calibre7">King’s College Criteria for Liver Transplantation consideration:</b></p>
<p class="noindent2">Acetaminophen ALF: arterial pH &lt;7.30 or Grade III/IV enceph + INR &gt;6.5 + Cr &gt;3.4</p>
<p class="noindent2">Non-acetaminophen ALF: PT &gt;100 or any 3: age &lt;10 or &gt;40 y, jaundice &gt;7 d prior to onsent of encephalopathy, PT &gt;50 or INR &gt;3.5, Tbili &gt;18, unfavorable disease (viral hepatitis, DILI, Wilson’s disease, or low factor V level)</p>
<p class="h">Prognosis <span class="r1">(</span><span class="r2">Ann Intern Med</span> <span class="r1">2016;164:724;</span> <span class="r2">World J Gastro</span> <span class="r1">2016;22:1523)</span></p>
<p class="noindent1">• Non-acetaminophen ALF mortality ~70%, acetaminophen-induced ALF mortality ~25–30%</p>
<p class="noindent1">• HBV, Wilson’s, AIH, DILI, Budd-Chiari ~ associated with ↓ prognosis</p>
<p class="noindent1">• Factor V level &lt;20% in Pts &lt;30 yrs or &lt;30% in &gt;30 yrs associated w/ poor prognosis</p>
<h2 class="ct"><a id="h51" class="calibre8"></a><a id="page_3-21" class="calibre8"></a><a href="part0003.html#rh57" class="calibre8">CIRRHOSIS</a></h2>
<p class="h">Definition <span class="r1">(</span><span class="r2">Dig Dis</span> <span class="r1">2016;34:374;</span> <span class="r2">NEJM</span> <span class="r1">2016;375:767;</span> <span class="r2">J Hep</span> <span class="r1">2016;64:717)</span></p>
<p class="noindent1">• Definition <b class="calibre7">fibrosis &amp; regenerative nodules</b> causing distortion of hepatic architecture</p>
<p class="noindent1">• <b class="calibre7">Decompensated</b> = complication due to ↑ portal pressure such as: variceal bleed, HCC, SBP, encephalopathy, ascites, hepatorenal or hepatopulmonary syndrome</p>
<p class="h">Etiologies</p>
<p class="noindent1">• <b class="calibre7">Alcohol</b>, toxins (eg, arsenic)</p>
<p class="noindent1">• <b class="calibre7">Nonalcoholic fatty liver disease (NAFLD</b>) is the cause of most “cryptogenic cirrhosis”</p>
<p class="noindent1">• <b class="calibre7">Viral hepatitis</b>: chronic HBV, HCV, HDV infection</p>
<p class="noindent1">• <b class="calibre7">Autoimmune hepatitis:</b> ♀, ↑ IgG, ⊕ ANA, ASMA, anti-LKM-1, anti-LC1</p>
<p class="noindent1">• <b class="calibre7">Metabolic diseases</b>: hemochromatosis, Wilson disease, α<sub class="calibre10">1</sub>-AT deficiency</p>
<p class="noindent1">• <b class="calibre7">Biliary tract diseases</b>: primary biliary cholangitis, secondary biliary cirrhosis (calculus, neoplasm, stricture, biliary atresia), primary sclerosing cholangitis</p>
<p class="noindent1">• <b class="calibre7">Vascular diseases:</b> Budd-Chiari syndrome, R-sided CHF, constrictive pericarditis, SOS</p>
<p class="noindent1">• <b class="calibre7">Medications:</b> amiodarone, methotrexate, vitamin A, valproic acid, isoniazid</p>
<p class="h">Clinical manifestations</p>
<p class="noindent1">• Nonspecific sx (anorexia, fatigue) or jaundice, encephalopathy, ascites, variceal bleeding</p>
<p class="h">Physical exam</p>
<p class="noindent1">• Liver: <i class="calibre6">initially</i> enlarged, palpable (L lobe predom), firm; <i class="calibre6">eventually</i> shrunken, nodular</p>
<p class="noindent1">• Signs of liver failure: jaundice (bili &gt;2.5), spider angiomata &amp; palmar erythema (↑ estra- diol), Dupuytren contractures, white nail lines (Muehrcke lines) &amp; proximal nail beds (Terry nails), ↑ parotid &amp; lacrimal glands, gynecomastia, testicular atrophy, asterixis, encephalopathy, clubbing, hypertrophic osteoarthropathy, anovulation in women</p>
<p class="noindent1">• Signs of portal HTN: splenomegaly, ascites, dilated superficial abd veins (caput medusae), epigastric Cruveilhier-Baumgarten venous hum (flow through recanalized umbilical vein)</p>
<p class="h">Laboratory studies</p>
<p class="noindent1">• LFTs: ↑ <b class="calibre7">bili</b>, ↑ <b class="calibre7">PT/INR</b> (poor correlation w/ bleeding; factor VIII nl b/c not synthesized by liver), ↓ <b class="calibre7">alb</b>, ± ↑ aminotransferases (AST &gt;ALT if late) and ↑ Aϕ (variable)</p>
<p class="noindent1">• Hematologic tests: anemia (marrow suppress., hypersplenism, Fe ± folate defic.), neutro-penia (hypersplenism), thrombocytopenia (hypersplenism, ↓ Tpo production, EtOH tox)</p>
<p class="noindent1">• Chem: ↓ Na (↑ ADH due to ↓ EAV); ↑ Fe/TIBC, ↑ ferritin (released from hepatocytes)</p>
<p class="noindent1">• Lab indices predictive of cirrhosis: AST/plt &gt;2; Lok index; Bonacini score <span class="r1">(</span><span class="r2">JAMA</span> <span class="r1">2012;307:832)</span></p>
<p class="noindent1">• Indirect markers of fibrosis: FibroTest/FibroSURE, Hepascore (good at differentiating significant fibrosis F2 to F4), FIB-4 index (NAFLD, HCV), NAFLD fibrosis score, APRI (HCV), non-invasive imaging (eg, U/S or MR elastography)</p>
<p class="h">Workup <span class="r1">(</span><span class="r2">Am J Gastro</span> <span class="r1">2017;112:18;</span> <span class="r2">Lancet</span> <span class="r1">2021;398:1359)</span></p>
<p class="noindent1">• Abd <b class="calibre7">U/S w/ Doppler:</b> liver size &amp; echotexture, r/o HCC, ascites, ✓ patency of vasculature</p>
<p class="noindent1">• Determine etiology: hepatitis serologies (HBsAg, anti-HBs, anti-HCV), autoimmune hepatitis studies (IgG, ANA, ASMA), Fe and Cu studies, α<sub class="calibre10">1</sub>-AT, AMA</p>
<p class="noindent1">• Assess fibrosis: biomarkers (FibroSURE = panel of 5 markers validated in HCV, ↑ score predictive of fibrosis); elastography (U/S or MR-based; measurement of liver stiffness)</p>
<p class="noindent1">• Liver bx (gold standard): percutaneous or transjugular (consider if ascites or coagulopathy), used to confirm presence of cirrhosis and dx etiology, not always needed</p>
<p class="h">Prognosis <span class="r">(<a href="http://www.mdcalc.com/child-pugh-score-cirrhosis-mortality" class="calibre4">www.mdcalc.com/child-pugh-score-cirrhosis-mortality</a>)</span></p>
<p class="noindent1">• <b class="calibre7">Modified Child-Turcotte-Pugh (CPS)</b> score based on ascites, enceph., &amp; labs (bili, alb &amp; INR; see Appendix). CPS A (5–6 pts): 1-y survival 100%, B (7–9): 80%; C (10–15): 45%.</p>
<p class="noindent1">• <b class="calibre7">MELD-Na</b> (<b class="calibre7">M</b>odel for <b class="calibre7">E</b>nd-Stage <b class="calibre7">L</b>iver <b class="calibre7">D</b>isease; <span class="r2">Gastro</span><span class="r1"> 2011;14:1952</span>): used to stratify liver Tx list &amp; predict 3-mo survival in cirrhosis and some acute forms of liver dis. Based on Cr, INR, total bili, Na. <span class="r1">Calculator: <a href="https://optn.transplant.hrsa.gov/resources/allocation-calculators/meld-calculator/" class="calibre4">https://optn.transplant.hrsa.gov/resources/allocation-calculators/meld-calculator/</a></span>.</p>
<p class="noindent2">If MELD &lt;21, additional predictors of mortality include refractory ascites, ↑ HVPG &amp; ↓ QoL.</p>
<p class="noindent2">MELD-Plus includes alb, chol, LOS, age, WBC <span class="r1">(</span><span class="r2">PLOS One</span> <span class="r1">2017;12:e0186301)</span>.</p>
<p class="h">Ascites <span class="r">(see “Ascites” for diagnostic eval;</span> <span class="r2">Dig Dis</span> <span class="r1">2017;35:402;</span> <span class="r2">Hepatology</span><span class="r1"> 2021;74:1014</span><span class="r">)</span></p>
<p class="noindent1">• Due to portal HTN (defined as hepatic venous pressure gradient [HVPG] &gt;5 mmHg)</p>
<p class="noindent1">• Develops in 60% w/in 10 y; often first decompensating event</p>
<p class="noindent1">• Treatment: ↓ <b class="calibre7">Na intake</b> (1–2 g/d); restrict intake of free water if Na &lt;125</p>
<p class="noindent2"><b class="calibre7">Diuretics:</b> goal diurese ~1 L/d. Use spironolactone ± furosemide in 5:2 ratio (uptitrate as able); urine Na/K &gt;1 implies effective natriuresis if Pt compliant w/ low-Na diet</p>
<p class="noindent2">Avoid NSAIDs/ACEI/ARBs in cirrhosis because interfere w/ diuretic action</p>
<p class="noindent2">Long-term albumin infusions ↓ mortality <span class="r1">(</span><span class="r2">Lancet</span> <span class="r1">2018;391:2417)</span>, but not widely adopted</p>
<p class="noindent1"><a id="page_3-22" class="calibre4"></a>• <b class="calibre7">Refractory ascites:</b> seen in 5–10% of Pts; 2-y survival 25%</p>
<p class="noindent2">Defined as diuretic-resistant if on 2-g Na diet w/ minimal weight loss on max diuretics, or diuretic-induced complications (AKI, Na &lt;125, ↑ K, encephalopathy)</p>
<p class="noindent2">Conflicting evid. for d/c’ing βB <span class="r1">(</span><span class="r2">Hep</span> <span class="r1">2016;63:1968;</span> <span class="r2">J Hepatol</span> <span class="r1">2016;64:574)</span>. Discontinue if SBP &lt;90 or MAP ≤82 mmHg, serum Na &lt;120 mEq/L, AKI, HRS, SBP, sepsis, severe alcohol-assoc hepatitis, or poor follow-up. If limited by HoTN, can add midodrine.</p>
<p class="noindent2"><b class="calibre7">Large-volume paracenteses</b> (LVP; &gt;5 L fluid removal): give 6–8 g albumin per L fluid removed (above 5 L) as colloid replacement a/w ↓ risk of post-para circulatory dysfxn &amp; possibly ↓ mortality <span class="r1">(</span><span class="r2">Hep</span> <span class="r1">2012;55:1172)</span>. Avoid LVP if SBP present because ↑ risk of AKI.</p>
<p class="noindent2"><b class="calibre7">Transjugular intrahepatic portosystemic shunt</b> (TIPS) <span class="r1">(</span><span class="r2">Gastro</span> <span class="r1">2017;152:157)</span></p>
<p class="noindent3">↓ ascites in 75%; ↑ CrCl, ↑ enceph, survival benefit over LVP remains controversial</p>
<p class="noindent3">Contraindic: grade II enceph, CHF or pulm HTN, active infxn or biliary obstruction</p>
<p class="noindent3">Complications: bleeding, fistula; stent thrombosis (1-y patency w/ coated stents ~80%); infxn (“endotipsitis”); new or ↑ enceph in 20–30% <span class="r1">(</span><span class="r2">Am J Gastro</span> <span class="r1">2016;111:523)</span>, hemolysis</p>
<p class="noindent2">Consider for liver transplant if above fail</p>
<p class="noindent1">• <b class="calibre7">Hepatic hydrothorax:</b> 2° diaphragmatic defect; often unilateral, R &gt;L, ± ascites</p>
<p class="noindent2">Treatment: avoid chest tube (↑ complications); Rx same as ascites (TIPS if refractory). Indwelling pleural catheter potential option if refractory for palliation <span class="r1">(</span><span class="r2">Chest</span> <span class="r1">2019;155:307)</span></p>
<p class="noindent2">Spontaneous <i class="calibre6">empyema</i> can occur (even w/o SBP) → dx thoracentesis; Rx abx</p>
<p class="h">Spontaneous bacterial peritonitis <span class="r">(SBP; see “Ascites”;</span> <span class="r2">Hepatology</span><span class="r1"> 2021;74:1014</span><span class="r">)</span></p>
<p class="noindent1">• High mortality rate; risk factors include ascitic TP &lt;1 g/dL, hx of SBP, current GIB</p>
<p class="noindent1">• Can p/w encephalopathy, abd pain, fever, <i class="calibre6">but often</i> (<i class="calibre6">25%</i>) <i class="calibre6">asx;</i> perform diagnostic paracentesis in all hospitalized patients with cirrhosis and ascites</p>
<p class="noindent1">• Micro: typically, monobacterial GNRs (<i class="calibre6">E. coli, Klebs</i>) &gt;GPCs (<i class="calibre6">S. pneumo, enterococcus</i>)</p>
<p class="noindent1">• Rx: 3<sup class="calibre19">rd</sup>-gen. ceph is 1<sup class="calibre19">st</sup> line; consider pip/tazo or mero if ↑ risk of MDRO; vanc if prior MRSA ⊕; IV albumin 1.5 g/kg at time of dx &amp; 1 g/kg on day 3 → ↑ survival <span class="r1">(</span><span class="r2">NEJM</span> <span class="r1">1999;341:403)</span></p>
<p class="noindent1">• Repeat paracentesis at 48 h: expect 25% ↓ in PMNs if Rx working.</p>
<p class="noindent1">• Indefinite Ppx if (1) h/o SBP or (2) ascitic TP &lt;1.5 plus: Na ≤130 or Cr ≥1.2 or BUN ≥25 or [CPS ≥9 + Tbili ≥3] <span class="r1">(</span><span class="r2">Am J Gastro</span> <span class="r1">2009;4:993)</span> → cipro 500 mg qd or Bactrim DS qd. Short-term Ppx: CTX 1 g IV × 7d if GIB (Δ to cipro 500 bid/Bactrim DS bid when eating).</p>
<p class="h">Gastroesophageal varices <span class="r"></span> UGIB <span class="r">(see also “GIB”;</span> <span class="r2">Hepatology</span><span class="r1"> 2017;65:310</span><span class="r">)</span></p>
<p class="noindent1">• Presence of varices correlates w/ severity of liver dis (40% of Child A Pts → 85% Child C)</p>
<p class="noindent1">• ↑ varix size, child B/C, &amp; red wale marks assoc w/ ↑ risk of bleeding</p>
<p class="noindent1">• UGIB 1° prevention: screen at time of dx w/ EGD; data best for Pts w/ med-large varices</p>
<p class="noindent2"><b class="calibre7">Nonselective</b> β<b class="calibre7">-blockers:</b> ~50% ↓ risk of bleeding &amp; ↓ mortality if med-large varices. Nadolol, propranolol, or carvedilol; latter ↓ MAP &amp; HVPG more than propranolol; delays progression of varices <span class="r1">(</span><span class="r2">Gut</span> <span class="r1">2017;66:1838)</span>; may use in Pts w/ HTN. Titrate to max tolerated dose; EGD not req. to document improvement. Hold for criteria listed above.</p>
<p class="noindent2"><b class="calibre7">Endoscopic variceal ligation</b> (EVL): superior to βB in ↓ risk of 1<sup class="calibre19">st</sup> bleed but no diff in mortality <span class="r1">(</span><span class="r2">Ann Hep</span> <span class="r1">2012;11:369)</span>; risk of serious complications (esoph perf, ulcers). Repeat q1–4wk until varices gone, w/ f/u EGD at 3 mo then q6–12mo.</p>
<p class="noindent2">βB vs. EVL: choice based on Pt/physician preference; βB often 1<sup class="calibre19">st</sup> for small varices; larger varices may benefit more from EVL; both for 1° Ppx currently not recommended</p>
<p class="noindent1">• 2° prevention: for all Pts after 1<sup class="calibre19">st</sup> bleed, given ~50% risk of rebleed &amp; ~30% mortality; βB + EVL &gt;either alone; TIPS if refractory, or consider in child B/C w/in 72 h of admission for EV bleed (↓ rebleeding, ↑ enceph., Ø Δ mort.) <span class="r1">(</span><span class="r2">Hepatology</span> <span class="r1">2017;65:310)</span></p>
<p class="h">Hepatic encephalopathy (HE) <span class="r1">(</span><span class="r2">NEJM</span> <span class="r1">2016;375:1660;</span> <span class="r2">Hepatology</span> <span class="r1">2014; 60:715)</span></p>
<p class="noindent1">• Pathogenesis: failure of liver to detoxify NH<sub class="calibre10">3</sub> + other substances (eg, ADMA; <span class="r2">J Hepatol</span> <span class="r1">2013;58:38</span>) that cause cerebral edema, ↓ O<sub class="calibre10">2</sub> consumption, ↑ ROS → brain dysfxn</p>
<p class="noindent1">• Precipitants: bleeding, infxn, med nonadherence, ↓ K, ↓ Na, dehydration, hypoxia, portosystemic shunt (eg, TIPS), meds (eg, sedatives), acute insult to liver (eg, PVT)</p>
<p class="noindent1">• Stages: see section in “Acute Liver Failure”</p>
<p class="noindent1">• Dx: serum NH<sub class="calibre10">3</sub> levels have poor Se for dx &amp; monitoring Rx; remains a <i class="calibre6">clinical dx</i></p>
<p class="noindent1">• Rx<i class="calibre6">:</i> identify/correct precipitants; <b class="calibre7">lactulose</b> (acidification of colon: NH<sub class="calibre10">3</sub> → NH<sub class="calibre10">4</sub><sup class="calibre19">+</sup>) w/ goal 2–4 stools/d (PEG may be as effective; <span class="r2">JAMA IM</span> <span class="r1">2014;174:1727</span>); add <b class="calibre7">rifaximin</b> 550 mg bid (↓ gut bacteria → ↓ NH<sub class="calibre10">3</sub> prod) if refractory or after 2<sup class="calibre19">nd</sup> recurrence HE on lactulose (NNT=3) <span class="r1">(</span><span class="r2">Am J Gastro</span> <span class="r1">2013;108:1458)</span>; FMT, oral branched-chain AAs, probiotics may have a role <span class="r1">(Cochrane Reviews 2017;2;</span> <span class="r2">Gastro</span><span class="r1"> 2019;156:1921)</span>; maintain K &gt;4, avoid alkalosis as able</p>
<p class="h">Hepatorenal syndrome (HRS) <span class="r1">(</span><span class="r2">Hepatology</span> <span class="r1">2021;74:1014,</span> <span class="r2">Gastro</span><span class="r1"> 2016;150:1525)</span></p>
<p class="noindent1">• Pathophys: splanchnic vasodilation and renal vasoconstriction w/ ↓ renal blood flow</p>
<p class="noindent1">• Criteria: (1) cirrhosis w/ ascites; (2) <b class="calibre7">acute kidney injury</b> (serum Cr ↑ ≥0.3 mg/dL w/in 48 h or ≥50% ↑ in serum Cr from baseline; <span class="r2">Gut</span> <span class="r1">2015;64:531</span>); (3) Ø improvement in Cr after d/c diuretic &amp; volume expansion (1 g/kg/d of albumin × 2 d); (4) Ø shock (prerenal azotemia/ATN); (5) Ø nephrotoxic meds; (6) Ø intrinsic kidney disease</p>
<p class="noindent2"><a id="page_3-23" class="calibre4"></a><b class="calibre7">HRS-AKI:</b> development in &lt;2 wk; usually occurs in severe liver failure, often following precipitating event (see later); median survival 2 wk</p>
<p class="noindent2"><b class="calibre7">HRS-CKD:</b> more indolent, median survival 6 mo; liver failure present &lt;than in HRS-AKI</p>
<p class="noindent1">• Precipitants: GIB, overdiuresis, infection, serial LVP, drugs (aminoglycosides, NSAIDs)</p>
<p class="noindent1">• Rx: <i class="calibre6">if critically ill</i> → vasopressor (eg, norepinephrine or vasopressin) + albumin (1 g/kg, max 100 g, bolus daily) to ↑ MAP 10 mmHg. <i class="calibre6">If not critically ill</i> → octreotide (100–200 mcg SC tid) + midodrine (max 15 mg PO tid) + 1 g/kg (max 100 g) albumin on day of presentation followed by 20–60 g albumin qd to ↑ MAP. Terlipressin + albumin ↑ 10 d survival (not yet approved in U.S. but now recommended by AASLD) <span class="r1">(</span><span class="r2">NEJM</span> <span class="r1">2021;384:818)</span>. May need dialysis or TIPS as bridge to liver transplant.</p>
<p class="h">Hepatocellular carcinoma <span class="r">(HCC; qv in Heme-Onc)</span> <span class="r1">(</span><span class="r2">Nature Reviews</span> <span class="r1">2021;7:6)</span></p>
<p class="noindent1">• ↑ risk w/ cirrhosis of any type (leading cause of death in cirrhosis, 1–6%/y) but esp. ↑ w/ viral (Hep B/C~3–8%/y), concomitant EtOH use, obesity related NASH, HFE or diabetes</p>
<p class="noindent1">• Clinical: asx vs. hepatic decompensation (eg, ascites, HE), PVT w/ tumor thrombus</p>
<p class="noindent1">• Dx: screen Pts w/ cirrhosis q6mo w/ U/S ± AFP; alternative is dual-phase CT/MRI</p>
<p class="noindent1">• Rx: see “HCC” in Heme-Onc</p>
<p class="h">Other complications</p>
<p class="noindent1">• <b class="calibre7">Hepatopulmonary syndrome</b> (HPS) <span class="r1">(</span><span class="r2">Dig Dis Sci</span> <span class="r1">2015;60:1914,</span> <span class="r2">Hepatology</span><span class="r1"> 2021;74:1014)</span></p>
<p class="noindent2">Abnl gas exchange (A-a gradient ≥15 or P<sub class="calibre10">a</sub>O<sub class="calibre10">2</sub> &lt;80) caused by intrapulmonary vascular dilatations leading to intrapulmonary shunting (improves with O<sub class="calibre10">2</sub>)</p>
<p class="noindent2">S/S: platypnea-orthodeoxia (dyspnea &amp; hypoxia w/ sitting up), clubbing, spider angiomas</p>
<p class="noindent2">Dx w/ contrast echo showing “late” A-V shunting (contrast in LA 3–6 cycles after RA)</p>
<p class="noindent2">Rx: O<sub class="calibre10">2</sub>; potential embolization if large vessel on CT, TIPS, liver tx only definitive Rx</p>
<p class="noindent1">• <b class="calibre7">Portopulmonary hypertension</b> (POPH) <span class="r1">(</span><span class="r2">Expert Rev Gastro Hepatol</span> <span class="r1">2015;9:983)</span></p>
<p class="noindent2">Pulm HTN in Pt w/ portal HTN w/o other cause. ESLD→ ↑ endothelin→ pulm vasoconst.</p>
<p class="noindent2">Rx w/ same therapies as for idiopathic PAH, incl prostacyclin analogs, endothelin receptor antagonists, sildenafil; liver transplant is often curative</p>
<p class="noindent1">• <b class="calibre7">Cirrhotic cardiomyopathy:</b> ↓ inotropic &amp; chronotropic response, ↓ systolic &amp; diastolic fxn, ↑ QT, hyperkinetic circulation, high output; ↑ troponin &amp; BNP</p>
<p class="noindent1">• <b class="calibre7">Infxns:</b> unless immune, vaccinate for HAV, HBV, PCV13, PPSV23, COVID-19; flu yearly. Cellulitis in ~20% of Pts hospitalized w/ cirrhosis, often in abd or LE a/w edema.</p>
<p class="noindent1">• <b class="calibre7">Endocrine:</b> diabetes (15–30%), ↑ frequency of adrenal insuffic. <span class="r1">(</span><span class="r2">Dig Dis Sci</span> <span class="r1">2017;62:1067)</span></p>
<p class="noindent1">• <b class="calibre7">Coagulopathy:</b> balanced defects w/ ↓ synth of coag factors, hyperfibrinolysis, ↓ plt balanced by ↓ synthesis anticoag factors (protein C/S), defic. of profibrinolytic factors, ↑ levels of vWF. No support for routine administration of FFP, plt, cryo unless DIC.</p>
<p class="noindent1">• <b class="calibre7">Nutrition:</b> monitor and supplement fat-soluble vitamins, zinc, screen for malnutrition, sarcopenia &amp; fraility; ensure protein intake 1.2–1.5 g/kg/d <span class="r1">(</span><span class="r2">Hepatology</span> <span class="r1">2021;74:1611)</span></p>
<p class="noindent1">• Meds: acetaminophen can be used up to 2 g/d; avoid ASA/NSAIDs; aminoglycosides contraindicated; oral hypoglycemics if compensated but insulin if decompensated</p>
<p class="h">Liver transplantation <span class="r1">(</span><span class="r2">Hepatology</span> <span class="r1">2014;59:1144)</span></p>
<p class="noindent1">• Undertake evaluation when MELD ≥15. Exception points added if HCC, HPS</p>
<p class="noindent1">• Indic: recurrent/severe enceph, refractory ascites, recurrent variceal bleeding, HRS, HPS, PPH, HCC (if no single lesion is &gt;5 cm <i class="calibre6">or</i> ≤3 lesions with largest ≤3 cm), ALF</p>
<p class="noindent1">• Contraindic: inadequate social support, active substance abuse (some exception), sepsis, advanced cardiopulm dis., extrahepatic Ca, cholangio Ca, hemangiosarcoma, persistent noncompliance, AIDS, ALF w/ sustained ICP &gt;50 mmHg or CPP &lt;40 mmHg</p>
<p class="noindent1">• Survival: 1-y up to 90%, 5-y up to 80<b class="calibre7">%</b>, though lower with autoimmune liver disease, such as AIH/PBC/PSC may recur in 10–30% (or more) of allografts</p>
<p class="h1cr">O<small class="calibre31">THER</small> E<small class="calibre31">TIOLOGIES</small> <small class="calibre31">OF</small> C<small class="calibre31">IRRHOSIS</small></p>
<p class="h">Hemochromatosis &amp; iron overload syndromes <span class="r1">(</span><span class="r2">Am J Gastro</span> <span class="r1">2019;114:1202)</span></p>
<p class="noindent1">• Recessive disorder of iron sensing or transport leading to tissue <b class="calibre7">iron deposition</b></p>
<p class="noindent1">• <b class="calibre7">HFE</b> mutations (85% of cases): typically C282Y homozyg. (~0.5% of N. Europeans), rarely C282Y/H63D compound heterozyg. C282Y homozygotes: 28% of ♂ &amp; 1% of ♀ develop sx (delayed since menses ↓ Fe load). C282Y/H63D: only 1.5% manifest dis.</p>
<p class="noindent1">• Non-HFE mutations: hemojuvelin, hepcidin, transferrin receptor 2, &amp; ferroportin</p>
<p class="noindent1">• 2° causes of iron overload: iron-loading anemias (eg, thalassemia major, sideroblastic anemia, aplastic anemia), parenteral iron overload (RBC transfusions, long-term HD), chronic liver disease (due to EtOH, HBV, HCV, NASH, etc.), dietary iron overload</p>
<p class="noindent1">• Sx: fatigue &amp; arthralgias, loss of libido in ♂. In <i class="calibre6">advanced disease</i> (rare): bronze skin (melanin + iron), hypogonadism (esp. in juvenile onset), DM, arthropathy (MCP), CHF, infxns (↑ risk <i class="calibre6">Vibrio</i>, <i class="calibre6">Listeria</i>, <i class="calibre6">Yersinia</i>), cirrhosis (↑ risk if EtOH/fatty liver disease; 15% risk of HCC). Disease also a/w ALS (H63D homozygotes) &amp; porphyria.</p>
<p class="noindent1"><a id="page_3-24" class="calibre4"></a>• Dx: iron sat &gt;45% (iron/TIBC × 100%); ↑ ferritin (acute phase reactant, so poor Sp; often nl in young Pts). If ↑ iron sat. → ✓ HFE to confirm dx, imaging by MRI (black liver). If HFE ⊕ &amp; ferritin &gt;1000 ng/mL or ↑ LFTs → liver bx for quant Fe index &amp; to stage fibrosis</p>
<p class="noindent1">• Treatment: phlebotomy (250 mL = 1 unit, ~250 mg of Fe) qwk until Fe sat &lt;50% &amp; ferritin 50–100 µg/L, then q3–4mo; PPI ↓ intestinal Fe absorption &amp; may ↓ need for phlebotomy; avoid vit C &amp; uncooked seafood; deferoxamine if phleb. contraindic.; genetic counseling</p>
<p class="h">Wilson disease <span class="r1">(</span><span class="r2">World J Hepatol</span> <span class="r1">2015;7:2859)</span></p>
<p class="noindent1">• Recessive disorder of copper transport (mutation in <i class="calibre6">ATP7B</i>) → <b class="calibre7">copper overload</b></p>
<p class="noindent1">• Epidemiology: 1 in ~30,000 w/ age of presentation generally ranging from 3 to 55 y</p>
<p class="noindent1">• Extrahepatic s/s: neuro ψ disease, parkinsonism, movement disorder (hepatolenticular disease), Kayser-Fleischer rings (⊕ in 99% w/ neuro ψ but in &lt;50% w/ hepatic disease), Coombs ⊖ hemolytic anemia, renal disease</p>
<p class="noindent1">• Dx: ↑ 24-h urine Cu, ↓ serum ceruloplasmin (Se 90%), liver bx w/ hepatic Cu content, genetic testing for ATP7B gene helpful if unclear dx. In <i class="calibre6">acute liver failure</i>, Aϕ/bili &lt;4 + AST/ALT &gt;2.2 better Se &amp; Sp than urine Cu or ceruloplasmin <span class="r1">(</span><span class="r2">Hepatology</span><span class="r1"> 2008;4:1167)</span>.</p>
<p class="noindent1">• Treatment: <b class="calibre7">chelation</b> w/ <small class="calibre9">D</small>-penicillamine (supplement B6 as <small class="calibre9">D</small>-pen inactivates); alternative is trientine (↓ toxicity w/ ≈ efficacy, but $$), ammonium or bis-choline tetrathiomolybdate (investigational) may ↓ neurologic deterioration compared to trientine. <b class="calibre7">Zinc:</b> ↓ intestinal Cu transport &amp; can help delay disease; best used in conjunction w/ chelation (give 5 h after chelators). Eliminate Cu-rich foods. Transplant for ALF or unresponsive to Rx.</p>
<p class="h">α<sub class="calibre10">1</sub>-antitrypsin deficiency (α<sub class="calibre10">1</sub>-AT) <span class="r1">(</span><span class="r2">J Hepatol</span> <span class="r1">2016;65:413;</span> <span class="r2">NEJM</span><span class="r1"> 2020;382:1443)</span></p>
<p class="noindent1">• Abnl α<sub class="calibre10">1</sub>-AT → polymerization in liver (cirrhosis) &amp; uninhibited protease activity in lung (emphysema). Affects 1/3000 of European ancestry. Varied presentations: neonatal hepatitis; cholestatic jaundice in children; ↑ AST/ALT or cirrhosis in children/adults.</p>
<p class="noindent1">• Extrahepatic disease: panlobular emphysema, necrotizing panniculitis, ANCA vasculitis</p>
<p class="noindent1">• Dx: serum α<sub class="calibre10">1</sub>-AT (acute phase reactant) w/ CRP level (to ensure not ↑ due to inflamm.)</p>
<p class="noindent2">gold standard = phenotyping of protease inhibitor (Pi). Alleles most a/w hepatic dis.: Z (63% of ZZ adults have chronic liver dis. and liver fibrosis, may be present in 35% of ZZ individuals w/o overt liver disease) &amp; M (malton) <span class="r1">(</span><span class="r2">J Hepatol</span> <span class="r1">2018;69:1357)</span>. Liver bx shows characteristic PAS ⊕ cytoplasmic inclusion bodies.</p>
<p class="noindent1">• Treatment: ↓ risk by avoiding EtOH, maintaining a normal BMI; liver transplant if severe</p>
<p class="h">Primary biliary cholangitis (PBC) <span class="r1">(</span><span class="r2">Hep</span> <span class="r1">2019;69:394;</span> <span class="r2">Nat Rev</span> <span class="r1">2020;17:93;</span> <span class="r2">Lancet</span><span class="r1"> 2020;396:1915)</span></p>
<p class="noindent1">• Autoimmune destruction of <i class="calibre6">intrahepatic</i> bile ducts</p>
<p class="noindent1">• Epi: ♀ 40–60 y; a/w Sjögren’s (50%), Raynaud’s, scleroderma, celiac &amp; thyroid disease; may be triggered by infxns or toxins; a/w X monosomy, variants in IL12α &amp; IL12R genes</p>
<p class="noindent1">• Sx: fatigue/sleep disturbance, pruritus, jaundice, 50% asx w/ only LFT abnormalities</p>
<p class="noindent1">• Ddx: PSC, AIH, hepatic sarcoidosis, meds, idiopathic adult ductopenia, biliary stricture/Ca</p>
<p class="noindent1">• Dx: ↑ Aϕ, ↑ bili, ↑ IgM, ↑ chol (mainly HDL-C), ⊕ (AMA) in 95%. If ⊕ AMA, liver bx not needed due to high Se &amp; Sp. 0.5% gen pop ⊕ AMA &amp; nl LFTs → 10% develop PBC at 6 y. If AMA ⊖, liver bx (Pts often ⊕ ANA, smooth muscle Ab; same prognosis as ⊕ AMA).</p>
<p class="noindent1">• Rx: <b class="calibre7">ursodeoxycholic acid</b> (UDCA) (13–15 mg/kg bid), monitor for 3–6 mos → ~25% complete response, ↑ survival &amp; ↓ histologic change &amp; ↓ complications (varices). Biochemical response predicts clinical outcome.</p>
<p class="noindent2">Obeticholic acid (FXR agonist): monoRx if cannot tolerate UDCA (but not in decompen cirrhosis) or if no Δ w/ UDCA after 1 y; found to ↓ Aφ, ↑ pruritus <span class="r1">(</span><span class="r2">NEJM</span> <span class="r1">2016;375:631)</span></p>
<p class="noindent2">Bezafibrate (not available in U.S. but fenofibrate similar) appears to be effective 2<sup class="calibre19">nd</sup>-line agent in combo w/ UDCA if inadequate response to UDCA <span class="r1">(</span><span class="r2">NEJM</span> <span class="r1">2018;378:2171)</span></p>
<p class="noindent2">Pruritus: cholestyramine (give 2–4 h after UDCA); if refractory sx: naltrexone, rifampin</p>
<p class="noindent2">If ESLD: liver tx; ~20% recur but no impact on long-term survival</p>
<p class="h">Primary sclerosing cholangitis (PSC) <span class="r1">(</span><span class="r2">NEJM</span> <span class="r1">2016;375:1161;</span> <span class="r2">Clin Liver Dis</span> <span class="r1">2020;15:125)</span></p>
<p class="noindent1">• Diffuse inflammation of <i class="calibre6">intrahepatic and extrahepatic</i> bile ducts leading to fibrosis &amp; stricturing of biliary system. A/w HLA-B8 and -DR3 or -DR4, frequent ⊕ autoantibodies.</p>
<p class="noindent1">• Epi: ♂ &gt;♀ (20–50 y) ~70% Pts w/ PSC have IBD (usually UC); only 1–4% w/ UC have PSC. ⊕ prognostic factors: ♂, absence of IBD, small duct PSC <span class="r1">(</span><span class="r2">Gastro</span> <span class="r1">2017;152:1829)</span>.</p>
<p class="noindent1">• Symptoms: fatigue, pruritus, jaundice, fevers, RUQ pain, IBD; 50% of Pts asymptomatic</p>
<p class="noindent1">• Ddx: extrahepatic obstruction, PBC, overlap w/ AIH, IgG4 autoimmune cholangitis, etc.</p>
<p class="noindent1">• Dx: cholangiography (MRCP ± ERCP) → <i class="calibre6">multifocal beaded bile duct strictures</i>; exclude 2<sup class="calibre19">°</sup> cause; may miss dx if confined to small intrahepatic ducts (“small duct PSC”).</p>
<p class="noindent2">Liver bx if unclear: “onion-skin” fibrosis around bile ducts + some findings similar to PBC.</p>
<p class="noindent1">• Treatment: supportive care, fat-soluble vitamins; no meds have improved survival</p>
<p class="noindent2">UDCA may ↓ Aϕ &amp; improve Sx, but unclear if beneficial</p>
<p class="noindent2">If dominant stricture → endoscopic dilation, stenting or surgical resection can help</p>
<p class="noindent2">Cholangiocarcinoma: 15% lifetime risk; annual surveillance w/ MRCP or U/S &amp; CA19-9</p>
<p class="noindent2">Liver transplantation: ~30% recurrence, though if UC, colectomy may ↓ recurrence</p>
<h2 class="ct"><a id="h52" class="calibre8"></a><a id="page_3-25" class="calibre8"></a><a href="part0003.html#rh58" class="calibre8">HEPATIC VASCULAR DISEASE</a></h2>
<div class="cap">
<p class="caption"><a id="fig3-5" class="calibre4"></a><b class="calibre7">Figure 3-5</b> Normal hepatic vasculature</p>
<p class="imagef1"><img src="../images/00059.jpeg" alt="" class="calibre5"/></p>
</div>
<p class="tfn">(Modified from <i class="calibre6">The Nature of Disease Pathology for the Health Professions, 2007. Hepatology</i> 2009;49:1729.)</p>
<p class="h">Portal vein thrombosis (PVT) <span class="r1">(</span><span class="r2">Clin Liver Dis</span> <span class="r1">2017;10:152;</span> <span class="r2">Gastro</span><span class="r1"> 2019;156:1582)</span></p>
<p class="noindent1">• Definition: thrombosis of portal vein often w/ extension into mesenteric vein/splenic vein</p>
<p class="noindent1">• Etiologies: commonly due to cirrhosis or hypercoaguable state (cancer, infection, OCP, collagen vascular diseases, Behçet’s, IBD, surgery, trauma, OCPs, preg)</p>
<p class="noindent1">• Clinical manifestations</p>
<p class="noindent2"><b class="calibre7">acute:</b> abd pain, fever, variceal bleed or asx w/ incidental finding on U/S or CT. If mesenteric vein involved may p/w intestinal infarct. If fever, consider pylephlebitis.</p>
<p class="noindent2"><b class="calibre7">chronic:</b> asx/incidental finding; may p/w s/s of <b class="calibre7">portal HTN</b> → hematemesis 2° variceal bleeding, splenomegaly, encephalopathy; ascites uncommon unless cirrhosis</p>
<p class="noindent1">• Dx: LFTs usually nl; begin w/ U/S w/ Doppler, confirm w/ MRA or CT (I<sup class="calibre19">+</sup>), angio; consider hypercoag w/u. “Portal cavernoma”: network of hepatopetal collaterals in chronic PVT—can rarely cause biliary obstruction &amp; cholestatic LFTs = portal cholangiopathy.</p>
<p class="noindent1">• Treatment: <b class="calibre7">Acute:</b> If noncirrhotic, LMWH → warfarin or DOAC × 6 mo, or indefinitely if irreversible cause. If cirrhotic, anticoag ↑ recanalization w/o ↑ bleeding <span class="r1">(</span><span class="r2">Gastro</span> <span class="r1">2017;153:480)</span>; screen for high-risk varices prior to Rx <span class="r1">(</span><span class="r2">Nat Rev Gastro Hep</span> <span class="r1">2014;11:435)</span>.</p>
<p class="noindent2"><b class="calibre7">Chronic:</b> Anticoag if noncirrhotic or hypercoag state. If cirrhotic, consider txp if sx or progression. In all, screen for varices; if present, variceal bleed Ppx prior to anticoag.</p>
<p class="h">Splenic vein thrombosis</p>
<p class="noindent1">• Can occur 2/2 local inflam. (eg, panc.). Can p/w isol. gastric varices. Splenectomy curative.</p>
<p class="h">Budd-Chiari syndrome <span class="r1">(</span><span class="r2">World J Hepatol</span> <span class="r1">2016;8:691)</span></p>
<p class="noindent1">• Hepatic outflow obstruction 2/2 occlusion of hepatic vein(s) or IVC → sinusoidal congestion and portal HTN. Can be 1° (eg, thrombosis) or 2° (eg, extravascular compression).</p>
<p class="noindent1">• Etiol.: ~50% due to myeloprolif. d/o a/w <i class="calibre6">JAK2</i> mutations (<i class="calibre6">P. vera</i>, etc.), hypercoag states (systemic, OCP, pregnancy), tumor invasion (HCC, renal, adrenal), trauma, idiopathic</p>
<p class="noindent1">• Symptoms: hepatomegaly, RUQ pain, ascites, dilated venous collaterals, acute liver failure</p>
<p class="noindent1">• Dx: ± ↑ AST, ALT &amp; Aϕ; Doppler U/S of hepatic veins (85% Se &amp; Sp); CT (I<sup class="calibre19">+</sup>) or MRI/MRV → vein occlusion or ↑ caudate lobe (separate venous drainage); hepatic venography gold standard w/ “spider- web” pattern + assess venous pressure; biopsy only if unclear</p>
<p class="noindent1">• Treatment: Rx underlying condition, anticoag (LMWH → warfarin); consider thrombolysis if acute; angioplasty &amp; stent if short stenosis; consider TIPS or DIPS (U/S-guided direct intrahepatic portosystemic shunt) (if other methods fail to treat sx of portal HTN); liver transplant if ALF or failed other options</p>
<p class="h">Sinusoidal obstruction syndrome (SOS) <span class="r1">(</span><span class="r2">Bone Marrow Transplant</span> <span class="r1">2020:55:485)</span></p>
<p class="noindent1">• Occlusion of hepatic venules &amp; sinusoids (formerly veno-occlusive disease) 2/2 toxic insult</p>
<p class="noindent1">• Etiologies: post HSCT (15%), chemo (cyclophosphamide, cytarabine), XRT, bush tea</p>
<p class="noindent1">• Clinical manifestations: painful hepatomegaly, RUQ pain, ascites, weight gain, ↑ bilirubin</p>
<p class="noindent1">• Dx: U/S w/ reversal of portal flow; dx made clinically (early weight gain, ↓ plt refractory to transfusion, ↑ bili, hx of recent toxins); if necessary, liver bx or HVPG (&gt;10 mmHg)</p>
<p class="noindent1">• Rx: supportive, diuretics; if severe → early defibrotide ↑ survival, but side effects &amp; expensive</p>
<p class="noindent1">• Ppx: defibrotide; ursodeoxycholic acid for high-risk HSCT pop; ? use of low-dose heparin</p>
<h2 class="ct"><a id="h53" class="calibre8"></a><a id="page_3-26" class="calibre8"></a><a href="part0003.html#rh59" class="calibre8">ASCITES</a></h2>
<p class="h">Pathophysiology <span class="r1">(</span><span class="r2">Hepatology</span> <span class="r1">2021;74:1014)</span></p>
<p class="noindent1">• Portal HTN → ↑ NO &amp; prostaglandins → splanchnic vasodilatation→ ↓ effective arterial volume → ↑ RAAS &amp; ADH → renal Na &amp; H<sub class="calibre10">2</sub>O retention → volume overload and ascites</p>
<p class="noindent1">• In malignant or inflammatory ascites, leaking of proteinaceous material occurs from tumor or from inflamed/infected/ruptured intraabdominal structures</p>
<p class="h">Symptoms</p>
<p class="noindent1">• ↑ abd girth, wt gain, new abd hernia, abd pain, dyspnea, nausea, early satiety</p>
<p class="h">Evaluation <span class="r1">(</span><span class="r2">World J Hepatol</span> <span class="r1">2013;5:251;</span> <span class="r2">JAMA</span> <span class="r1">2016;316:340)</span></p>
<p class="noindent1">• Physical exam: <b class="calibre7">flank dullness</b> <span class="r1">(</span>&gt;1500 mL needed), shifting dullness (Se ~83%)</p>
<p class="noindent1">• Radiologic: <b class="calibre7">U/S</b> detects &gt;100 mL fluid; MRI/CT (also help with Ddx)</p>
<p class="noindent1">• <b class="calibre7">Paracentesis</b>: perform in all Pts w/ new ascites, suggested in all hosp. Pts w/ cirrhosis + ascites. Low complic. rate (~1% hematoma formation). Prophylactic FFP or plts does <i class="calibre6">not</i> ↓ bleeding complic. Most useful tests: cell count, alb, total protein (for SAAG), &amp; culture</p>
<p class="noindent1">• <b class="calibre7">Serum-ascites albumin gradient (SAAG):</b> serum alb (g/dL) – ascites alb (g/dL)</p>
<p class="noindent2">SAAG ≥1.1 diagnoses portal HTN with ~97% accuracy <span class="r1">(</span><span class="r2">Ann Intern Med</span> <span class="r1">1992;117:215)</span></p>
<p class="noindent2">If portal HTN + another cause (seen in ~5% of cases) SAAG still ≥1.1</p>
<table class="tabb">
<colgroup class="calibre11">
<col class="calibre26"/>
<col class="calibre26"/>
</colgroup>
<thead class="calibre14">
<tr class="calibre15">
<td class="th" colspan="2"><p class="tbodyc"><b class="calibre7">Etiologies</b></p></td>
</tr>
</thead>
<tbody class="calibre16">
<tr class="calibre15">
<td class="th1"><p class="tbodyh"><b class="calibre7">Portal HTN Related (SAAG ≥1.1)</b></p></td>
<td class="th1"><p class="tbodyh"><b class="calibre7">Non–portal HTN Related (SAAG &lt;1.1)</b></p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbodyh"><i class="calibre6">Presinusoidal</i> obstruction portal or splenic vein thrombosis, schisto- somiasis, sarcoidosis</p>
<p class="tbodyh"><i class="calibre6">Sinusoidal</i> obstruction: <b class="calibre7">cirrhosis</b>, acute hepatitis (including EtOH), malignancy (HCC or mets)</p>
<p class="tbodyh"><i class="calibre6">Postsinusoidal</i> obstruction right-sided <b class="calibre7">CHF</b> (ex: constriction, TR), Budd-Chiari syndrome, SOS</p></td>
<td class="th1"><p class="tbodyh">Malig: <b class="calibre7">peritoneal carcinomatosis</b>; chylous ascites from malignant lymphoma (↑ TG); Meigs’ syndrome (ovarian tumor)</p>
<p class="tbodyh">Infection: TB, chlamydia/gonorrhea (ie, Fitz-Hugh-Curtis syndrome)</p>
<p class="tbodyh">Inflam: pancreatitis, ruptured pancreatic/biliary/lymph duct; bowel obstrxn, serositis (SLE)</p>
<p class="tbodyh">Hypoalbuminemic states: nephrotic syndrome, protein-losing enteropathy</p></td>
</tr>
</tbody>
</table>
<p class="noindent1">• Ascites fluid total protein (<b class="calibre7">AFTP</b>): useful when SAAG ≥1.1 to distinguish cirrhosis (AFTP &lt;2.5 g/dL) from cardiac ascites (AFTP ≥2.5 g/dL). Low AFTP (&lt;1 g/dL) assoc. w/ ↑ risk of SBP (see “Cirrhosis” for guidelines on SBP Ppx based on AFTP).</p>
<p class="noindent1">• <b class="calibre7">Cell count:</b> normal limit of PMNs in ascitic fluid up to 250 PMNs/mm<sup class="calibre19">3</sup>. Bloody tap (typically from traumatic para) can skew cell count; subtract 1 PMN for every 250 RBCs to correct PMN count. Ascitic PMNs ≥250 suggest infection.</p>
<p class="noindent1">• Other tests: amylase (pancreatitis, gut perforation); bilirubin (test in dark brown fluid, suggests bile leak or proximal intestinal perf); TG (chylous ascites); BNP (HF); cytology (peritoneal carcinomatosis, ~95% Se w/ 3 samples). SBP a/w ↓ glc &amp; ↑ LDH. Ascites culture (prior to abx if possible, should have both aerobic &amp; anerobic w/ 10 cc per bottle)</p>
<p class="h">Treatment <span class="r">(see “Cirrhosis” for details)</span></p>
<p class="noindent1">• If 2° to portal HTN: ↓<b class="calibre7"> Na intake</b> (&lt;2 g/d) + <b class="calibre7">diuretics</b>; if refractory → LVP (serial) or TIPS</p>
<p class="noindent1">• If non–portal HTN related: depends on underlying cause (TB, malignancy, etc.)</p>
<p class="h">Bacterial peritonitis <span class="r1">(</span><span class="r2">Gut</span> <span class="r1">2012;61:297;</span> <span class="r2">Hepatology</span><span class="r1"> 2021;74:1014)</span></p>
<table class="tabb">
<colgroup class="calibre11">
<col class="calibre28"/>
<col class="calibre13"/>
<col class="calibre20"/>
</colgroup>
<tbody class="calibre16">
<tr class="calibre15">
<td class="th"><p class="tbodyc"><b class="calibre7">Ascites PMN</b></p></td>
<td class="th"><p class="tbodyc">⊕ <b class="calibre7">Ascites Culture</b></p></td>
<td class="th"><p class="tbodyc">⊖ <b class="calibre7">Ascites Culture</b></p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbody">≥<b class="calibre7">250/µL</b></p></td>
<td class="th1"><p class="tbodyh"><b class="calibre7">Spontaneous bacterial peritonitis (SBP):</b> gut bacterial translocation to ascites. In cirrhosis, ↓ ascites opsonins (esp. if ↓AFTP) ↑ risk of infxn. Infection usually monomicrobial: most common → <i class="calibre6">E. coli</i>, <i class="calibre6">Klebs</i>, <i class="calibre6">S. pneumo</i>; rarely <i class="calibre6">Staph</i> &amp; <i class="calibre6">Pseudo</i>. Rx 3<sup class="calibre27">rd</sup>-gen ceph; carbapenem if critically ill.</p>
<p class="tbodyh"><b class="calibre7">2° bacterial peritonitis:</b> 2/2 intra-abd abscess, perf. Runyon’s criteria: AFTP &gt;1 g/dL, glc &lt;50 mg/dL, LDH &gt;ULN for serum. Cx polymicrobial. Rx 3<sup class="calibre27">rd</sup>-gen ceph. + MNZ; urgent abd imaging ± ex lap.</p></td>
<td class="th1"><p class="tbody"><b class="calibre7">Culture-</b>⊖ <b class="calibre7">neutrocytic ascites (CNNA):</b> cell counts suggest infxn but cx ⊖. No recent abx, w/o other explan. for counts. Often do have SBP and should be treated with empiric regimen.</p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbody">&lt;<b class="calibre7">250/µL</b></p></td>
<td class="th1"><p class="tbody"><b class="calibre7">Nonneutrocytic bacterascites (NNBA):</b> ⊕ cx w/o ↑ PMNs. Natural course may resolve w/o Rx. Start abx if symptomatic; if asymptomatic repeat para in 48 hrs.</p>
<p class="tbody">Cx w/ 1 org.: Misc. GPC, <i class="calibre6">E. coli</i>, <i class="calibre6">Klebs</i>, misc. GNR.</p></td>
<td class="th1"><p class="tbody">(Normal)</p></td>
</tr>
<tr class="calibre15">
<td class="th1" colspan="3"><p class="tbody"><b class="calibre7">Peritoneal dialysis-associated:</b> cloudy fluid, abd pain, fever, nausea. Dx can be made with &gt;50 PMNs. Culture most often GPC (50%) or GNR (15%).</p>
<p class="tbody">Rx: vanc + gent (IV load, then administer in PD).</p></td>
</tr>
</tbody>
</table>
<h2 class="ct"><a id="h54" class="calibre8"></a><a id="page_3-27" class="calibre8"></a><a href="part0003.html#rh60" class="calibre8">BILIARY TRACT DISEASE</a></h2>
<p class="h1cr">C<small class="calibre31">HOLELITHIASIS</small> (G<small class="calibre31">ALLSTONES</small>)</p>
<p class="h">Epidemiology &amp; pathogenesis <span class="r1">(</span><span class="r2">J Hepatol</span> <span class="r1">2016;65:146;</span> <span class="r2">Gastro</span><span class="r1"> 2016;151:351)</span></p>
<p class="noindent1">• Affects ~10% of Western populations, 15–25% of people develop sx over 10–15 y</p>
<p class="noindent1">• Bile = bile salts, phospholipids, cholesterol; ↑ cholesterol saturation in bile + accelerated nucleation + gallbladder hypomotility → gallstones</p>
<p class="noindent1">• Risk factors: ♀; South, Central, Native American; ↑ age (&gt;40 y); obesity, TPN, rapid ↓ wt; dyslipidemia; preg., drugs (OCPs, estrogen, clofibrate, octreotide); ileal dis., genetics</p>
<p class="noindent1">• Statin use ↓ risk of sx gallstones &amp; cholecystectomy <span class="r1">(</span><span class="r2">Hepatol Res</span> <span class="r1">2015;45:942)</span></p>
<p class="h">Types of gallstones <span class="r1">(</span><span class="r2">J Hepatol</span> <span class="r1">2016;65:146)</span></p>
<p class="noindent1">• Cholesterol (90%): 2 subtypes</p>
<p class="noindent2">mixed: contain &gt;50% cholesterol; typically smaller, multiple stones</p>
<p class="noindent2">pure: 100% cholesterol; larger, yellow, white appearance</p>
<p class="noindent1">• Pigment (10%)</p>
<p class="noindent2"><i class="calibre6">Black:</i> unconjugated bili &amp; calcium; seen w/ chronic hemolysis, cirrhosis, CF, Gilbert synd</p>
<p class="noindent2"><i class="calibre6">Brown:</i> stasis &amp; infxn in bile ducts → bacteria deconjugate bilirubin → precipitates w/ Ca; found pred in bile ducts; seen w/ biliary strictures, parasites, post-cholecystectomy</p>
<p class="h">Clinical manifestations</p>
<p class="noindent1">• Asx in ~80%. Biliary pain develops in 1–4%/y. Once sx, rate of complications ~1–3%/y.</p>
<p class="noindent1">• <b class="calibre7">Biliary pain = episodic RUQ or epigastric pain;</b> begins abruptly, continuous, resolves slowly and lasts 30 min–3 h; ± radiation to scapula; precip by <b class="calibre7">fatty foods</b>; <b class="calibre7">nausea</b></p>
<p class="noindent1">• Physical exam: afebrile, ± RUQ tenderness or epigastric pain</p>
<p class="h">Diagnostic studies</p>
<p class="noindent1">• Labs normal in most</p>
<p class="noindent1">• RUQ U/S: Se &amp; Sp &gt;95% for stones &gt;5 mm; should be performed after ≥8 h fast for distended, bile-filled gallbladder. If ⊖, repeat in 1 mo to detect missed stones</p>
<p class="noindent1">• Endoscopic U/S (EUS): Se 94–98% in Pts w/ biliary pain but nl U/S <span class="r1">(</span><span class="r2">J Hepatol</span> <span class="r1">2016;65:146)</span></p>
<p class="noindent1">• CT scan/KUB is less Se; stones often isodense w/o enough calcium &amp; will be missed</p>
<p class="h">Treatment <span class="r1">(</span><span class="r2">Am Fam Physician</span> <span class="r1">2014;89:795;</span> <span class="r2">J Hepatol</span><span class="r1"> 2016;65:146)</span></p>
<p class="noindent1">• Cholecystectomy (CCY), usually laparoscopic, if symptomatic (earlier is better)</p>
<p class="noindent1">• CCY in <i class="calibre6">asx</i> Pts if: GB calcification (↑ risk of cancer), GB polyps &gt;10 mm, stones &gt;3 cm; Pts undergoing bariatric surgery, cardiac Tx candidates, hemolytic anemia (sickle cell)</p>
<p class="noindent1">• Options if ↑ risk for surgery: percutaneous drainage, endoscopic transpapillary drainage</p>
<p class="noindent1">• UDCA can be trialed for cholesterol stones w/ biliary pain or if poor surgical candidate, but takes ~3 mo to work; ↓ risk of gallstone formation that occurs w/ rapid wt ↓</p>
<p class="noindent1">• Pain: NSAIDs drugs of choice, efficacy ≈ opiates &amp; avoids ↑ sphincter of Oddi pressure</p>
<p class="h">Complications</p>
<p class="noindent1">• Cholecystitis: 20% of Pts with symptomatic biliary pain progress to cholecystitis w/in 2 y</p>
<p class="noindent1">• Choledocholithiasis → cholangitis or gallstone pancreatitis</p>
<p class="noindent1">• Mirizzi syndrome: hepatic duct compression by GB stone → jaundice, biliary obstruction</p>
<p class="noindent1">• Cholecystenteric fistula: stone erodes through gallbladder into bowel, ~15% w/ colon</p>
<p class="noindent1">• Gallstone ileus: SBO (usually at term ileum) due to stone in intestine that passed thru fistula</p>
<p class="noindent1">• Gallbladder carcinoma: ~1% in U.S., often found late stage, a/w poor prognosis</p>
<p class="h1cr">C<small class="calibre31">HOLECYSTITIS</small> <span class="r3">(</span><span class="r4">JAMA</span> <span class="r3">2022;327:965)</span></p>
<p class="h">Pathogenesis</p>
<p class="noindent1">• Acute cholecystitis: stone impaction in cystic duct → inflammation behind obstruction → GB swelling ± secondary infection (50%) of biliary fluid</p>
<p class="noindent1">• Acalculous cholecystitis: GB stasis &amp; ischemia (w/o cholelithiasis) → necroinflammation. Occurs in critically ill. A/w postop major surgery, TPN, sepsis, trauma, burns, opiates, immunosuppression, infxn (eg, CMV, <i class="calibre6">Candida</i>, <i class="calibre6">Crypto, Campylobacter</i>, typhoid fever).</p>
<p class="h">Clinical manifestations</p>
<p class="noindent1">• History: RUQ/epigastric pain ± radiation to R shoulder/back, nausea, vomiting, fever</p>
<p class="noindent1">• Physical exam: <b class="calibre7">RUQ tenderness</b>, <b class="calibre7">Murphy’s sign</b> = ↑ RUQ pain and inspiratory arrest with deep breath during palpation of R subcostal region, ± palpable gallbladder</p>
<p class="noindent1">• Laboratory evaluation: <i class="calibre6">may</i> see ↑ WBC, ± mild ↑ bilirubin, Aϕ, ALT/AST, amylase; if AST/ALT &gt;500 U/L, bili &gt;4 mg/dL or amylase &gt;1000 U/L → choledocholithiasis</p>
<p class="h">Diagnostic studies</p>
<p class="noindent1">• <b class="calibre7">RUQ U</b>/<b class="calibre7">S:</b> high Se &amp; Sp for stones, but need <i class="calibre6">specific signs of cholecystitis:</i> GB wall thickening &gt;4 mm, pericholecystic fluid and a sonographic Murphy’s sign</p>
<p class="noindent1"><a id="page_3-28" class="calibre4"></a>• <b class="calibre7">HIDA scan:</b> most Se test (80–90%) for acute cholecystitis. IV inj of HIDA (selectively secreted into bile). ⊕ if HIDA enters BD but not GB. 10–20% false ⊕ (cystic duct obstructed 2/2 chronic cholecystitis, lengthy fasting, liver disease).</p>
<p class="h">Treatment <span class="r1">(</span><span class="r2">Ann Surg</span> <span class="r1">2013;258:385;</span> <span class="r2">NEJM</span><span class="r1"> 2015;373:357)</span></p>
<p class="noindent1">• NPO, IV fluids, nasogastric tube if intractable vomiting, analgesia</p>
<p class="noindent1">• <b class="calibre7">Antibiotics</b> (<i class="calibre6">E. coli</i>, <i class="calibre6">Klebsiella</i> and <i class="calibre6">Enterobacter</i> sp. are usual pathogens) ([2<sup class="calibre19">nd</sup>- or 3<sup class="calibre19">rd</sup>-generation cephalosporin or FQ] + MNZ) or piperacillin-tazobactam</p>
<p class="noindent1">• <b class="calibre7">CCY</b> (typically laparoscopic) w/in 24 h ↓ morbidity vs. waiting 7–45 d</p>
<p class="noindent1">• If unstable for surgery, EUS-guided transmural, ERCP-guided transcystic duct drainage, or percutaneous cholecystotomy (if w/o ascites or coagulopathy) are alternatives to CCY</p>
<p class="noindent1">• Intraoperative cholangiogram or ERCP to r/o choledocholithiasis in Pts w/ jaundice, cholangitis or stone in BD on U/S (see below)</p>
<p class="h">Complications</p>
<p class="noindent1">• Gangrenous cholecystitis: necrosis w/ risk of empyema and perforation</p>
<p class="noindent1">• Emphysematous cholecystitis: infection by gas-forming organisms (air in GB wall)</p>
<p class="noindent1">• Perforation: ~10% of cases, due to delay in diagnosis; pericholecystic abscess forms</p>
<p class="noindent1">• Post CCY: bile duct leak, BD injury or retained stones, cystic duct remnant, sphincter of Oddi dysfxn</p>
<p class="h1cr">C<small class="calibre31">HOLEDOCHOLITHIASIS</small></p>
<p class="h">Definition</p>
<p class="noindent1">• Gallstone lodged in common bile duct (CBD)</p>
<p class="h">Epidemiology</p>
<p class="noindent1">• Occurs in 15% of Pts w/ gallbladder stones; can form de novo in CBD due to biliary stasis</p>
<p class="h">Clinical manifestations</p>
<p class="noindent1">• RUQ/epigastric pain 2° obstrxn of bile flow → ↑ CBD pressure, jaundice, pruritus, nausea</p>
<p class="noindent1">• Rarely asymptomatic</p>
<p class="h">Diagnostic studies <span class="r1">(</span><span class="r2">J Hepatol</span> <span class="r1">2016;65:146;</span> <span class="r2">Gastrointest Endosc</span> <span class="r1">2019;89:1075)</span></p>
<p class="noindent1">• Labs: ↑ bilirubin, Aϕ; transient spike in ALT or amylase suggests passage of stone</p>
<p class="noindent1">• RUQ U/S: BD stones seen ~50–80% of cases; usually inferred from dilated CBD (&gt;6 mm)</p>
<p class="noindent1">• ERCP preferred modality when likelihood high (eg, visualized stone, cholangitis, bili &gt;4, <i class="calibre6">or</i> dilated CBD on U/S + bili 1.8–4 mg/dL); cholangiogram (percutaneous, operative) if ERCP unavailable or unsuccessful; EUS/MRCP to exclude BD stones if suspicion intermediate (eg, no stone, dilated ducts on U/S, bili 1.8–4 mg/dL, gallstone panc., age &gt;55, or abnl non-bili LFT)</p>
<p class="h">Treatment</p>
<p class="noindent1">• ERCP &amp; papillotomy w/ stone extraction (± lithotripsy)</p>
<p class="noindent1">• CCY w/in 6 wk unless contraindication (&gt;15% Pts develop indication for CCY if unRx’d)</p>
<p class="h">Complications</p>
<p class="noindent1">• Cholangitis, cholecystitis, pancreatitis, stricture</p>
<p class="h1cr">C<small class="calibre31">HOLANGITIS</small></p>
<p class="h">Definition &amp; etiologies <span class="r1">(</span><span class="r2">World J Gasrointest Pathophysiol</span> <span class="r1">2018:9:1)</span></p>
<p class="noindent1">• Bile duct obstruction causes stasis → infection proximal to the obstruction</p>
<p class="noindent1">• Etiologies: <b class="calibre7">BD stone</b> (~85%); malignant (biliary, pancreatic) or benign stricture; infection w/ fluke (<i class="calibre6">Clonorchis sinensis, Opisthorchis viverrini</i>); recurrent pyrogenic cholangitis</p>
<p class="h">Clinical manifestations</p>
<p class="noindent1">• Charcot’s triad: RUQ pain, jaundice, fever/chills; present in ~70% of Pts</p>
<p class="noindent1">• Reynolds’ pentad: Charcot’s triad + shock and Δ MS; present in ~15% of Pts</p>
<p class="h">Diagnostic studies</p>
<p class="noindent1">• RUQ U/S: often demonstrates dilation of bile ducts</p>
<p class="noindent1">• Labs: ↑ WBC (with left shift), bilirubin, Aφ, amylase; may see ⊕ BCx</p>
<p class="noindent1">• ERCP; percutaneous transhepatic cholangiogram if ERCP unsuccessful</p>
<p class="h">Treatment</p>
<p class="noindent1">• <b class="calibre7">Antibiotics</b> (broad spectrum) to cover common bile pathogens (see above) ampicillin + gentamicin (or levofloxacin) ± MNZ (if severe); carbapenems; pip/tazo</p>
<p class="noindent1">• ~80% respond to conservative Rx and abx → biliary drainage on elective basis</p>
<p class="noindent1">• ~20% require <b class="calibre7">urgent biliary decompression</b> via ERCP (papillotomy, stone extraction, and/or stent insertion). If sphincterotomy cannot be performed (larger stones), decompression by biliary stent or nasobiliary catheter can be done; otherwise, percutaneous transhepatic biliary drainage or surgery.</p>


  </div>

  
  <div class="calibreToc">
    <h2><a href="../../j09u21sl.html">Table of contents
</a></h2>
    <div>
  <ul>
    <li>
      <a href="part0000.html#0-96ac16803db7461d85d0589a1c192bcf">Cover</a>
    </li>
    <li>
      <a href="part0001.html#UGI0-96ac16803db7461d85d0589a1c192bcf">Title Page</a>
    </li>
    <li>
      <a href="part0002.html#1T140-96ac16803db7461d85d0589a1c192bcf">Copyright Page</a>
    </li>
    <li>
      <a href="part0003.html#2RHM0-96ac16803db7461d85d0589a1c192bcf">Contents</a>
    </li>
    <li>
      <a href="part0004.html#3Q280-96ac16803db7461d85d0589a1c192bcf">Contributing Authors</a>
    </li>
    <li>
      <a href="part0005.html#4OIQ0-96ac16803db7461d85d0589a1c192bcf">Foreword</a>
    </li>
    <li>
      <a href="part0006.html#5N3C0-96ac16803db7461d85d0589a1c192bcf">Preface</a>
    </li>
    <li>
      <a href="part0007.html#6LJU0-96ac16803db7461d85d0589a1c192bcf">CARDIOLOGY</a>
      <ul>
        <li>
          <a href="part0007.html#h1">Electrocardiography</a>
        </li>
        <li>
          <a href="part0007.html#h2">Chest Pain</a>
        </li>
        <li>
          <a href="part0007.html#h3">Noninvasive Evaluation of CAD</a>
        </li>
        <li>
          <a href="part0007.html#h4">Coronary Angiography &amp; PCI</a>
        </li>
        <li>
          <a href="part0007.html#h5">Stable Ischemic Heart Disease</a>
        </li>
        <li>
          <a href="part0007.html#h6">Acute Coronary Syndromes</a>
        </li>
        <li>
          <a href="part0007.html#h7">PA Catheter and Tailored Therapy</a>
        </li>
        <li>
          <a href="part0007.html#h8">Heart Failure</a>
        </li>
        <li>
          <a href="part0007.html#h9">Cardiomyopathies</a>
        </li>
        <li>
          <a href="part0007.html#h10">Valvular Heart Disease</a>
        </li>
        <li>
          <a href="part0007.html#h11">Pericardial Disease</a>
        </li>
        <li>
          <a href="part0007.html#h12">Hypertension</a>
        </li>
        <li>
          <a href="part0007.html#h13">Aortic Aneurysms</a>
        </li>
        <li>
          <a href="part0007.html#h14">Acute Aortic Syndromes</a>
        </li>
        <li>
          <a href="part0007.html#h15">Arrhythmias</a>
        </li>
        <li>
          <a href="part0007.html#h16">Atrial Fibrillation</a>
        </li>
        <li>
          <a href="part0007.html#h17">Syncope</a>
        </li>
        <li>
          <a href="part0007.html#h18">Cardiac Rhythm Management Devices</a>
        </li>
        <li>
          <a href="part0007.html#h19">Cardiac Risk Assessment for Noncardiac Surgery</a>
        </li>
        <li>
          <a href="part0007.html#h20">Peripheral Artery Disease</a>
        </li>
      </ul>
    </li>
    <li>
      <a href="part0008.html#7K4G0-96ac16803db7461d85d0589a1c192bcf">PULMONARY</a>
      <ul>
        <li>
          <a href="part0008.html#h21">Dyspnea</a>
        </li>
        <li>
          <a href="part0008.html#h22">Pulmonary Function Tests</a>
        </li>
        <li>
          <a href="part0008.html#h23">Asthma</a>
        </li>
        <li>
          <a href="part0008.html#h24">Anaphylaxis</a>
        </li>
        <li>
          <a href="part0008.html#h25">Chronic Obstructive Pulmonary Disease</a>
        </li>
        <li>
          <a href="part0008.html#h26">Solitary Pulmonary Nodule</a>
        </li>
        <li>
          <a href="part0008.html#h27">Hemoptysis</a>
        </li>
        <li>
          <a href="part0008.html#h28">Bronchiectasis</a>
        </li>
        <li>
          <a href="part0008.html#h29">Cystic Fibrosis</a>
        </li>
        <li>
          <a href="part0008.html#h30">Interstitial Lung Disease</a>
        </li>
        <li>
          <a href="part0008.html#h31">Pleural Effusion</a>
        </li>
        <li>
          <a href="part0008.html#h32">Venous Thromboembolism</a>
        </li>
        <li>
          <a href="part0008.html#h33">Pulmonary Hypertension</a>
        </li>
        <li>
          <a href="part0008.html#h34">Respiratory Failure</a>
        </li>
        <li>
          <a href="part0008.html#h35">Mechanical Ventilation</a>
        </li>
        <li>
          <a href="part0008.html#h36">Acute Respiratory Distress Syndrome</a>
        </li>
        <li>
          <a href="part0008.html#h37">Sepsis and Shock</a>
        </li>
        <li>
          <a href="part0008.html#h38">Toxicology</a>
        </li>
        <li>
          <a href="part0008.html#h39">Lung Transplant</a>
        </li>
      </ul>
    </li>
    <li>
      <a href="part0009.html#8IL20-96ac16803db7461d85d0589a1c192bcf">GASTROENTEROLOGY</a>
      <ul>
        <li>
          <a href="part0009.html#h40">Esophageal and Gastric Disorders</a>
        </li>
        <li>
          <a href="part0009.html#h41">Gastrointestinal Bleeding</a>
        </li>
        <li>
          <a href="part0009.html#h42">Diarrhea</a>
        </li>
        <li>
          <a href="part0009.html#h43">Dysmotility &amp; Nutrition</a>
        </li>
        <li>
          <a href="part0009.html#h44">Disorders of the Colon</a>
        </li>
        <li>
          <a href="part0009.html#h45">Inflammatory Bowel Disease</a>
        </li>
        <li>
          <a href="part0009.html#h46">Intestinal Ischemia</a>
        </li>
        <li>
          <a href="part0009.html#h47">Pancreatitis</a>
        </li>
        <li>
          <a href="part0009.html#h48">Abnormal Liver Tests</a>
        </li>
        <li>
          <a href="part0009.html#h49">Hepatitis</a>
        </li>
        <li>
          <a href="part0009.html#h50">Acute Liver Failure</a>
        </li>
        <li>
          <a href="part0009.html#h51">Cirrhosis</a>
        </li>
        <li>
          <a href="part0009.html#h52">Hepatic Vascular Disease</a>
        </li>
        <li>
          <a href="part0009.html#h53">Ascites</a>
        </li>
        <li>
          <a href="part0009.html#h54">Biliary Tract Disease</a>
        </li>
      </ul>
    </li>
    <li>
      <a href="part0010.html#9H5K0-96ac16803db7461d85d0589a1c192bcf">NEPHROLOGY</a>
      <ul>
        <li>
          <a href="part0010.html#h55">Acid-Base Disturbances</a>
        </li>
        <li>
          <a href="part0010.html#h56">Sodium and Water Homeostasis</a>
        </li>
        <li>
          <a href="part0010.html#h57">Potassium Homeostasis</a>
        </li>
        <li>
          <a href="part0010.html#h58">Kidney Disease</a>
        </li>
        <li>
          <a href="part0010.html#h59">Glomerular Disease</a>
        </li>
        <li>
          <a href="part0010.html#h60">Urinalysis</a>
        </li>
        <li>
          <a href="part0010.html#h61">Nephrolithiasis</a>
        </li>
      </ul>
    </li>
    <li>
      <a href="part0011.html#AFM60-96ac16803db7461d85d0589a1c192bcf">HEMATOLOGY-ONCOLOGY</a>
      <ul>
        <li>
          <a href="part0011.html#h62">Anemia</a>
        </li>
        <li>
          <a href="part0011.html#h63">Disorders of Hemostasis</a>
        </li>
        <li>
          <a href="part0011.html#h64">Platelet Disorders</a>
        </li>
        <li>
          <a href="part0011.html#h65">Coagulopathies</a>
        </li>
        <li>
          <a href="part0011.html#h66">Hypercoagulable States</a>
        </li>
        <li>
          <a href="part0011.html#h67">Disorders of Leukocytes</a>
        </li>
        <li>
          <a href="part0011.html#h68">Transfusion Therapy</a>
        </li>
        <li>
          <a href="part0011.html#h69">Myelodysplastic Syndromes</a>
        </li>
        <li>
          <a href="part0011.html#h70">Myeloproliferative Neoplasms</a>
        </li>
        <li>
          <a href="part0011.html#h71">Leukemia</a>
        </li>
        <li>
          <a href="part0011.html#h72">Lymphoma and CLL</a>
        </li>
        <li>
          <a href="part0011.html#h73">Plasma Cell Dyscrasias</a>
        </li>
        <li>
          <a href="part0011.html#h74">Hematopoietic Stem Cell Transplantation</a>
        </li>
        <li>
          <a href="part0011.html#h75">Lung Cancer</a>
        </li>
        <li>
          <a href="part0011.html#h76">Breast Cancer</a>
        </li>
        <li>
          <a href="part0011.html#h77">Prostate Cancer</a>
        </li>
        <li>
          <a href="part0011.html#h78">Colorectal Cancer</a>
        </li>
        <li>
          <a href="part0011.html#h79">Pancreatic Tumors</a>
        </li>
        <li>
          <a href="part0011.html#h80">Other Solid Tumors</a>
        </li>
        <li>
          <a href="part0011.html#h81">Immunotherapy &amp; Cellular Therapy</a>
        </li>
        <li>
          <a href="part0011.html#h82">Oncologic Emergencies</a>
        </li>
        <li>
          <a href="part0011.html#h83">Chemo Side Effects</a>
        </li>
      </ul>
    </li>
    <li>
      <a href="part0012.html#BE6O0-96ac16803db7461d85d0589a1c192bcf">INFECTIOUS DISEASES</a>
      <ul>
        <li>
          <a href="part0012.html#h84">Pneumonia</a>
        </li>
        <li>
          <a href="part0012.html#h85">Fungal Infections</a>
        </li>
        <li>
          <a href="part0012.html#h86">Infxns in Immunosuppressed Hosts</a>
        </li>
        <li>
          <a href="part0012.html#h87">Urinary Tract Infections</a>
        </li>
        <li>
          <a href="part0012.html#h88">Sexually Transmitted Infections</a>
        </li>
        <li>
          <a href="part0012.html#h89">Skin and Soft Tissue Infections</a>
        </li>
        <li>
          <a href="part0012.html#h90">Infections of the Nervous System</a>
        </li>
        <li>
          <a href="part0012.html#h91">Bacteremia &amp; Endocarditis</a>
        </li>
        <li>
          <a href="part0012.html#h92">Tuberculosis</a>
        </li>
        <li>
          <a href="part0012.html#h93">HIV/AIDS</a>
        </li>
        <li>
          <a href="part0012.html#h94">Tick-Borne Diseases</a>
        </li>
        <li>
          <a href="part0012.html#h95">Fever Syndromes</a>
        </li>
      </ul>
    </li>
    <li>
      <a href="part0013.html#CCNA0-96ac16803db7461d85d0589a1c192bcf">ENDOCRINOLOGY</a>
      <ul>
        <li>
          <a href="part0013.html#h96">Pituitary Disorders</a>
        </li>
        <li>
          <a href="part0013.html#h97">Thyroid Disorders</a>
        </li>
        <li>
          <a href="part0013.html#h98">Adrenal Disorders</a>
        </li>
        <li>
          <a href="part0013.html#h99">Calcium Disorders</a>
        </li>
        <li>
          <a href="part0013.html#h100">Diabetes Mellitus</a>
        </li>
        <li>
          <a href="part0013.html#h101">Lipid Disorders</a>
        </li>
      </ul>
    </li>
    <li>
      <a href="part0014.html#DB7S0-96ac16803db7461d85d0589a1c192bcf">RHEUMATOLOGY</a>
      <ul>
        <li>
          <a href="part0014.html#h102">Approach to Rheumatic Disease</a>
        </li>
        <li>
          <a href="part0014.html#h103">Rheumatoid Arthritis</a>
        </li>
        <li>
          <a href="part0014.html#h104">Adult-Onset Still’s Disease &amp; Relapsing Polychondritis</a>
        </li>
        <li>
          <a href="part0014.html#h105">Crystal Deposition Arthritides</a>
        </li>
        <li>
          <a href="part0014.html#h106">Seronegative Spondyloarthritis</a>
        </li>
        <li>
          <a href="part0014.html#h107">Infectious Arthritis &amp; Bursitis</a>
        </li>
        <li>
          <a href="part0014.html#h108">Connective Tissue Diseases</a>
        </li>
        <li>
          <a href="part0014.html#h109">Systemic Lupus Erythematosus</a>
        </li>
        <li>
          <a href="part0014.html#h110">IgG4-Related Disease</a>
        </li>
        <li>
          <a href="part0014.html#h111">Vasculitis</a>
        </li>
        <li>
          <a href="part0014.html#h112">Autoinflammatory Syndromes</a>
        </li>
        <li>
          <a href="part0014.html#h113">Amyloidosis</a>
        </li>
      </ul>
    </li>
    <li>
      <a href="part0015.html#E9OE0-96ac16803db7461d85d0589a1c192bcf">NEUROLOGY</a>
      <ul>
        <li>
          <a href="part0015.html#h114">Change in Mental Status</a>
        </li>
        <li>
          <a href="part0015.html#h115">Seizures</a>
        </li>
        <li>
          <a href="part0015.html#h116">Alcohol Withdrawal</a>
        </li>
        <li>
          <a href="part0015.html#h117">Dizziness</a>
        </li>
        <li>
          <a href="part0015.html#h118">Stroke</a>
        </li>
        <li>
          <a href="part0015.html#h119">Weakness &amp; Neuromuscular Dysfunction</a>
        </li>
        <li>
          <a href="part0015.html#h120">Headache</a>
        </li>
        <li>
          <a href="part0015.html#h121">Back and Spinal Cord Disease</a>
        </li>
      </ul>
    </li>
    <li>
      <a href="part0016.html#F8900-96ac16803db7461d85d0589a1c192bcf">CONSULTS</a>
      <ul>
        <li>
          <a href="part0016.html#h122">Surgical Issues</a>
        </li>
        <li>
          <a href="part0016.html#h123">Ob/Gyn Issues</a>
        </li>
        <li>
          <a href="part0016.html#h124">Ophthalmic Issues</a>
        </li>
      </ul>
    </li>
    <li>
      <a href="part0017.html#G6PI0-96ac16803db7461d85d0589a1c192bcf">APPENDIX</a>
      <ul>
        <li>
          <a href="part0017.html#h125">ICU Medications</a>
        </li>
        <li>
          <a href="part0017.html#h126">Antibiotics</a>
        </li>
        <li>
          <a href="part0017.html#h127">Formulae and Quick Reference</a>
        </li>
      </ul>
    </li>
    <li>
      <a href="part0018.html#H5A40-96ac16803db7461d85d0589a1c192bcf">ABBREVIATIONS</a>
    </li>
    <li>
      <a href="part0019.html#I3QM0-96ac16803db7461d85d0589a1c192bcf">INDEX</a>
    </li>
    <li>
      <a href="part0020.html#J2B80-96ac16803db7461d85d0589a1c192bcf">PHOTO INSERTS</a>
      <ul>
        <li>
          <a href="part0020.html#h128">Radiology</a>
        </li>
        <li>
          <a href="part0020.html#h129">Echocardiography</a>
        </li>
        <li>
          <a href="part0020.html#h130">Coronary Angiography</a>
        </li>
        <li>
          <a href="part0020.html#h131">Peripheral Blood Smears</a>
        </li>
        <li>
          <a href="part0020.html#h132">Leukemias</a>
        </li>
        <li>
          <a href="part0020.html#h133">Urinalysis</a>
        </li>
      </ul>
    </li>
    <li>
      <a href="part0021.html#K0RQ0-96ac16803db7461d85d0589a1c192bcf">ACLS</a>
    </li>
  </ul>
</div>


  </div>
  

  <div class="calibreEbNav">
    
      <a href="part0008.html" class="calibreAPrev">previous page
</a>
    

    <a href="../../j09u21sl.html" class="calibreAHome">start
</a>

    
      <a href="part0010.html" class="calibreANext">next page
</a>
    
  </div>

</div>

</body>
</html>
